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The interrelation of inflammation and pain 
The body´s homeostasis is regulated by three well-connected systems: the nervous system, 
the endocrine system, and the immune system. Direct cell-to-cell contact, soluble signaling 
molecules like neuropeptides, hormones, and cytokines together provide effective and rapid 
channels for mutual communication [1]. For this reason, inflammation and pain are closely 
related and the severity of both correlate to each other (Figure 1). 
 
 
Figure 1: Relationship between innervation, inflammation, vascularization, damage, and pain. 
This neuroimmune interplay is bidirectional. 
 
Based on this relationship, if inflammation regresses, pain symptoms should also be relieved. 
In contrast, in autoimmune diseases, the state of inflammation and pain is ongoing. This 
phenomenon which is attributed to neuroinflammation, also called neurogenic inflammation. 
This kind of inflammation is characterized by the release of inflammatory substances from 
peripheral endings of primary afferent nerve fibers, which seem to be responsible for 
preserving the status of inflammation and pain in an unending cycle. These inflammatory 
substances are categorized as neuropeptides [2]. These peptides are able to interfere between 
the central nervous system (CNS) and the periphery because they are released from nerves 
in the CNS and from peripheral nerves, endothelial tissues, and various immune cells, 
including T and B lymphocytes, monocytes/macrophages, neutrophils, and mast cells [3, 4]. 
The combination of up-regulation of expression of these substances and their receptors in 
the pathophysiological state of an autoimmune disease, together with further factors like the 
release of cytokines, appears to cause an inflammatory state. Inflammation may include 
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clinical symptoms such as heat, redness, swelling, pain, and decreased function, symptoms 
that significantly reduce the quality of life of affected patients [5]. Neuropeptides, like 
substance P, bradykinin, or calcitonin gene-related peptide (CGRP) induce vasodilatation 
and plasma extravasation of proteins to the site of injury, which causes swelling. Substance 
P is a sensory neuropeptide. Ulf von Euler and John Gaddum identified substance P in 1931; 
they concentrated it in a powdered form and therefore named it substance P [6]. 
In the case of rheumatoid arthritis (RA), the volume of synovial fluid in the joint cavity is 
increased compared to the unaffected joint, due to the presence of neuropeptides. 
Osteoarthritis (OA) may develop in later stages, which is characterized by cartilage 
breakdown, the outgrowth of bone, bone sclerosis, and synovitis [5]. In contrast to RA, OA 
is not defined as an inflammatory disorder because the leukocyte number in the synovial 
fluid is below the typical threshold of 2000 cells/mm3 [7]. However, in both disease states, 
patients feel pain because of the activation of primary afferent nociceptors, which innervate 
the joint´s synovial membrane and are connected to the spinal cord for transmitting the 
received stimuli to higher brain centers where the perception of pain occurs. In contrast to 
the synovium, healthy cartilage does not contain blood vessels and is therefore a hostile area 
for a deep innervation by nerve fibers. The perivascular localization of nerves implies that 
vascularization is the driver behind innervation [8]. With increasing cartilage destruction, 
vascularization and innervation increase and is therefore an indicator for severity and may 
be a potential source of pain, particularly in patients with OA. 
Arthritic pain affects millions of people worldwide, but understanding of the origin of the 
painful sensation is still limited. Current understanding is that during inflammation, the joint 
nerves become sensitized to mechanical stimuli through the actions of neuropeptides, 
eicosanoids, activated receptors, and ion channel ligands [9]. 
That neuropeptide antagonists have anti-inflammatory characteristics is well proven, but 
whether they can act as analgesics is controversial and has only be confirmed in experiments 
with animals, not with humans. It is suggested that in particular pain states, antagonists 
against the neurokinin-1 receptor (NK1R) may be effective analgesics or at least may be used 
as adjuvants to existing analgesics [10]. Many NK1R antagonists have failed trials of a 
variety of clinical pain states, although they have shown in preclinical studies that they can 
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attenuate nociceptive responses. However, they have not reached the efficacy of typical 
nonsteroidal anti-inflammatory drugs, or NSAIDs, which are directed against the 
biosynthesis of prostaglandins by cyclooxygenase, or COX inhibition [10, 11]. In rats, it has 
been shown that the presence of NK1R in the knee joint cavity contributes to the induction 
of pain response, but seems not to be involved in the maintenance of arthritic pain [12]. It is 
also not clear which neuropeptides are involved in immune response and pain enhancement. 
Some believe that it is not substance P that increases inflammation and hyperalgesia, but 
hemokinin-1, which is also able to bind to several neurokinin receptors with very high 
affinity to NK1Rs [13, 14]. Because of its low receptor selectivity compared to substance P, 
this aspect could be a further reason that selective NK1R blockers do not reach the desired 
anti-inflammatory and analgesic effects. In contrast, substance P and glutamate together 
have been found to contribute to arthritic pain and joint swelling. This concept was proven 
in an arthritic rat model by co-administration of respective substance P and glutamate 
antagonists to common dexamethasone therapy [15]. It seems that NK1R is one component, 
but not the only key component at the interface of immune and pain responses. 
Peripheral targeting of substance p/ NK1R interactions 
The therapeutic potential of targeting substance P and NK1R interactions in peripheral 
inflammatory and CNS-associated disorders and their impact on the pharmacology of pain 
are a focus of research [16, 17]. One cornerstone is the observation that NK1Rs are expressed 
on common immune cells and cells of the brain with immune cell-like properties, known as 
glia cells and astrocytes. The major ligand of NK1R, substance P, is mainly stored together 
with CGRP and other transmitters in dorsal root ganglion cells of the spinal cord. Upon 
depolarization, sensory nerve fiber terminals can quickly and ubiquitously release both 
neuropeptides throughout the body´s peripheral tissues. This release is triggered by various 
proinflammatory factors [18]. Substance P and CGRP are responsible for either peripheral 
neurogenic inflammatory responses or equivalent responses in the CNS by cell activation 
via their respective surface receptors. The NK1R target cells can be either vascular or non-
vascular endothelial cells, various immune cells, or other cell types. Together with cytokines, 
overexcited substance P/NK1R interactions can initiate and promote some autoimmune 
diseases, e.g., RA and inflammatory bowel disease, as well as pathogen derived or sterile 
neuroinflammatory disorders, e.g., meningitis or multiple sclerosis [17]. The impact of 
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NK1R activation is also discussed in studies for a variety of psychiatric disorders, including 
anxiety and depression [19]. Since substance P crosses the blood-brain barrier (BBB) and is 
responsible for BBB permeabilization, it seems to be a key factor in the transmission of 
peripheral inflammatory response to the CNS and therefore a main trigger of autoimmune 
diseases by activating monocyte-like parenchymal microglia [20]. Like systemic 
macrophages, microglia cells also express innate immune receptors and have the ability for 
phagocytosis and therefore represent the brain´s own immune system. However, not only 
substance P but also cytokines, like interleukins and growth factors, modulate the actions in 
both defense systems, because they are also produced by microglia [21]. Besides increased 
cytokine concentrations in the blood and liquor, which is evident during inflammation, it 
could be found that sensory nerves also have higher neuropeptide content [22]. In parallel, 
the presence of cytokines regulates NK1Rs. Figure 2 shows the cross-talk between the CNS 
and peripheral systems by blood-derived immune cells and peripheral nerve fibers. 
 
 
Figure 2: Cross-talk between the CNS and various peripheral systems in which the NK1R is 
upregulated under pathological conditions. Substance P binds to the NK1R by autocrine, 
paracrine, and/or endocrine mechanisms, and is released from nerve terminals. The 
neuropeptide reaches the whole body through the bloodstream. This figure is adapted 
from [23]. 
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Implication of NK1R expression in cancer and rheumatoid 
arthritis 
The recruitment of immune cells into the joint space is one similarity of RA to the pathology 
of cancer caused by increased angiogenesis and higher permeability of blood vessels. 
Therefore, common strategies for RA treatment exactly pick up regulatory mechanisms in 
the context of angiogenesis or inflammation for selective interruption. For cancer, some 
well-known examples are the antibody treatments with bevacizumab or trastuzumab, which 
both have antiangiogenic, anti-inflammatory, and growth inhibitory effects. In RA, the 
treatment of choice is also anti-inflammatory, e.g., with etanercept or infliximab to reduce 
the action of cytokines like TNF-α [24]. Its neutralization leads to the subsequent inhibition 
of other proinflammatory cytokines. Besides increased cytokine levels, a second similarity 
between cancer and RA is increased levels of substance P in the blood and in the CNS, and 
for RA in particular, in the synovial fluid within the joint space. In cancer, substance P is 
considered a mitogen because it has been associated with tumor growth and metastasis [25]. 
High cytokine and substance P concentrations are synergistically linked to each other since 
the release of substance P from local peripheral nerve fiber terminals is a result of cytokine 
stimulation. Substance P then significantly contributes on the one hand to the production of 
further cytokines, such as IL-1β, TNF-α and the neutrophil chemoattractant IL-6 by direct 
NK1R interaction on present immune cells. On the other hand, NK1R interaction on vascular 
endothelial cells involves substance P in the recruitment of further immune cells, which 
causes higher permeability and vasodilatation [26]. Other proinflammatory effects are the 
release of lysosomal enzymes, nitric oxide, and prostaglandin E2 [5, 12]. This increasing 
inflammation leads in later stages to tissue destruction and hyperalgesia. There is also strong 
evidence that angiogenesis and inflammation are two major driving forces for the progress 
of early and later OA stages. Both are closely integrated perpetuating processes, such that 
inflammation can trigger angiogenesis, and angiogenesis can speed up inflammation, rather 
than cause it, by facilitating the immigration of more inflammatory cells that generate 
angiogenic factors [27, 28]. In arthritis, vascular proliferation contributes to the pathogenesis 
of synovitis, pannus growth, bone and cartilage destruction, and the formation of 
osteophytes [29]. Beside substance P, many more substances are localized or released within 
osteoarthritic human synovium, synovial fluid, and articular chondrocytes [30]. One of those 
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is angiotensin II, which is released from the synovium into the synovial fluid and seems to 
join with substance P. Several other factors, like various cytokines such as IL-1, IL-4, IL-8, 
IL-18, and TNF-α are responsible for angiogenesis and may exacerbate inflammation. 
However, IL-10 and TGF-β, as well as cytokine inhibitors such as IL-1ra and soluble TNF-R, 
are also produced as anti-inflammatory counterparts [26]. All these factors were found in 
increased levels in the synovial fluid from patients with arthritis [29]. 
Function of different NK1R isoforms 
Accumulating evidence has suggested that NK1R is closely related to immune responses and 
may be recognized as a key factor in neuroinflammation. Therefore, NK1R may represent a 
potential therapeutic target in the neuro-immune axis. For a better understanding of NK1R-
ligand interactions it is important to know that other neurokinin receptor types exist (NK2R 
and NK3R) [31], two different isoforms with different intracellular pathways. The broad 
spectrum of different receptors and their distinct selectivity for certain ligands makes the 
topic of specific receptor ligand interaction even more complex. The exact functional 
pathways and the reason for different neurokinin receptor types, different expression 
profiles, and different ligand affinities, in addition to different NK1R isoforms with distinct 
molecular masses is still not clarified. Differences in lengths arise from a lack of 96 amino 
acids at the intracellular C-terminal end of the receptor, which vary from 407 amino acids 
for the full-length receptor isoform to 311 amino acids for the truncated receptor isoform [3]. 
These isoforms originate from two differently spliced mRNAs. It is suggested that the 
different receptor versions may have a regulatory role in receptor desensitization, since the 
short form has a 10-fold lowered affinity for substance P and is not able to elicit intracellular 
G-protein binding, which induces the activation of NFκB via kinase-cascade activation and 
eventually results in the production of proinflammatory cytokines [32, 33]. After repeated 
induction of these intracellular mechanisms by binding agonists, the full-length receptor 
becomes internalized by endosomes. This is not the case for the truncated receptor version 
because of the loss of C-terminal Ser/Thr residues, which are essential for receptor 
internalization upon G-protein-coupled receptor kinase interaction and β-arrestin 
recruitment [34]. The prevalence of different splice variants seems to be distributed into 
brain and peripheral tissues, where the full-length form is mostly found in the brain and the 
truncated form is mostly found in peripheral tissues [35]. There is evidence that, especially 
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in cancer, the short receptor form is over-expressed and offers a potential target site for 
anti-substance P and NK1R treatment [36]. It has been shown recently that the truncated 
NK1R also has important functional roles concerning the modulation of immune responses 
by cytokines and the chemotaxis of macrophages [37]. 
Multivalent antagonistic NK1R targeting 
Antagonistic treatment of neuropeptide receptors, especially NK1R, could be a promising 
approach to anti-inflammatory pharmacotherapy [1]. The main benefit arises from using a 
multivalent technique such as coupling antagonists on the surface of nanoparticles where an 
increased effectiveness of treatment by the blockade of multiple receptors at the same time 
is expected. This aspect depends on high receptor densities on cell surfaces, which is the 
case in neurogenic inflammatory states, where NK1Rs are over-expressed. The generation 
of a spatial proximity of multiple ligands on the surface of the nanoparticle to a highly 
receptor crowded cell surface determines whether a receptor blockade is sustained. Keeping 
several ligands close to receptors after the initial binding of the first ligand preserves this 
proximity. The likelihood for a second ligand binding is relatively high. This state, when 
several ligands bind several receptors at the same time, is called multivalency, and the 
effect—that an initial receptor binding promotes the binding of a second one—is called 
cooperativity. This potent docking principle to cells´ surfaces was found for various 
viruses [38]. Other approaches focus on hetero-multivalent binding drugs since single drug 
treatments often suffer from limited efficacy and/or high toxicity. Depending on the 
nanoparticles´ core material for the design of multivalently acting drugs, cell and organ 
toxicity are an issue. For experimental studies, the visibility of particles, homogeneity in 
size, and charge are major demands. Quantum dots offer all these benefits and are therefore 
a perfect tool to investigate multivalent interactions. Although quantum dots perfectly meet 
the specifications for experimental studies, strong evidence suggests cell toxicity in higher 
concentrations because of their bright fluorescent cadmium core, and little is known about 
QD metabolism [39]. In addition, dense surface PEGylation might increase blood half-life, 
and precludes elimination from the body. This results in a large area under the exposure-
time curve and increases the likelihood of toxicity [40]. However, if the concept of 
multivalent receptor targeting is proven for a target receptor, there are several possibilities 
for exchanging the nanoparticle species. 
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Peptide and non-peptide NK1R antagonists 
There are two fundamental parameters that determine the binding quality of a drug to its 
receptor binding site: the affinity and the efficacy. The affinity specifies the propensity of a 
ligand to form a reversible complex with its receptor. The efficacy describes the intrinsic 
activity of the ligand, which is the ability to produce a functional response in the form of a 
signaling cascade in cells and tissues [41, 42]. A full agonist can generate a maximal 
response and tends to stabilize the active state of the G-protein-coupled receptors, whereas 
full antagonists have no functional effect. The typical stabilized receptor conformation plays 
an important role for the resulting intracellular signaling or determining if the receptor is 
simply blocked [43]. For example, substance P binds to the extracellular loops of the NK1R, 
whereas small hydrophobic molecular antagonists like aprepitant bind more deeply between 
the transmembrane segments III–VII [44] (see Figure 3). Partial agonists induce only a 
submaximal effect and seem to reduce the rate of G-protein turnover, relative to a full 
agonist, by strongly stabilizing the ternary complex [45]. In general, partial and full agonists 
share a certain binding topography, but stabilize distinct receptor conformations [46]. 
 
 
Figure 3: Pattern of 7-transmembrane segments of NK1R. The arrows indicate different 
binding sites for small molecular lipophilic antagonists and more hydrophilic peptide agonists. 
 
In the case of NK1R downstream signaling, a full and potent agonist, such as substance P, 
would result in intrinsic activity in the form of a great calcium influx into the cytosol even 
in picomolar concentrations. Aprepitant is known to act as a full antagonist, which does not 
trigger intrinsic activity and can be seen as a receptor blocker. Most full antagonists are 
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synthetic compounds and therefore do not appear in nature, unlike full agonists like 
substance P. However, the assumption that synthetic compounds produce no functional 
response is false. On the contrary, most known synthetic drugs exhibit a range of responses 
between full agonism and full antagonism and are termed partial agonists because their 
intrinsic response is reduced compared to their full agonistic analogs. Partial agonists can 
elicit different receptor responses depending on their environment: In the presence of 
agonists with higher intrinsic activity, partial agonists can demonstrate antagonist properties 
by blocking access to the receptor, but on their own they will act as agonists [41]. The design 
of peptide NK1R antagonists has focused on the introduction of D-amino acids [47]. 
However, there are several drawbacks; for example, binding affinities are several orders of 
magnitude lower than their natural agonists and therefore exhibit poor potency. In addition, 
partial residual agonist activity and mast cell degranulation activity and neurotoxicity have 
been observed. Another disadvantage is the inability to discriminate between different 
tachykinin receptor types [48, 49]. In addition, these peptides are not able to gain access to 
the CNS through the BBB [50]. Depending on the desired application, though, this aspect 
may not be a limiting factor except for drugs that explicitly address the brain, such as 
neurotherapeutics [51]. It can be concluded that peptide as well as non-peptide antagonists 
are useful for peripheral NK1R targeting. In the context of this work, both species were 
selected for in vitro multivalent binding experiments. Spantide I was chosen as the peptide 
antagonist, and the influence of PEGylation on binding affinity was checked prior to 
coupling to PEG-coated quantum dots. As the non-peptide antagonist, aprepitant was 
modified by a short alkyl linker to make it accessible for polyethylene glycol (PEG) 
coupling. 
Cost-benefit balancing of drug PEGylation 
Up-to-date PEGylation is one post-synthetic strategy of choice with the aim of increasing 
the solubility and circulatory half-lives of sparely soluble and/or enzymatically unstable 
drugs. The PEG coatings on the surface of nanoparticles have an additional shielding effect, 
which prevents them from aggregation, opsonization, and phagocytosis [52]. The reasons 
for the popularity of PEG are simple. Polyethylene glycol is a water-soluble, non-toxic, non-
immunogenic, and commercially available polymer that is approved by the United States 
Food and Drug Administration and sold with various functional groups at the polymer chain 
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endings for individual arbitrary chemical modification by customers [53, 54]. But the 
challenges for drug PEGylation are many: degree of PEGylation, determination of an ideal 
position within the molecule for PEG-linkage, evaluation of an ideal PEG type and PEG 
length, choice of PEGylation chemistry, preservation of the drug´s affinity, control of loss 
in specificity and selectivity, and the avoidance of the gain of unwanted binding effects. 
Altogether, an extensive chemical and biological analysis of the PEGylated drug cannot be 
avoided. In the context of hydrophobic ligands on the surface of PEG-coated nanoparticles, 
the existence of individual PEG and ligand configurations comes into question, depending 
on the PEG density and ligand properties. This aspect is important since the behavior of the 
ligand in proximity to a dense PEG shell significantly influences the characteristics of the 
particle in respect to its charge and its impact on cell binding and uptake. Two possible 
configurations are known for PEG: brush and mushroom, differentiated by PEG chain 
density. As a high PEG density is expected to yield a brush conformation with good shielding 
properties and high particle mobility, this conformation is favored for PEG in nanoparticle 
targeting in respect to ligand coupling. However, a high PEG density implies the risk for 
hydrophobic ligand shielding, which could drastically minimize the exposure of the ligands 
to the outer nanoparticle surface and therefore reduce the potential for multivalent receptor 
binding. 
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Mechanistic concept of enzymatic nanoparticle activation 
in the context of diabetic nephropathy and rheumatoid 
arthritis 
The concept of enzyme-based nanoparticle activation at the site of the disease as a further 
strategy for active targeting is discussed in the literature. In particular, metalloproteinases, 
which are expressed ubiquitously, are the focus of nanoparticle shell conversion to make 
underlying ligands available [55]. But no concept currently focuses on the induction of 
multivalency by enzyme driven ligand conversion on the surface of nanoparticles. 
For earlier disease stages in RA, David A. Walsh and colleagues found that increased levels 
of angiotensin-converting enzyme (ACE), a membrane metallopeptidase are present in the 
synovial fluid of patients because of the increasing density of ACE-bearing stromal cells and 
not because of an increase in vascular delivered ACE [29, 56]. Angiotensin-converting 
enzyme primarily converts angiotensin I to the vasoactive angiotensin II and can therefore 
be one reason for the progress of disease with respect to the formation of new small blood 
vessels in the synovium [29]. Especially in the acute inflammation phase of arthritis, 
bradykinin, substance P, CGRP, angiotensin II, prostaglandin E2, nitric oxide, histamine, 
and hyaluronic acid (low molecular weight) contribute to angiogenesis. In the chronic phase, 
other influences like vascular endothelial growth factor and other growth factors, such as 
interleukins, TNF-α, TGF-β, and the platelet-derived endothelial cell growth factor play a 
role. All these factors can be designated as angiogenic factors, and subclassified in acute and 
chronic inflammation [29]. The inhibition of angiogenesis may be of therapeutic interest to 
stop the progress of arthritic diseases. Angiotensin I-modified quantum dots may be useful 
for further investigation of the influence of ACE in the progression of RA and for the 
identification of target cells for enzymatically processed quantum dots. Moreover, these 
quantum dots may be used as a diagnostic marker for different disease states. Since it is 
known that, in addition to synovium derived cells, bovine chondrocytes in a 2D cell culture 
express AT1 receptors for angiotensin II, cartilage cells could also be a potential target for 
antiangiogenic drugs. Nanoparticles would reach these cells by simple diffusion, especially 
in a pathological condition where the extracellular matrix is leaky because of cartilage 
destruction. In preclinical research, such quantum dots could aid understanding of the 
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mechanism of action of ACE in RA after local administration into either inflamed or healthy 
joint space. In general, the selective inhibition of undesired angiogenesis is challenging 
because angiogenesis itself also has a physiological function and occurs in the absence of 
inflammation. Therefore, for the development of angiostatic therapeutics it is necessary to 
understand and distinguish among different regulatory mechanisms in both the healthy state 
and the disease state. In the healthy state, articular cartilage is avascular, and its nutrition is 
dependent from factors released from the synovium into the fluid-filled joint cavity. The 
normal synovium must be well supplied with capillaries to fulfill this function. This status 
is profoundly changed in the presence of inflammation because the morphology of the 
synovium is altered in respect to number, density, and spatial distribution of the 
vasculature [28]. In contrast to the healthy state, there is more vasculature in the disease 
state, but paradoxically the blood supply is inadequate. The consequences are hypoxia, 
hypercapnia, and acidosis [28]. If angiogenesis inhibitors reach off-targets, they could have 
potentially detrimental effects on wound healing or on the female reproductive capacity, for 
example [28]. Along with angiotensin I, substance P and bradykinin are also susceptible to 
ACEs. Compared to angiotensin, these proinflammatory kinins become inactive [57]. 
Substance P and bradykinin are known to induce plasma extravasation and to increase blood 
flow [56, 58]. Therefore, it is therapeutically beneficial to stimulate ACE in the inflamed 
joint, rather than to inhibit it. 
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The goal of this thesis was to investigate the neurokinin-1 receptor as a potential target site 
for multivalent receptor blockade. Taking previous findings on multivalent G-protein-
coupled receptor (GPCR) targeting into account, e.g. the increase in selectivity, specificity 
and ligand affinity to the target site, this work focused on challenging aspects of PEGylation 
of synthetic hydrophobic peptide and non-peptide NK1R antagonists and their coupling to 
PEGylated quantum dots (QDs). Irrespective of neurokinin-1 receptor targeting, the 
principle of enzymatic peptide ligand activation on the surface of nanoparticles was 
investigated, based on angiotensin I to angiotensin II conversion by ACE and AT1 receptor 
targeting as a new tool for site-specific targeting. 
As the neurokinin-1 receptor is involved in inflammation and pain, its role is also discussed 
in the context of autoimmune diseases, like RA, but also in cancer. An efficient antagonistic 
targeting could be highly beneficial in their therapy. Since the NK1R is peripherally 
expressed on different cell types of the human body and its expression increases at the time 
when an immune response occurs, this receptor seems to offer great potential for selective 
and specific antagonistic surface receptor targeting with a minimizing effect of inflammation 
and pain. The interrelation of the neurokinin-1 receptor to inflammation and pain in general 
and how different ligands can interact with the neurokinin-1 receptor, as well as the cost-
benefit of PEGylation of such ligands are described in Chapter 1. 
Based on this scientific background, the expression status of the NK1R was checked on 
different cell types, e.g. bovine chondrocytes as a potential target cell in RA, different cancer 
cell types, and transfected CHO cells as a positive control. Within these expression studies, 
the influence of the main neurokinin-1 receptor agonist, substance P was tested in respect to 
intracellular pathways. These studies are shown in Chapter 3. 
The idea behind multivalent binding antagonists is to make potent ligands more selective 
against cells with overexpression of the respective target receptor and the receptor blockade 
itself more efficient because of a prolonged arrest of the multivalent binding ligand at the 
target site. Fluorescent nanoparticles are a common tool to investigate such multivalent 
interactions. Therefore, fluorescent PEGylated QDs were used for ligand coupling to the 
surface of nanoparticles and to study their interactions with neurokinin-1 receptor positive 
cells. The synthesis strategy and the nanoparticle characterization are shown in Chapter 4. 
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Besides PEGylated QDs, branched 8-arm PEGs were used for multivalent cell interaction 
studies. In contrast to QDs, PEGs are classified as non-toxic biomaterials and they do not 
interfere with luminescence-based calcium assays. Therefore, they offered an effective tool 
for determining their binding affinities as well as the ligand coupling efficiency. These 
binding studies are depicted in Chapter 5. 
Besides peptide-based antagonists, a small molecular weight antagonist, named aprepitant 
was modified to make it amenable for further PEG coupling, either to branched PEGs or 
PEG-coated nanoparticles. The synthesis strategy is shown in Chapter 6. 
Another new strategy for site-specific multivalent nanoparticle targeting is presented in 
Chapter 7, the final chapter. This strategy is based on an enzyme driven activation 
mechanism of ligands, which are immobilized on the surface of nanoparticles. For these 
studies, the ACE driven angiotensin I to angiotensin II conversion was used and the 
successful conversion was checked by AT1 receptor binding studies. 
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Abstract 
The neurokinin-1 receptor (NK1R) is a quite promising target receptor for multivalently 
binding nanoparticles for either tumor or non-tumor targeting because of its strict 
overexpression in pathological states and because of its action at the interface of the immune 
and nervous system. Though its direct role in the generation and perception of pain responses 
is controversial, its influence in the initiation and promotion of the immune response is 
certain. The presence of high local immune cell-derived cytokine concentrations leads to the 
release of substance P from peripheral afferent nerve terminals. Substance P is the major 
ligand for the NK1R and triggers the immune response by pro-angiogenesis mechanisms, 
which facilitate the recruitment of further immune cells. This so-called neurogenic 
inflammation represents an effective way to protect the body from noxious stimuli. The main 
disadvantage of neurogenic inflammation is that there is a risk for irrepressible immune 
responses, especially in the case of cancer and autoimmune diseases (e.g. RA). Therefore, 
proinflammatory cytokine dependent NK1R expression on various human glioblastoma and 
breast cancer cells and chondrocytes, obtained from bovine cartilage was investigated. Here, 
IL-1 dependent NK1R mRNA expression was found in all tested cells. However, the 
existence of the functional full-length receptor version was not verified in calcium assays. 
In bovine chondrocytes, substance P directly contributes to cartilage destruction by up-
regulation of the matrix-metalloproteinase MMP-13. Therefore, an effective antagonistic 
treatment of the NK1R may be a highly promising strategy to relieve typical inflammatory 
symptoms in early RA and prevent further destructive processes in later disease stages. 
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Introduction 
The peripheral nervous system and the immune system cannot be considered as two 
separately acting machineries [1]. The crosslink between both is drawn by the same 
molecular recognition pathways, which offer them a way to communicate. This mechanism 
is called neurogenic inflammation, with the goal of forming an integrated and rapid 
protective defense of the body. Due to the high speed of the signal transduction pathway of 
sensory and autonomic nerve fibers, which are widely distributed in peripheral tissues and 
organs, the neurogenic modulation of immunity is quite effective [1]. However, in the case 
of pathological states, as in cancer or autoimmune diseases (e.g. RA), this interaction also 
contributes to the exacerbation and progression of the disease [2]. 
The NK1R and its primary agonist, substance P are two of the key players in neurogenic 
inflammation, since they are both upregulated during inflammation [3]. It is suggested that 
elevated substance P levels in plasma and synovial fluid may be a hallmark of chronic 
inflammation [4]. Substance P conveys vasodilatation, indicated by an increase in blood 
vessel size and an increase in permeability as well as neovascularization. Recent evidence 
suggests that substance P mediated stimulation of angiogenesis occurs in inflamed peripheral 
tissues like the synovial membrane in RA or different types of tumors [5,6]. Through these 
newly formed highly permeable blood vessels, immune cells are able to infiltrate into the 
joint cavity or into tumor tissues to release in turn cytokines like IL-1α and IL-1β and other 
pro-inflammatory factors, like TNF-α [7]. In the case of RA, the synovial membrane 
becomes hypertrophic and the high doses of inflammatory factors provoke the release of 
neuropeptides like substance P from articular afferent unmyelinated C nerve fibers within 
the soft tissues of the joint [7–9]. An additional factor for substance P release is local 
mechanical overload, which causes increasing compressive forces and hypoxia and may 
further sensitize these nerves and contribute to pain [10]. Prolonged peripheral nerve 
sensitization leads to enhanced responses of the spinal cord and thalamic neurons [11] 
(Figure 1). The released substance P activates NK1Rs, which are typically over-expressed 
on glial cells of the CNS and peripheral infiltrated immune cells in the synovium and 
synovial endothelial cells and even on articular chondrocytes [12–15]. In RA, a chronic stage 
is reached, when the inflammatory symptoms last more than three months. In this state, the 
immune cells are underrepresented and are replaced by tissue destruction, mainly caused by 
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ECM degrading matrix-metalloproteinases (MMPs), which are promoted by inflammatory 
transmitters and substance P [13]. 
 
Figure 1: The dominating part in neuronal innervations of an inflamed tissue is taken by 
sensory nerve fibers. In response to cytokine stimulation, the ends of these nerve fibers release 
various neuropeptides, including substance P, which cause vasodilatation and the recruitment 
of immune cells into the inflamed tissue. Reprinted from Nat Rev Rheumatol 9, 2, 117–126 by 
G. Pongratz and R. H. Straub, 2013. Copyright by Nature Publishing Group. Reprinted by 
permission [16]. 
 
An effective antagonistic targeting of substance P by a neurokinin-1 receptor blockade seems 
to be a promising strategy to mitigate typical inflammatory and painful symptoms in either 
cancer or in early and late stages of RA. For this reason, the NK1R expression on different 
tumor cell lines as well on bovine chondrocytes as potential target cells for multivalent 
nanoparticle-based antagonistic NK1R treatment was investigated. In this context, it was 
additionally looked on NK1R mRNA expression levels in response to stimulation with the 
proinflammatory factor IL-1β. Further, whether substance P has an influence on MMP-1 and 
MMP-13 expression on IL-1β stimulated bovine chondrocytes was investigated. The aspect 
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of ECM degradation in response to cytokines and neuropeptides is intriguing since it is a 
substantial requirement for nanoparticle diffusion into cartilage and subsequent NK1R 
targeting on chondrocytes. Because NK1R mRNA levels do not directly reflect the functional 
receptor density on the cell surface, calcium assays were performed with all cell lines to 
identify a target cell with high NK1R density for multivalent drug testing.
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Materials and methods 
All chemicals were obtained from Sigma Aldrich (Taufkirchen, Germany) in analytical 
grade unless stated otherwise. Dulbecco’s phosphate-buffered saline (DPBS) pH 7.4 
consisting of 1.5 mM KH2PO4, 8 mM Na2HPO4, 2.7 mM KCl and 138 mM NaCl was 
purchased from Life Technologies/Thermo Scientific (Darmstadt, Germany). Ultrapure 
water was obtained from a Milli-Q water purification system (Millipore, Billerica, MA, 
USA). 
Tumor cell lines, U87 MG gliloblastoma, MDA-MB-231 and MCF-7 breast cancer cell lines 
were purchased from ATCC [17,18]. U87 MG cells were grown in Eagle´s Minimum 
Essential Medium (EMEM) without pyruvat with 10% FCS, MDA-MB-231 in McCoy´s 
medium with 5% FCS and MCF-7 in EMEM with pyruvat and 10% FCS. Primary bovine 
chondrocytes were isolated by Johanna Lempp from the department of Pharmaceutical 
Technology (Universität Regensburg) from freshly obtained bovine knee joints and grown 
in cell culture medium (CCM), consisting of DMEM (Gibco/Thermo Scientific, Darmstadt, 
Germany), 10 mM HEPES, non-essential amino acid (Gibco/Thermo Scientific, Darmstadt, 
Germany), 46 µg/ml proline, 50 µg/ml ascorbic acid, 1% Penicillin/Streptomycin 
(Gibco/Thermo Scientific, Darmstadt, Germany), 10% FCS. DBA-1J mouse knee joints 
were kindly provided from Prof. Rainer Straub (Klinik und Poliklinik für Innere Medizin, 
Universität Regensburg). Dr. Ralf Schwandner (Amgen Research GmbH, BioPark 
Regensburg) kindly provide a stable transfected neurokinin-1 receptor expressing CHO cell 
line. Cells were grown in DMEM:F12 (1:1) medium with 1.2 g/l NaHCO3, 15 mM HEPES, 
1% Penicillin-Streptomycin, 10% FCS and 600 µg/ml hygromycin B (Carl Roth, Karlsruhe, 
Germany) supplementation. 
The peqGOLD Total RNA Kit and the peqGOLD DNase I Digest Kit were used to extract 
mRNA and to remove potentially present DNA. For reverse transcription, two kits were 
used: The AffinityScript QPCR cDNA Synthesis Kit was bought from Agilent Technologies, 
Waldbronn Germany and the PeqGOLD cDNA Synthesis Kit H Minus was bought from 
Peqlab, Erlangen, Germany. For classical Polymerase chain reaction (PCR), the peqGOLD 
Taq-DNA-Polymerase Kit from Peqlab, Erlangen, Germany was used. As reaction buffer, 
the 10x reaction buffer S was always chosen, with a MgCl2 content of 15 mM. For 
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quantitative real-time PCR, the SYBR Green qPCR Kit was obtained from Agilent 
Technologies, Waldbronn, Germany. 
Human interleukin-1α (IL-1α) was purchased from PeproTech, Hamburg, Germany. Human 
interleukin-1β (IL-1β) was purchased either from MACS Miltenyi Biotec, Bergisch 
Gladbach, Germany or from PeproTech, Hamburg, Germany. Reconstitutions were made by 
dissolving 10 µg of provided interleukins in 100 µl sterile filtered Millipore water to obtain 
0.1 mg/ml stock solutions. Working solutions of 0.01 mg/ml were prepared in 0.1% BSA in 
DPBS. 
Neurokinin-1 receptor expression studies in 2D cancer 
cell culture upon 24 hours interleukin-1β stimulation by 
RT-PCR 
U87 MG and MDA-MB-231 cells were seeded in a six-well cell culture plate in a cell density 
of 0.5*106 cells per well and were grown overnight at 37°C and 5% CO2 in a medium with 
10% FCS. Stimulation over 24 hours was started 12 hours after cell adherence in a medium 
without FCS. On the second day after seeding, stimulation time points of 6 hours, 3 hours, 
1 hour and the control without stimulation were prepared equivalently. 
After IL-1β stimulation, the medium was removed and replaced by 1 ml phenol containing 
TRIzol reagent for cell lysis and incubated for 5 min at room temperature. In each well, the 
total cell lysate was removed with the help of a cell scraper and transferred to a 2 ml 
Eppendorf tube. For phase separation, 200 µl of chloroform were added and mixed by 
thorough up and down pipetting for 15 seconds. To induce complete phase separation, the 
mixture was centrifuged at 12000 rcf for 15 min at 4°C. The upper phase was transferred in 
a fresh Eppendorf tube and washed with 500 µl isopropanol by gentle shaking, and RNA 
was precipitated by incubation at room temperature for 10 min. The extracted RNA was 
sedimented by a further centrifugation at 14000 rcf for 30 min at 4°C. Then the supernatant 
was removed and the obtained RNA pellet was air dried. Then the pellet was washed in 1 ml 
75% ethanol by gentle shaking and a centrifugation step at 9400 rcf for 5 min at 4°C. The 
RNA pellet was dried again after removal of the supernatant. The obtained RNA was 
dissolved in 15 µl RNase free water and heated to 55°C for at least 10 min. The obtained 
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samples were stored at -80°C until use. The RNA content was determined with a NanoDrop 
UV meter. For cDNA generation, 2 µg RNA were reverse-transcribed with an oligo(dT) 
primer and random primer mix, consisting of 170 ng and 30 ng respectively. It was 
considered that an existing short receptor version, lacking some C-terminal amino acids for 
G-protein binding, has no Poly-A tail for oligo(dT) primers. With the obvious excess of 
oligo(dT) primers, the mRNA of full-length receptor version should be preferably 
transcribed in the RT reaction. The resulting cDNAs were used as templates for 
amplification in PCRs. 
Neurokinin-1 receptor expression studies in 2D bovine 
chondrocyte cell culture by 24 hours IL-1α and IL-1β 
stimulation by RT-PCR 
To evaluate whether the NK1R is expressed in general and whether there is a change in 
expression in the state of inflammation, primary bovine chondrocytes were stimulated in a 
2D culture with two different interleukins, and mRNA was subsequently isolated for 
RT-PCR. Therefore, bovine chondrocytes of the first passage were cultured in T25 cell 
culture flasks (Corning, Wiesbaden, Germany) in CCM. Confluent cells were washed with 
warm DPBS and then stimulated with interleukins, either 10 ng/ml IL-1α or IL-β 
(PreproTech, Hamburg, Germany) in phenol red free CCM without FCS and 0.1% BSA and 
incubated for 24 h at 37°C and 5% CO2 atmosphere. The peqGOLD Total RNA Kit and the 
peqGOLD DNase I Digest Kit were used to extract mRNA and to remove potentially present 
DNA. Both kits were used according to the manufacturer´s instructions. The RNA content 
was determined at a NanoDrop UV meter. Then 1 µg RNA was reverse-transcribed with the 
peqGOLD cDNA Synthesis Kit H Minus, using an oligo(dT) primer and random primer mix 
of 170 ng to 30 ng. The resulting cDNAs were used as templates for amplification in PCRs. 
Polymerase chain reaction (PCR) 
There are two versions of neurokinin-1 receptors - a full-length form and a truncated form 
generated by alternative splicing [19]. Compared to the full-length receptor version, the 
truncated receptor lacks 96 amino acids in the C-terminal part of the receptor sequence in 
Identification of target cell candidates with NK1R expression Chapter 3 
 
 
 
- 31 - 
the cytosol and is therefore not able to bind and activate a G-protein and trigger intracellular 
calcium release upon extracellular agonist binding [20,21]. For the evaluation of cell lines, 
which express both types of neurokinin-1 receptors, appropriate primer pairs for PCR that 
span the cDNA for the full-length and the truncated receptor version were used. The PCR 
primers were ordered from Eurofins Genomics, Ebersberg, Germany and are listed in Table 
1. 
Table 1: Primer sequences 
Target Sequence (5´-> 3´) Tm in °C GC content 
in % 
Human NK1R [22] 
Forw.: AGGACAGTGACGAACTATTTTCTGG 
Rev.: CTGCTGGATAAACTTCTTCAGGTAG 
61.3 
61.3 
44.0 
44.0 
Bovine NK1R [23] 
Forw.: TATTTACTCCATGACGGCTG 
Rev.: AGTCCCCAGGGATCTCACT 
55.3 
58.8 
45.0 
57.9 
Human GAPDH  Forw.: CTGACTTCAACAGCGACACC Rev.: CCCTGTTGCTGTAGCCAAAT 
59.4 
57.3 
55.0 
50.0 
For the detection of human neurokinin-1 receptor expression levels, a PCR was performed 
using the peqGOLD Taq-DNA-Polymerase Kit. For each reaction, a total volume of 25 µl 
with a primer content of 20 pmol (human NK1R) and 10 pmol (bovine NK1R) and 1 µl of 
cDNA template were used [22]. As reaction buffer, 10x reaction buffer S was chosen with a 
MgCl2 content of 15 mM. All other components were applied according the manufacturer´s 
instructions. 
The PCR program was based on those mentioned in the literature [22]: 
1. Denaturation  94°C   9 min1)/2 min2)/3) 
2. Denaturation 94°C   30 sec1)3)/10 sec2) 
3. Annealing   50°C1)/55°C2)/3) 30 sec          451)/402)/353) cycles 
4. Elongation   72°C   30 sec1)/35 sec2)/15 sec3) 
5. Final elongation 72°C1)/2)/76°C3) 7 min1)/2 min2)/6 min3) 
6.   4°C  ∞ 
1) human NK1R, 2) bovine NK1R, 3) bovine MMP-1 and MMP-13 (see following section) 
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The amplified cDNA was finally observed in a gel electrophoresis with 2% agarose 
(Invitrogen/Thermo Scientific, Darmstadt, Germany) in 1x TAE buffer. The bands were 
detected with 0.4 µg/ml ethidium bromide, which was added to the pre-solid gel. For sample 
load, 20 µl of PCR reaction product were mixed with 4 µl 6x Loading Dye (Peqlab, Erlangen, 
Germany). For fragment size determination either the peqGOLD 50 bp (Peqlab, Erlangen, 
Germany) or 100 bp DNA ladder (Invitrogen/ ThermoFisher Scientific, Darmstadt, 
Germany) were used. 
RT-PCR and qPCR for MMP-1 and MMP-13 mRNA 
expression analysis upon substance P stimulation in 2D 
bovine chondrocyte cell culture 
Because of the lack of specific bovine neuokinin-1 receptor primers to study the influence 
of substance P on receptor expression in real-time qPCR, substance P mediated matrix-
metalloproteinase (MMP-1 and MMP-13) expression was investigated, which would be an 
indirect proof for the existence of neurokinin-1 receptors on the surface of chondrocytes. 
Therefore, two different stimulation experiments were performed. In the first experiment, 
various substance P concentrations in a fixed timeframe of 24 hours were tested, starting 
from 1 nM and increasing up to 3 µM substance P. In the second experiment, a fixed 
concentration of 1 µM substance P was used, and the stimulation time was varied from 
1 hour up to 48 hours. The RNA extraction and reverse transcription were performed as 
described in the former section. The resulting cDNAs were used as templates for 
amplification in polymerase chain reactions and for quantitative real-time PCR (qPCR) 
analysis, where expression levels were normalized to GAPDH housekeeping gene 
expression. Template cDNA was used in a volume of 10.5 µl and mixed to a final volume 
of 25 µl with components of the SYBR Green qPCR Kit (Agilent Technologies, Waldbronn, 
Germany), according to the manufacturer´s instructions, and mixed with 10 pmol of 
prepared bovine MMP-1, bovine MMP-13, or bovine GAPDH primer mix (primer 
sequences and characteristics are shown in Table 2). Real-time gene amplification was 
performed in a 96-well non-skirted plate with adhesive foil seal (4titude®Ltd., Berlin, 
Germany), using a spectrofluorometric thermal Mx3005P QPCR System (Agilent 
Technologies, Santa Clara, CA, USA). The cycling program started with an initial cycle at 
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95°C for 15 minutes, followed by 40 cycles, each starting at 95°C for 10 seconds and 
decreasing the temperature to 60°C and holding for 30 seconds, and ended with a final cycle 
at 95°C for 1 min, decreasing to 55°C and holding for 30 seconds, then increasing again to 
95°C for 30 seconds. Data evaluation was performed with the system connected QPCR 
software MxPro (Agilent Technologies, Waldbronn, Germany). 
Table 2: Primer sequences 
Target Sequence (5´-> 3´) Tm in °C GC content in % 
Bovine MMP-1 [24] 
Forw.: GCTTATGAGGTTGCCGACAG 
Rev.: ACGTTTTCCCAGTATCTTCCTC 
59.4 
58.4 
55.0 
45.5 
Bovine MMP-13 [24] 
Forw.: CGCGGAGAAACACTGATCTT 
Rev.: TCATAGGCGGCATCAATACG 
57.3 
57.3 
50.0 
50.0 
Bovine GAPDH 
Forw.: TTCTGGCAAAGTGGACATCG 
Rev.: CGTTCTCTGCCTTGACTGTG 
57.3 
59.4 
50.0 
55.0 
 
Neurokinin-1 receptor immunostaining on cells in 2D 
culture 
Because there is no guarantee for the presence of functional NK1Rs in the cellular membrane 
by just verifying its expression at the RNA level, there was an attempt to detect the NK1R 
on tumor cells with a specific human NK1R antibody and a secondary fluorescent FITC 
antibody. The U87 MG, MDA-MB-231, and the receptor positive CHO-NK1R cells were 
each seeded in a density of 105 cells/well in an 8-well µ-slide for microscopy purposes (Ibidi, 
Martinsried, Germany). After cell adherence overnight, the U87 MG and MDA-MB-231 
cells were stimulated with 4 ng/ml IL-1β in Leibovitz medium for 3 hours and 1 hour to 
check for cytokine dependent receptor expression. Unstimulated cells served as a control. 
All cells were fixed with 4% paraformaldehyde in DPBS for 10 min at room temperature. 
The fixing solution was replaced by 10% goat serum in Leibovitz medium to block free 
valencies for at least 30 min at 37°C. Then the cells were incubated with 10 µg/ml of the 
primary NK1R specific antibody (Novus Biologicals, Littleton, Colorado, USA) for 30 min 
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at 37°C. The primary antibody was removed and the cells were washed four times with 10% 
goat serum in DPBS. 10 µg/ml of the secondary FITC conjugated antibody (Abcam, 
Cambridge, UK) were administered to the cells and incubated for further 30 min at 37°C. 
The cells were washed again with 10% goat serum in DPBS. Finally, the cells were covered 
with Leibovitz medium. For FITC excitation, a 488 nm argon laser was used, and 
fluorescence emission was detected using a 505-530 band-pass filter. The pinhole was set at 
252 µm. Gain adjustment was performed individually for each cell type by normalization 
against a control sample with only secondary FITC-antibody. 
Fura-2 AM calcium assay as functional proof of NK1R 
expression 
Because the full-length NK1R variant is a Gq-protein-coupled receptor, the measurement of 
intracellular calcium release in response to agonistic receptor stimulation is a smart, fast, and 
antibody-independent test for functional GPCR expression. Therefore, primary bovine 
chondrocytes, the glioblastoma cell line U87 MG and two breast cancer cell lines, MDA-
MB-231 and MCF-7, were tested in a calcium assay for functional NK1R expression. The 
CHO-NK1R cells served as a positive control. The assay was performed exactly as described 
in Chapter 6. 
Neurokinin-1 receptor immunostaining of bovine 
cartilage and DBA-1J mouse joint cryosection slices 
In the final NK1R expression experiment, chondrocytes with artificially induced arthritis in 
two different 3D models were used. The first was a bovine in vitro model, which was 
developed by Johanna Lempp, and the second was the well-established murine DBA-1J 
in vivo model with type II collagen-induced arthritis [25]. For the bovine in vitro model, 
cylindrical punches from the patella cartilage were incubated with the inflammation factors 
IL-1α and OSM in CCM media to obtain directed cartilage destruction [24]. In contrast to 
soft bovine cartilage tissue punches, the mouse joints had to be subjected to a preliminary 
decalcification step to soften the bones for tissue slice preparation. Therefore, the dissected 
knee joints of 16-week old DBA-1J mouse were fixed for 48 hours in 4% PFA solution and 
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washed two times with PBS buffer. Then the bones were softened by RDO rapid decalcifier 
(Apex Engineering Products Corporation, Aurora Illinois) over three days. The knee joints 
were then subjected to 20% sucrose and 5% fixing gel (Tissue-Tek® O.C.T. Compound 
medium) in DPBS overnight for cryoprotection. The bovine chondrocyte punches and mouse 
joints were separately embedded in fixing gel (Tissue-Tek® O.C.T. Compound medium) in 
Cryomold® trays (Sakura Finetek, Alphen aan den Rijn, The Netherlands) and frozen in 
liquid nitrogen cooled isopentane. Tissue slices of bovine cartilage of 10 µm thickness and 
8 µm slices of DBA-1J mouse knee joints were produced at a Microm HM550 cryostat 
microtome (Thermo Scientific, Darmstadt, Germany) and transferred on SuperFrost® Plus 
microscope specimen slides and air dried. The tissues were rehydrated three times with 
DPBS and surrounded with a hydrophobic ImmEdgeTM pen (Vector Laboratories, Inc., 
Burlingame, California). Each tissue section was blocked for 45 min with a blocking 
solution, consisting of 10% BSA, 10% goat serum in DPBS. For the bovine cartilage punches 
only, additional 10% FCS were used for blocking. The slices were washed three times with 
PBS for 5 min. The primary NK1R specific antibody (Novus Biologicals, Littleton, 
Colorado, USA) was diluted to 10 µg/ml in 1% BSA in DPBS for bovine cartilage and in 
1% BSA with 0.1% Tween 20 in DPBS for mouse knee joints and transferred onto the tissue 
sections and incubated at 4°C overnight. Controls without primary antibody were treated the 
same. The next day, the sections were made permeable by washing three times in 0.3% triton 
X-100 in DPBS for 5 min. Then the secondary Alexa Fluor 546 goat anti-rabbit IgG (H+L) 
was administered in a final concentration of 20 µg/ml, diluted in 1% BSA in DPBS onto 
bovine cartilage and 4 µg/ml in 1% BSA with 0.1% Tween 20 in DPBS onto mouse joints 
and incubated for at least 1.5 hours in a wet chamber at room temperature protected from 
light. All slices were washed again three times for 5 min in 0.3% triton X-100 in DPBS and 
one time in pure PBS. Then the slices were covered with one droplet of Mowiol-Mounting 
medium with 0.1% DABCO (1,4-Diazabicyclo[2.2.2]octane) and finally capped with a 
cover slip. Chondrocytes´ nuclei were stained with 0.2 µg/ml DAPI diluted in 500 µl 
Mowiol/DABCO. Microscopy fluorescence images were captured with an Axiovert 200 
fluorescence microscope (Zeiss, Jena, Germany), connected to an AxioCamHR camera. The 
63x objective was used and the samples were lightened by a mercury-vapor lamp for 300 ms 
using the Alexa Fluor 546 reflector and 1 ms using the DAPI reflector. 
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Results and discussion 
RT-PCR for NK1R expression analysis upon interleukin 
stimulation 
That inflammatory factors have a direct influence on substance P and NK1R expression in 
tumor cells is well documented in the literature. In this context, it has been shown that an 
inappropriate expression or regulation of tachykinin receptors on tumor cells, including the 
NK1R, contribute to tumor growth and invasion by autocrine stimulation [7,17,22,26]. 
Therefore, mRNA expression analysis studies of the NK1R upon IL-1β stimulation of 
U87 MG glioblastoma, MDA-MB-231 breast cancer cells, and bovine chondrocytes in 2D 
cell culture were performed. The results of these experiments suggested that the receptor 
expression was influenced in a time- and concentration-dependent manner of interleukin 
stimulation (Figure 2). 
 
Figure 2: Stimulation of U87 MG glioblastoma cells (pass. 133) and MDA-MB-231 breast 
cancer cells (pass. 93) with 4 ng/ml human IL-1β and primary bovine chondrocytes with either 
10 ng/ml human IL-1α or IL-1β in 2D culture. The human NK1R was influenced by IL-1 in a 
time- and concentration-dependent manner. Long-term stimulation ≥3 hours resulted in NK1R 
down-regulation. NK1R bands were detected at 666 bp (human) and at 338 bp (bovine). 
 
For U87 MG, it was found that 3 hours of 4 ng/ml IL-1β stimulation were ideal to reach a 
slight increase in NK1R expression after a preliminary receptor mRNA down-regulation 
within the first hour of stimulation. This effect could be circumvented by increasing the 
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IL-1β concentration to 10 ng/ml. In MDA-MB-231 cells, the highest NK1R expression was 
observed after 1 hour of stimulation with 4 ng/ml. In contrast to U87 MG cells, the increase 
of IL-1β to 10 ng/ml completely inhibited NK1R expression in MDA-MB-231 cells. This 
observation of NK1R down-regulation for long-term IL-1β stimulation was also made by 
Johnson & Johnson for human astrocytoma cell line UC11 [27]. For bovine chondrocytes, it 
was found that equivalent to the other IL-1β treated cell lines, an increase of the stimulation 
period up to 24 hours for either IL-1α or β lead to a decrease in NK1R mRNA. It should be 
noted that, in contrast to the human NK1R RT-PCRs, where specific bands were detected at 
666 bp, the bovine NK1R primers were not specific and multiple bands occurred beside the 
expected band at 338 bp (Figure 2). 
RT-PCR and qPCR for MMP-1 and MMP-13 expression 
analysis upon substance P stimulation 
To investigate whether there is a concentration-dependent effect of substance P on MMP-1 
and MMP-13 expression in bovine chondrocytes, which were also stimulated with IL-1β, 
various substance P concentrations from 1 nM up to 3 µM in FCS free medium were tested 
within a stimulation period of 24 hours. In addition, a further look was taken at the effect of 
spantide I (SP I) in 10-fold excess as a competitor for substance P and NK1R antagonist. In 
a preliminary classical RT-PCR, it was found that MMP-1 expression levels seem to be 
influenced by varying substance P concentrations (Figure 3). 
 
Figure 3: Stimulation of bovine chondrocytes in 2D cell culture with different substance P 
concentrations. MMP-1 was detected at 178 bp and MMP-13 at 128 bp. Band intensities are 
not related to GAPDH expression. 
 
For a look in detail, a quantitative real-time PCR was performed and mRNA levels were 
normalized to GAPDH mRNA expression levels (Figure 4). The results indicated that 
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MMP-1 and MMP-13 mRNA expression significantly decrease with increasing substance P 
concentrations up to 300 nM, whereas MMP levels significantly increased by 1 µM 
substance P stimulation. For MMP-13 in particular, a significantly higher expression could 
be measured for 1 µM substance P stimulation compared to non-stimulated chondrocytes. In 
addition, it was found that if the NK1R inhibitor spantide I was added in a concentration of 
10 µM, the MMP expression could be suppressed, which indicate a direct influence of NK1R 
mediated regulation of MMP expression. With a higher substance P concentration of 3 µM, 
the MMP expression could be down-regulated significantly. 
 
Figure 4: Quantitative real-time PCR of chondrocytes´ MMP-1 and MMP-13 mRNA 
expression upon stimulation with different substance P concentrations within 24 hours. 
 
In further RT-PCR experiments, the influence of incubation time of substance P stimulation 
on MMP-1 and MMP-13 mRNA expression levels in bovine chondrocytes in 2D cell culture 
were investigated (Figure 5). Here, a constant substance P concentration of 1 µM in FCS 
free medium was used for stimulation within a time frame of 48 hours without substance P 
renewal. 
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Figure 5: Stimulation of bovine chondrocytes in 2D cell culture with 1 µM substance P for 
48 hours. MMP expression levels were examined. 
 
In a quantitative real-time PCR, it was found that there are no significant changes for MMP-1 
and MMP-13 expression levels during a stimulation period of 12 hours. Only after 24 hours 
substance P stimulation was a significantly higher MMP-13 expression detected, which 
decreased again to the basal expression level after 48 hours (Figure 6). 
 
Figure 6: Quantitative real-time PCR of chondrocytes´ MMP-1 and MMP-13 mRNA 
expression upon substance P stimulation over 48 hours. After 24 hours, there is a significant 
change in expression of MMP-13, but not for MMP-1. After 48 hours, the MMP-13 expression 
decreases again to the basis mRNA level. 
Identification of target cell candidates with NK1R expression Chapter 3 
 
 
 
- 40 - 
Neurokinin-1 receptor immunostaining 
NK1R immunostaining experiments were carried out for CHO-NK1R cells as a positive 
control and for the tumor cell lines U87 MG and MDA-MB-231 with and without 
preliminary 4 ng/ml IL-1β stimulation over 3 hours and 1 hour, respectively (Figure 7). It 
was found that there is specific FITC fluorescence detectable for both tumor cell lines, but 
less compared to the positive CHO-NK1R control (Figure 7A, B, D). In addition, no 
significant changes in fluorescence intensity could be observed for IL-1β stimulated cells, 
which indicated no difference in functional receptor expression (Figure 7C, E). U87 MG 
cells particularly seem to suffer from IL-1β stimulation, which resulted in an increasing 
number of cell debris and are detectable as bright shining green spots (Figure 7C). The used 
primary antibody does not discriminate between the full-length and the intracellular 
C-terminal truncated NK1R version because it is able to bind to an extracellular N-terminal 
binding domain of the NK1R. Therefore, even with the presence of any NK1R version, a 
positive staining is yielded. 
 
Figure 7: NK1R immunostaining of different cells. Compared to CHO-NK1R cells (A), there is 
less receptor staining for U87 MG and MDA-MB-231 tumor cells (B, D). U87 MG cells suffered 
from 3 hours IL-1β stimulation (C), since many cell debris in the form of bright shining green 
spots were visible. For both tumor cell lines, there is no significantly different receptor staining 
between unstimulated (B, D) and IL-1β stimulated (C, E) cells. 
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Fura-2 AM calcium assay 
In a functional calcium assay, only about 2% of the maximum reached calcium signal 
(obtained by the positive CHO-NK1R cell line) was measured for bovine chondrocytes and 
for the tumor cell lines U87 MG and MDA-MB-231 upon stimulation with 1 µM substance 
P. The literature mentions that the binding affinity of substance P to the extracellular 
N-terminal region is 10-fold reduced for the truncated NK1 receptor version and elicits a 
strongly diminished or even absent calcium response because of the shortened C-terminus 
and therefore missing Gq-protein binding site [28,29]. The results of this experiment 
suggested that, although NK1R expression was detected for bovine chondrocytes, U87 MG, 
and MDA-MB-231 cells at the mRNA level, with and without IL-1 stimulation, the 
full-length receptor density is either too low or tends to be zero. Therefore, these cell lines 
are not useful for affinity studies with multivalently binding nanoparticles by calcium assays. 
For this reason, CHO-NK1R cells were used for further binding studies (Figure 8). 
 
Figure 8: All tested cells did not show a significant response to 1 µM substance P, compared to 
the positive CHO-NK1R control cells. The signal intensity is only about 2% of the maximum 
measured calcium signal. These data suggested that the NK1R is not present on the cell surface 
in an adequate receptor density to perform binding studies with multivalently binding 
nanoparticles. 
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Neurokinin-1 receptor immunostaining of bovine 
cartilage and DBA-1J mouse joint cryosection slices 
In bovine cartilage tissue slices, a slight specific NK1R immunostaining on chondrocytes 
could be identified, although the antibody was not yet tested for bovine specificity (Figure 
9). As functional neurokinin-1 receptors could not be detected on isolated bovine 
chondrocytes in 2D cell culture in a calcium assay, this experiment raised the hope of finding 
NK1Rs on chondrocytes within their natural extracellular matrix (ECM) environment. 
Another aspect is that chondrocytes in this model did not suffer from 2D cell culture related 
enzymatic treatments such as collagenase or trypsin, which could be one cause for GPCR 
loss. Nevertheless, in RA, cartilage becomes progressively destroyed by matrix-
metalloproteinase (MMP) triggered ECM degradation. This is due to the accumulation of 
inflammatory factors in the synovium, which are able to diffuse into cartilage to incite 
chondrocytes to produce MMPs, which in turn destroy the ECM and make it progressively 
leakier. In such a pathological state, chondrocytes will become increasingly accessible for 
nanoparticle-based treatment [24]. According to our current knowledge, antagonistic NK1R 
targeting could reduce or even stop chondrocyte derived MMP expression and could 
consequently prevent further cartilage destruction. 
 
 
Figure 9: NK1R immunostaining of chondrocytes in artificially destructed bovine cartilage 
tissue slices. Cell nuclei were DAPI-stained for orientation. 
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For DBA-1J mouse joints, no specific NK1R staining could be detected. The reasons for this 
could be manifold. The loss of GPCRs during the decalcifying procedure should not be 
overlooked, but also, the immunostaining conditions, in respect to antibody concentrations 
and incubation time, etc. could have been somehow inappropriate (Figure 10). 
 
Figure 10: Kryosections of DBA-1J mouse joints: A) Bright field with equivalent B) 
Background fluorescence picture. C) Immunostaining of NK1R with red secondary Alexa Fluor 
546 antibody against specific primary NK1R antibody. D) Control with only secondary 
antibody. There is no receptor staining visible for articular chondrocytes. Arrows: 1) joint 
space, 2) articular surface, 3) deep zone, 4) tidemark, 5) meniscus, 6) bone, 7) no specific red 
NK1R staining of articular chondrocytes in the articular surface and deep zone. 
 
Conclusion 
Based on the results of this chapter, it is concluded that the inflammatory factor IL-1β has a 
direct influence on NK1R expression levels in U87 MG glioblastoma and MDA-MB-231 
breast cancer cell lines and primary bovine chondrocytes in 2D cell culture. For U87 MG 
and MDA-MB-231 cells, it was found that the NK1R mRNA is upregulated within the first 
3 hours IL-1β stimulation, but down-regulated for long-term IL-1β stimulation. Here, less 
NK1R expression at the mRNA level was observed for MDA-MB-231 cells than for U87 
MG cells. In further experiments, a closer look was taken at the expression of functional 
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NK1Rs in the cellular membrane by NK1R immunostaining and substance P induced calcium 
influx measurements. For both cancer cell lines, the data indicated only low receptor density. 
In calcium experiments, which offered the opportunity to discriminate between a full-length 
(with G-protein binding site) and a truncated receptor version (without G-protein binding 
site), only about 2% of maximum reached calcium signal (obtained by the positive 
CHO-NK1R cell line) were measured for both cancer cell lines, U87 MG and MDA-MB-231. 
These results were quite disappointing because these non-transfected cells could not be used 
for further receptor binding studies of antagonist modified multivalent binding nanoparticles 
in fluorescence-based calcium assays. Nevertheless, NK1R mRNA was found in bovine 
chondrocytes, and the results of NK1R immunostaining in bovine cartilage tissue sections 
were quite promising. In addition, it could be demonstrated in 2D cell culture that IL-1β and 
substance P contribute together to the regulation of the chondrocytes´ surrounding ECM 
behavior by the selective regulation of MMP´s gene expression. In this context, it could be 
shown that MMP-13 in particular is regulated in a time- and concentration-dependent 
manner by substance P and can be antagonized by the specific NK1R antagonist spantide I, 
which lets assume that this intracellular signaling pathway is triggered via NK1Rs. This 
aspect is intriguing since the literature also mentions that MMP-13 has an impact on the 
progression of arthritis [30]. Finally, it is concluded that the short version of the NK1R may 
be more prominent on the surface of all tested cell types and offer the opportunity for NK1R 
targeting, specifically due to the impact on MMP regulation. Due to the lack of the 
C-terminal Gq-protein binding site of this truncated NK1R splice variant, no intracellular 
calcium signals were detectable. For this reason, the NK1R transfected CHO cells were used 
for further studies to predict the affinity of generated multivalent ligands. 
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Abstract 
Multivalent receptor binding nanoparticles represent one option to make cellular membrane 
receptor targeting more selective, more specific, and even more efficient. In some 
pathological states, certain GPCR types with relevant influence on cell behavior seem to be 
overrepresented on the cell surface. These kinds of GPCR offer a great potential to serve as 
target sites for cell treatment in the form of efficient receptor blockade by antagonists, which 
are immobilized on the outer shell of nanoparticles. The neurokinin-1 receptor (NK1R) is 
one of these GPCRs, which is expressed ubiquitously by cells in the body in the 
physiological state, but its expression increases rapidly onto immune competent cells in 
various autoimmune diseases (e.g. RA) or cancer. In particular, spantide I functionalized 
QDs, which are shielded by a PEG corona, would be a powerful nanoparticle-based 
theranostic tool to investigate the prevalence of the receptor at target sites with raising 
immune response and to study their anti-inflammatory and analgesic potential. Therefore, 
spantide I, which is an NK1R antagonistic peptide, was coupled to amino-PEG coated QDs. 
In this chapter, the favored ligand coupling strategy to QDs and their characterization are 
depicted. Finally, the particles were tested for specific interactions with CHO-NK1R positive 
cells.  
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Introduction 
Active GPCR targeting by nanoparticles decorated with bioactive ligands is a major topic in 
the nanomedicine field [1–4]. In cancer therapy, for example, a primary research goal for 
ligand coated nanoparticles is an accumulation in a controlled and selective manner to cells 
and tissues carrying a specific target above a threshold surface concentration [5,6]. This is 
in contrast to passive transportation of nanoparticles and their accumulation at the site of a 
tumor by leaky vasculature and poor lymphatic drainage based on EPR effect (enhanced 
permeability and retention). Besides effective receptor blockade by a multivalent binding 
mode with high avidity of antagonist coated nanoparticles, research has also focused on 
directed drug delivery into cells via endocytotic pathways [7]. In particular, the therapeutic 
index of multivalently binding nanoparticles, which are able to bind several target GPCRs 
simultaneously, will increase, while lowering systemic side effects, because off-target cells 
are left with lower surface GPCR coverage unaffected [7]. Not to be overlooked is the fact 
that repeating chemical patterns on the nanoparticle´s surface cause an increased risk of 
immune response. The challenge here is to find an ideal ligand-to-PEG ratio on the surface 
of the nanoparticle to reach multivalent binding effects on the one hand and long half-lives 
for the nanoparticles due to PEG derived stealth properties to minimize unspecific uptake on 
the other hand [8,9]. Since nanoparticles cannot easily cross the BBB [10], nanoparticle-
based antagonistic targeting of the NK1R is limited to peripheral target cells, e.g. of the 
peripheral immune system and peripheral pain transmitting nerve endings, which reside, for 
example, in the synovial membrane within the joint. It is expected that efficient multivalent 
antagonistic NK1R targeting would therefore offer great potential to reduce local 
inflammatory and pain symptoms in autoimmune diseases like RA, without unwanted side 
effects in the CNS. The nanoparticles of choice for the experiments in the present chapter 
were semiconductor QDs, due to their excellent optical properties and their great potential 
in biomedical fields [11]. In this work, spantide I, a peptide NK1R antagonist, was coupled 
to amino-PEG shielded QDs and tested for specific cell binding in in vitro tests with NK1R 
positive CHO cells. For QD coupling, a sulfhydryl group was introduced in the amino acid 
sequence of the peptide [12]. The chemistry used for spantide I coupling to amino-PEG 
shielded QDs and subsequent nanoparticle characterization are presented in this chapter. In 
this context, amino-PEG QDs from different companies were used for spantide I coupling 
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to investigate whether the source of nanoparticles has an impact on nanoparticle charge 
properties, on coupling efficiency, and finally on specific or unspecific binding to target 
cells.  
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Materials and Methods 
All chemicals were purchased from Sigma Aldrich (Taufkirchen, Germany) in analytical 
grade or higher if not stated otherwise. Dulbecco´s phosphate-buffered saline (DPBS) pH 7.4 
was composed of 1.5 mM KH2HPO4, 2.7 mM KCl, 138 mM NaCl. Nanoparticle binding 
buffer for FACS analysis was composed of 20 mM Tris, 150 mM NaCl, 2 mM CaCl2, 1 mM 
MgCl2, 1 mM MnCl2 and 10% FCS, pH 7.4. Ultrapure water was obtained from a Milli-Q 
water purification system (Millipore, Billerica, MA, USA). 
Dr. Ralf Schwandner (Amgen Research GmbH, BioPark Regensburg) kindly provide a 
stable transfected neurokinin-1 receptor expressing CHO cell line. Cells were grown in 
DMEM:F12 (1:1) medium with 1.2 g/l NaHCO3, 15 mM HEPES, 1% Penicillin-
Streptomycin, 10% FCS and 600 µg/ml hygromycin B (Carl Roth, Karlsruhe, Germany) 
supplementation. 
Peptide ligands, spantide I (D-Arg1, D-Trp7,9, Leu11)-Substance P, a neurokinin-1 receptor 
antagonist, and angiotensin I (1-9) trifluoroacetate salt, an agonistic precursor peptide for 
angiotensin II receptor targeting (AT1R), were ordered from Bachem (Bubendorf, 
Switzerland). 
Yellow to red emitting amino-PEG-QDs were ordered from different companies. 
Qdots® 655 ITK™ amino (PEG) CdSe/ZnS core shell QDs in 50 mM borate, pH 8.3, 
FWHM <30 nm, quantum yield >80% were ordered from Life Technologies/Thermo 
Scientific (Darmstadt, Germany). Orange amino (PEG) CdSe/ZnS core shell QDs 
(QSA-620) in water, FWHM <25 nm, quantum yield >50% and orange carboxy CdSe/ZnS 
QDs (QSH-620) were ordered from Strem Chemicals Inc. (Kehl, Germany) (Figure 1). 
Yellow amino (PEG) CdSe/ZnS core shell QDs (QSA-580) in water, FWHM <25 nm, 
quantum yield >50% and red amino (PEG) CdSSe/ZnS core shell QDs (QSA-665) in water, 
FWHM <35 nm, quantum yield >50% were ordered from Ocean NanoTech (San Diego, 
USA). 
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Figure 1: Yellow to red emitting QDs consist of a Cd(S)Se core and a ZnS shell. The organic 
layers are formed by a monolayer of oleic acid/octadecylamine (shown in orange) and a 
monolayer of amphiphilic polymer (shown in black). The thickness of the organic layer of 
carboxy QDs (Left: QSH-QDs) is 4 nm and for amino-PEG QDs (Right: QSA-QDs) is about 
6 nm, according to the manufacturer. The hydrodynamic size is 8–10 nm larger for carboxy 
QDs and 12–14 nm larger for amino-PEG coated QDs than their respective inorganic core sizes 
(Figures are adapted from Strem Chemicals Inc. product catalog and [13]). 
 
Nanoparticle modification for peptide coupling 
For ligand to amino-PEG-QD coupling, the heterobifunctional linker chemistry with 
sulfo-SMCC (Sulfosuccinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate) was 
used to make the particles reactive for covalent thiol group coupling [14]. The sulfo-NHS 
ester group of the sulfo-SMCC-linker reagent is an amine reactive group for QD activation 
against sulfhydryl-containing ligands. Such ligands can be coupled in form of a Michael 
addition reaction to the maleimide group (Figure 2). 
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Figure 2: Pattern of peptide and QD functionalization for thiol-free peptide ligands. Thiolated 
peptides were coupled in a Michael addition to maleimide functionalized PEGylated QDs. 
 
All reaction steps were carried out in LoBind Eppendorf tubes to minimize peptide and 
particle adsorption to the vial material. For a single coupling reaction, 160 pmol QDs were 
mixed with sulfo-SMCC linker reagent in 1000-fold excess. The reaction took place in a 
total volume of 200 µl in 50 mM borate buffer pH 8.5 for 1 hour at room temperature under 
gentle shaking. To separate unreacted sulfo-SMCC from activated QDs, a size exclusion 
chromatography with a disposable Sephadex G-25, PD-10 column (GE Healthcare, Munich, 
Germany) was performed. PBS buffer was used as mobile phase. Quantum dot fluorescence 
containing fractions were collected. 
Peptide thiolation for nanoparticle coupling 
Because there are no thiol groups in all neurokinin-1 receptor antagonists, e.g. spantide I and 
also angiotensin receptor agonists, e.g. angiotensin I and II, sulfhydryl groups were 
introduced using 2-iminothiolane (Traut´s reagent), which is reactive with α- or ε-amine 
groups (Figure 2). The Traut´s reagent can be used within a pH-range of 7–10 and preserves 
the positive charge of peptide ligands to keep them soluble. For one thiolation reaction, about 
2 mg peptide was weighted in a LoBind Protein Eppendorf tube and solubilized in 0.1 M 
borate buffer, 1 mM EDTA, pH 8.0 to a highly concentrated stock solution of 4 mM. The 
Traut´s reagent was diluted in the same borate buffer and subsequently added to the peptide 
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in 2.5-fold excess. The reaction was performed in a glass vial with a magnetic stirrer at room 
temperature for 24 h at pH 8.0. To avoid the formation of N-substituted iminothiolane, the 
product was acidified to pH 4.5 by adding a small volume of acetic acid. Afterwards the 
excess of not reacted 2-iminothiolane was removed by a 48 h dialysis. For this purpose, a 
1 ml Float-A-Lyzer® G2 dialysis unit with a molecular-weight cutoff (MWCO) of 
100-500 Da was used in 300 ml dialysis buffer. Two different acidic sodium acetate dialysis 
buffers were used. The first one consisted of 50 mM sodium acetate and 1 mM EDTA, 
pH 4.5 and the second one consisted of a 10-fold reduced sodium acetate concentration of 
5 mM. Each buffer was changed twice during 48 hours dialysis. 
Determination of peptide thiolation efficiency by RP-
HPLC 
To separate sulfhydryl-containing peptides from non-thiolated peptides, a gradient 
RP-HPLC was performed. A C18(2) column with 100 Å particle diameter and pore size of 
5 µm, 250x4.6 mm was used (Phenomenex, Luna®, Aschaffenburg, Germany). The mobile 
phase was a mixture of water + 0.1% TFA (A) and acetonitrile + 0.1% TFA (B). The gradient 
was run from 40% B to 60% B within 15 min and returned to 40% B within 7 min for 
thiolated spantide I and from 10% B to 70% B within 15 min and back to 10% B within 
7 min for thiolated angiotensin I. Prior to the sample injection, the system was run for 3 min 
with the initial mobile phase mixture. The oven temperature was set to 35°C and flow to 
1 ml/min. The peptides (spantide I and angiotensin I) were detected at 280 nm and 275 nm, 
respectively, because. 2-iminothiolan was detected via UV-Vis at 248 nm. 
Quantification of sulfhydryl groups via Ellman´s assay 
After dialysis and proof of Traut´s reagent complete removal by RP-HPLC, the amount of 
sulfhydryl groups was determined using an Ellman´s assay. The Ellman´s reagent (DTNB = 
5.5'-dithio-bis-[2-nitrobenzoic acid]) reacts quantitatively with free sulfhydryl groups in 
their reduced form. For sulfhydryl quantification, the resulting yellow product was detected 
at 412 nm. An L-Cysteine hydrochloride standard curve served for quantification. 
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Peptide ligand to nanoparticle coupling 
Prior to use of the peptide for QD coupling, 60 nmol of the thiolated peptide were reacted 
with 35-fold molar excess of the disulfide reducing agent tris (2-carboxyethyl) phosphine 
(TCEP) for 30 min under gentle shaking. In parallel, 6 to 12 nmol of reduced peptide were 
immediately added to Sulfo-SMCC activated QDs. The pH was checked and found to be at 
7.0-7.5 and the mixture was reacted for 1 h at room temperature. Unreacted maleimide 
groups were inactivated by adding 5 µl of 1:1000 diluted 2-mercaptoethanol to the reaction 
and reacted for a further 30 min. The following purification procedure consisted of 
alternating ultrafiltration and size exclusion chromatography steps. An Amicon 
ultrafiltration unit with an MWCO of 100 kDa (Millipore, Billerica, MA, USA) was used to 
remove unreacted peptide and 2-mercaptoethanol by centrifugation for 10 min at 1500xg, 
using a swinging rotor, followed by a size exclusion purification using a Sephadex G-25, 
PD-10 column (GE Healthcare, Munich, Germany) and a further equivalent ultrafiltration 
step. The resulting concentrated sample was quantified by fluorescence measurement in 
96-well plate format, calibrated against unreacted QD dilutions, using a FluoStar Omega 
fluorescence microplate reader (BMG Labtech, Ortenberg, Germany). Depending on the 
QDs used, various excitation and emission wavelengths were used. 
Agarose gel electrophoresis 
The peptide ligand modification of amino-PEG coated QDs was followed by agarose gel 
electrophoresis, which is a common strategy to characterize the electrophoretic mobility of 
nanoparticles due to their PEG shell size and charge characteristics. Therefore, a 0.5% 
agarose gel was prepared in basic TAE buffer. In each gel pocket, 1 pmol of QD sample was 
loaded before and after ligand functionalization. The electrophoresis was run at 80 Volt in 
TAE buffer for 2 hours. In the case of smaller and more mobile carboxy-QDs (QSH-620) 
without PEG coating, the gel was run for only 10 min. The localization of QDs in the gel 
was observed by UV illumination. 
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TEM images of quantum dots before and after coupling 
2 x 1 µl of 60 mM QD solution in water were fixed on TEM grids. Although QDs show high 
self-contrast, they were stained with 2 x 1 µl 1% phosphotungstic acid, pH 7. 
Zeta potential 
Zeta potential measurements were performed with dynamic light scattering using a Zetazizer 
instrument (Malvern, Herrenberg, Germany). The QDs were diluted in water and filled in a 
clear disposable zeta potential cuvette. 
Flow cytometry analysis for nanoparticle binding and 
uptake 
Red (QSA-665) or yellow (QSA-580) QD samples (Ocean NanoTech, San Diego, CA, USA) 
in 20 nM concentation, either spantide I-modified with and without antagonist excess for 
nanoparticle displacement (10 µM spantide I or 10 µM aprepitant) or non-modified QDs as 
a check for unspecific binding were diluted in binding buffer. CHO-NK1R positive cells 
were seeded in a 24-well plate in a cell density of 106 and grown for 48 hours. The cells were 
washed with warm DPBS and then incubated with pre-warmed nanoparticle solutions for 
1 hour at 37°C, with 5% CO2 for nanoparticle binding and uptake. The solutions were 
aspirated and the cells were washed with warm DPBS, harvested by trypsinization for 5 min 
at 37°C. After adding the double volume of 10% FCS in Leibovitz, the cell suspensions were 
spun down at 200 g for 5 min at 4°C. Cell pellets were washed with ice cold DPBS and 
centrifuged again at 200 g for 5 min at 4°C. For FACS analysis, the cells were resuspended 
in cold PBS and stored on ice until measurement at a FACSCalibur flow cytometer (Becton 
Dickinson, Franklin Lakes, NJ, USA). Red QSA-665 and yellow QSA-580 QDs were 
excited at 488 nm and emission was detected in the FL3 channel with a 670 nm longpass 
filter for red and FL2 channel with a 585 nm/42 nm band-pass filter for yellow QDs. Flow 
cytometry data were analyzed by Flowing Software version 2.5 (Turku Centre for 
Biotechnology, Turku, Finland). The geometrical mean of fluorescence values was 
determined for 105 counts from fluorescence histograms and the background was corrected 
by control cells without QDs. One-way analysis of variance (ANOVA) statistical analysis 
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was carried out with SigmaPlot 12.5 with pairwise multiple comparison procedures (Holm-
Sidak method) with P<0.05. 
Fluorescence microscopy for nanoparticle binding and 
uptake 
The unmodified and spantide I-modified QDs were tested for cellular binding and uptake by 
fluorescence microscopy and to determine whether a competing free antagonist reduces cell 
binding. CHO-NK1R positive transfected cells were seeded into 8-well microscopy µ-slides 
(Ibidi, Martinsried, Germany) at a cell density of 105 cells per well and grown for 48 hours 
at 37°C and 5% CO2. After washing the cells with warm DPBS, pre-warmed 10 nM QD 
samples in Leibovitz´s medium supplemented with 0.1% BSA were added onto the cells and 
incubated for 1 hour at 37°C and 5% CO2. The cells were washed with DPBS and finally 
covered with Leibovitz´s medium for microscopy with a Plan-Apochromat 63x/1.4 Oil 
objective of a Zeiss Axiovert 200 microscope with heating unit and an LSM 510 laser-
scanning device (Zeiss, Jena, Germany). Quantum dots were excited with a 488 nm argon 
laser and emission was detected using a band-pass filter 560-615 nm. 
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Results and discussion 
Determination of thiolation efficiency of spantide I and 
angiotensin I by gradient RP-HPLC 
After one hour of thiolation of spantide I, only 19.5% of total peptide contained a thiol group 
(Figure 3). Therefore, the thiolation reaction was prolonged to 24 hours. After removal of 
unreacted 2-iminothiolan by dialysis, the yield of thiolated peptide increased to 59%. The 
removal of unbound 2-iminothiolan is an essential step, since it is known that Traut´s reagent 
interacts with Ellman´s detergent and distorts thiol quantification by Ellman´s assay. 
 
Figure 3: Comparison of gradient RP-HPLC of spantide I after 1 hour and 24 hours thiolation. 
The gradient run took 15 min from 40% acetonitrile to 60% with 0.1% TFA. Spantide I was 
detected by tryptophan absorbance at 280 nm. Peak integration for total peptide and only 
thiolated peptide give information about thiolation efficiency and offers the opportunity to 
compare with data obtained from Ellman´s assay. After 24 hours thiolation the proportion of 
thiolated to non-thiolated spantide I shifted to the thiol-product side. 
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The quantification of peptide was accomplished by integration of free spantide I in different 
concentrations to get a standard curve out of the area calculated under the curves. Reacted 
spantide I was run with the same gradient integrated in the same manner to calculate total 
peptide amount, thiolated, and non-thiolated spantide I. The chromatogram of the thiolated 
spantide I sample was integrated after 24 hours from minute 8.5 to 10.5 to calculate thiolated 
peptide amount and relate it to total peptide amount by integration from minute 6.5 to 10.5 
(Figure 3). It was found that 59% of total peptide contains thiol groups. 
For angiotensin I, 93% peptide related thiol groups were observed (Figure 4). Peak shoulders 
for spantide I indicated different peptide species with more than one thiol group, which was 
also confirmed by HPLC-MS analysis. In contrast, the thiolation of angiotensin I was very 
efficient and only mono-thiolated products were detected. 
 
Figure 4: Gradient RP-HPLC of angiotensin I after 24 hours thiolation and acidic dialysis. The 
gradient run took 25 min from 10% acetonitrile to 70% with 0.1% TFA. Thiolation efficiency 
is 93% for angiotensin I. Only one mono-thiolated product is formed. 
 
The gradient RP-HPLC offered a quality check for the successful removal of unreacted 
Traut´s reagent and unwanted cyclic N-substituted 2-iminothiolane at an absorbance of 
248 nm (Figure 5). Compared to the thiolated product without acidic dialysis, there is no 
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unbound and N-substituted 2-iminothiolane present after 48 hours acidic dialysis. Therefore 
an acidic dialysis is highly recommended to reach a pure thiolated product on the one hand 
and to hydrolyze N-substituded 2-iminothiolane products to prevent the loss of sulfhydryl 
groups due to ring formation at basic pH values on the other hand [15]. 
 
Figure 5: Dialysis is an efficient method for removing unreacted Traut´s reagent and avoiding 
the formation of N-substituted 2-iminothiolane. Thiolated spantide I, before and after dialysis 
was detected at 248 nm and free 2-iminothiolane was detected at 220 nm. 
 
Thiol group quantification by Ellman´s assay 
The differential spectra of Ellman´s reagent reacted thiolated spantide I and angiotensin I 
showed that, after acidic dialysis, the absorbance maximum at 248 nm is drastically 
decreased and the tryptophan absorbance peak at 280 nm becomes more prominent for 
spantide I (Figure 6). In contrast, the absorbance peak at 412 nm is lowered, which is also a 
hint for the successful removal of unreacted 2-iminothiolane by the dialysis process. The 
quantified thiolated peptides were used for the coupling reaction with Sulfo-SMCC activated 
amino-PEG coated QDs. 
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Figure 6: Differential spectra of spantide I and angiotensin I samples reacted with Ellman´s 
reagent. Thiols were quantified at 412 nm by using an L-Cystein hydrochloride standard curve 
(0.25 to 1.5 mM). Unreacted 2-iminothiolane can be successfully removed by acidic dialysis. 
 
Nanoparticle characterization by gel electrophoresis 
Small negatively loaded and not PEGylated Carboxy-QDs run, because of their negative 
surface charge, within a short time frame of 10 min to the positive pole; they were detected 
as a narrow band (Figure 7). Amino-PEG modified QDs were able to run in both directions 
of the gel, depending on their PEG shell properties [16]. This would be expected, since low 
molecular weight amino-PEG chains cannot completely cover underlying negatively 
charged carboxy groups on the QD core and run, therefore, like pure Carboxy-QDs to the 
positive pole, but with less speed. With an increasing PEG chain length, these negatively 
charged carboxy groups become counterbalanced by the charge properties of amine groups 
at the ends of PEG chains and the QDs move to the negative pole. If peptide ligands are 
coupled to amine groups of QDs, the charge and size properties change, and the particles 
consequently move differently in the gel, compared to unmodified QDs. The literature 
mentions that the movement in the gel is pH independent [17]. Amino-PEG QDs of different 
distributors (Life Technology, Strem Chemicals Inc., and Ocean NanoTech) show different 
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characteristics. Life Technology QDs have a lower PEG density, compared to Strem 
Chemicals Inc. and Ocean NanoTech QDs. The latter have similar characteristics. 
 
Figure 7: Agarose gel electrophoresis (0.5% agarose). Amino-PEG QDs of different 
distributors showed different mobility properties within 2 hours at 80 V. Independent from 
coupled peptide (spantide I or angiotensin I) coupling, the moving directions were changed for 
QSA-620 QDs and red QSA-665 QDs, but not for 655 ITK™ QDs and yellow QSA-580 QDs. 
Smaller sized carboxy-functionalized QDs moved to the anode within 10 min. 
 
TEM images of quantum dots before and after coupling 
Based on TEM imaging, it was found, that only moderate aggregation occurs for amino-
PEG QDs after ligand coupling (Figure 8). A corona is visible for the PEGylated QDs, which 
could be due to the quite dense PEG shell, surrounding the dark QD core. The QDs show 
the expected core size of 10 nm. Carboxy QDs without PEG shell had a higher tendency to 
aggregate and were therefore not equally distributed, compared to amino-PEG-QDs. Also, 
for spantide I-modified QDs, islands of aggregated particles occurred (Figure 8). Since it is 
known that the ideal size for interaction with cells is 40–50 nm, QDs fit perfectly due to their 
hydrodynamic size in this size range [18]. 
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Figure 8: TEM images of amino-PEG QDs (Strem Chemicals Inc.), before and after 
modification with spantide I and naked carboxy QDs. 
 
Zeta potential 
All used unconjugated QD species had negative zeta potentials (Figure 9): Quantum dots 
from Strem Chemicals: Carboxy QDs: -46.5 mV ± 7.8 (according to manufacturer: -30 mV 
to -50 mV), amino-PEG-QDs: -5.6 mV ± 4.5 (according to manufacturer: -20 mV 
to +10 mV). Quantum dots from Ocean NanoTech: Red QSA-665 amino-
PEG-QDs: -5.9 mV ± 11.8 and yellow QSA-580 amino-PEG-QDs: -18.0 mV ± 5.9. After 
peptide ligand modification, the zeta potentials changed. Angiotensin I-modified QDs 
showed a more negative zeta potential of -26.8 mV ± 12.7 compared to unmodified 
amino-PEG-QDs, whereas spantide I-modified QDs tended to have less negative zeta 
potentials or even a positive potential, depending on the QDs used. For Strem Chemicals 
QDs, a zeta potential of 2.1 mV ± 7.0 was measured, and for red and yellow Ocean 
NanoTech QDs, potentials of 4.1 mV ± 7.6 and 5.4 mV ± 6.3 were observed, respectively. 
These findings were reasonable, as there is a gain of free carboxy groups for angiotensin I-
modified QDs because of the unprotected C-termini of the peptide ligands. This is not the 
case for spantide I, because of its amidation of the C-terminal amino acids and the higher 
content of positively charged amino acids like lysine and arginine. 
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Figure 9: Zeta potentials of unmodified amino-PEG-QDs are slightly negative and become 
more negative after angiotensin I coupling, whereas spantide I-modified QDs tended to have 
less negative zeta potentials or even a positive potential, depending on the QDs used. Non-
PEGylated carboxy QDs are shown as a control. 
 
FACS analysis 
For quantitative analysis of nanoparticle binding and uptake, different spantide I-modified 
QDs were tested by flow cytometry with CHO-NK1R cells (Figure 10). It was found that the 
red QDs, which have shown different mobility in agarose gel electrophoresis after ligand 
coupling have a significant specific receptor binding in contrast to yellow QDs, where the 
mobility in agarose gel electrophoresis was unchanged and indicated non-efficient spantide I 
coupling (Figure 7C). A high unspecific nanoparticle binding was observed for unmodified 
amino-PEG QDs. A phenomenon that was observed for all amino-PEG QDs obtained from 
different distributors. A simple explanation could be a charge dependent effect that is also 
mentioned by other working groups, in particular beside negatively charged particles for 
positively charged particles, compared to neutral particles [2]. 
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Figure 10: FACS analysis showed that spantide I-modified QDs can be displaced by the free 
NK1R antagonists spantide I and aprepitant, which indicated specific binding of red spantide I 
coated QSA-655 QDs. Yellow spantide I coated QSA-580 QDs showed the same tendency, but 
here the test for significance was negative, which could be explained by inefficient ligand 
labeling. The unspecific binding of unmodified QDs to CHO-NK1R cells is similar to NK1R 
specific binding of spantide I-modified QDs. 
 
Ligand specific uptake of peptide coupled quantum dots 
It is well known from literature data that unspecific QD uptake depends on particle size, 
charge, and shape, even if the particles are shielded by a PEG corona [19]. The data, obtained 
by fluorescence microscopy, showed that most particle fluorescence was obtained by 
unmodified amino-PEG QDs (Figure 11). This result confirmed the hypothesis for 
unspecific nanoparticle uptake, driven by free exposed amine groups on the nanoparticle 
surface [20]. One hurdle of such nanoparticle uptake studies is that it is quite difficult to 
discriminate between unspecific pinocytosis and receptor mediated internalization [19,21]. 
One method for detecting GPCR mediated nanoparticle binding and uptake is to perform a 
displacement experiment by the addition of a competitive free antagonist to the receptor 
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positive cells. In the present experiment, only a limited reduction of neurokinin-1 receptor 
mediated binding and uptake could be obtained by the addition of free spantide I to 
spantide I-modified QDs in the displacement study. 
 
Figure 11: Fluorescence microscopy images of QD uptake in neurokinin-1 receptor positive 
CHO cells. A high unspecific uptake was observed for unmodified amino-PEG-QDs (Strem 
Chemicals Inc.). NK1R-mediated binding could not be confirmed for certain by reduced 
nanoparticle binding if free ligand was added as a competitor to cells. 
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Conclusion 
The introduction of thiol groups into cystein-free peptide ligands is a common strategy for 
water-soluble ligands to couple them to maleimide functionalized nanoparticles, like QDs. 
It was found that thiolation reaction is quite efficient for the very hydrophilic angiotensin I, 
whereas it is highly reduced for spantide I, although there are two different modification 
sites for 2-iminothiolane. In other experiments (data not shown), zero thiolation was 
produced in the trial to introduce sulfhydryl groups in shorter and more hydrophobic spantide 
variants. In nanoparticle uptake experiments with receptor positive CHO-NK1R cells, high 
unspecific nanoparticle binding was examined for amino-PEG modified QDs. This 
unspecific binding was even stronger than the binding obtained for spantide I functionalized 
nanoparticles. In this context two aspects are discussed in the literature: Nanoparticle charge 
and PEG density seem to play a critical role for unspecific cell binding capacity. Here in 
particular, free amino-PEG groups showed high unspecific binding to cells. Unspecific 
nanoparticle binding strongly hampers the proof of concept of receptor mediated multivalent 
nanoparticle binding and uptake by GPCR. However, it could be shown in FACS 
displacement experiments with high concentrations of free competing antagonists that 
nanoparticle binding was inhibited, which indicates receptor mediated nanoparticle binding. 
The low thiolation efficiency for the peptide could be the main reason for a resulting low 
nanoparticle coupling propensity. In addition, double thiolated peptides could also be the 
reason for low ligand densities on the surface of nanoparticles. This also minimizes the 
chance for multivalent interactions. Since the C-terminal receptor interacting part of the 
peptide mainly consists of hydrophobic amino acids, there is also the chance for ligand 
inversion inside the PEG shell, a phenomenon that is also discussed for highly hydrophobic 
small non-peptide receptor antagonists [22]. 
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Supplementary information 
Excitation and emission spectra of the QDs, which were used in the FACS binding studies 
show, that there are no spectral shifts after ligand modification, which could have influenced 
the fluorescence properties (Figure 12 and Figure 13). 
 
 
Figure 12: Excitation and emission spectra of yellow QSA-580 QDs before and after spantide I 
coupling. There are no spectral differences. 
 
 
Figure 13: Excitation and emission spectra of red QSA-665 QDs before and after spantide I 
coupling. There are no spectral differences. 
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The challenge of site-specific ligand PEGylation in 
the synthesis of multivalently binding drugs 
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Abstract 
Multivalent binding drugs can be designed using different scaffolds for individual 
modification with multiple equal or different ligand types, which are then able to bind 
multiple over-expressed GPCRs at the same time with high avidity. Examples for such 
scaffolds are branched PEGs, for example 8armPEGs or PEG-coated nanoparticles. The 
requirements for PEG scaffolds are that they have appropriate functional groups for ligand 
coupling on the one hand, and on the other hand that their chain lengths are ideal to reach 
multiple receptors in the cell membrane. The first requirement involves several challenges, 
which include that the PEG reaction site should be not localized in the receptor interacting 
region of the ligand and the PEGylation should be site-specific to hold the ligand´s binding 
affinity loss at a minimum. In this context, it was demonstrated, based on spantide I, a 
neurokinin-1 receptor peptide antagonist, that PEGylation can radically change the ligands´ 
binding properties to its receptor. It was found that, due to two possible reaction sites, double 
PEGylations occur if the PEG is used in excess. Besides changing the peptide to PEG ratio 
to the side of peptide excess, it is also possible to use protective groups to prevent double 
PEGylation. Interestingly, it was discovered that some peptide antagonists also show 
different agonistic potentials upon PEGylation in aequorin based luminescence calcium 
assays. Furthermore, it was found that the N-terminal region beside the C-terminal region 
seems to be somehow essential for receptor recognition and binding since truncation of the 
peptide also led to a loss in affinity. 
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Introduction 
The conjugation of peptides and proteins to PEG is established as a common strategy to alter 
the pharmacokinetic profiles of drugs, and thereby improve their therapeutic potential [1]. 
There are several advantages of PEG conjugation: The circulation of drugs is prolonged 
because of the protection against enzymatic digestion, the filtration by the kidneys is slowed 
down and fewer neutralizing antibodies are generated [2–4]. One challenge of drug 
PEGylation is to overcome random multiple PEGylation to prevent a total efficacy loss of 
the drug due to steric interference with the drug-target binding interaction [5,6]. Multiple 
PEGylation takes place if more than one functional group for PEG coupling is present in the 
chemical structure of the drug molecule [7]. In the case of linear PEG chains, this would 
result in a substantial affinity loss, greater than for mono-PEGylated products. For branched 
PEG polymers, there is the additional aspect of intra- and intermolecular cross-linking. This 
fact should also be considered when drugs are coupled to the PEG chains of nanoparticles, 
like PEG-coated QDs. Multiple reaction sites for the PEG chains to one drug molecule result 
in a decreased drug modification rate of the particle on the one hand, which means a 
decreased number of ligands per particle; on the other hand, particle aggregation as a result 
of cross-linking can occur. These observations were made for different peptide ligands, such 
as the neurokinin-1 receptor. For example, besides its N-terminal α-amine group, spantide I 
also has an ε- amine group of a lysine side chain, which is likely to couple to NHS-ester 
functionalized PEGs. Single PEGylated products are gained either by use of an excess of 
free peptide ligand or by introducing a protective group for the N-terminal amine group, by 
acetylation, for example. If the N-terminal lysine containing part of the peptide ligand is not 
mandatory for receptor binding, it is also possible to use truncated peptide molecules. Both 
strategies have some disadvantages. For the first strategy, there is the need for a very efficient 
purification strategy to remove the excess of unreacted peptide ligands, which could cause 
interference in affinity measurements and disturb uptake experiments because free 
molecules compete with particle bound molecules. For the second strategy, missing 
positively charged residues cause the loss of solubility, which make chemistry in aqueous 
solution impossible. In summary, this chapter addresses chemical challenges concerning 
changes in the peptide´s amino acid composition, the covalent coupling of a PEG chain, and 
the influence of these chemical modifications on the biological activity the drug. 
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Materials and methods 
All chemicals were purchased from Sigma Aldrich (Taufkirchen, Germany) in analytical 
grade or higher if not stated otherwise. Dulbecco´s phosphate-buffered saline pH 7.4 
consisting of 1.5 mM KH2PO4, 8 mM Na2HPO4, 2.7 mM KCl, and 138 mM NaCl was 
purchased from Life Technologies/Thermo Scientific (Darmstadt, Germany). Full-length 
peptides, substance P-methyl ester and spantide I, were ordered from Bachem (Bubendorf, 
Switzerland). Short peptide versions (GlyShortSP I, LysShortSP I, and AcLysShortSP I) 
were synthesized by Synpeptide Co., Ltd. (Shanghai, China), see Table 1. 
Table 1: Neurokinin-1 receptor agonists and antagonists 
Peptide Sequence 
substance P-methyl 
ester H-Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-OMe 
spantide I H-D-Arg-Pro-Lys-Pro-Gln-Gln-D-Trp-Phe-D-Trp-Leu-Leu-NH2 
GlyShortSP I Gly-Pro-Gln-Gln-D-Trp-Phe-D-Trp-Leu-Leu-NH2 
LysShortSP I Lys-Pro-Gln-Gln-D-Trp-Phe-D-Trp-Leu-Leu-NH2 
AcLysShortSP I Ac-Lys-Pro-Gln-Gln-D-Trp-Phe-D-Trp-Leu-Leu-NH2 
 
Peptide truncation 
There exist several N-terminal truncated short-version peptides of the neurokinin-1 receptor 
agonists and antagonists, so-called C-terminal fragments [8]. In particular, the short agonist 
versions of substance P (hexa(6-11)-, hepta(5-11)- and octa(4-11)-substance P) show 
equipotent or even more potent binding characteristics than the full version peptide [9,10]. 
This strengthens the assumption that the N-terminal peptide region is not essential for 
The challenge of site-specific ligand PEGylation Chapter 5 
 
 
 
- 77 - 
neurokinin-1 receptor recognition and activation. Based on this fact, spantide I was modified 
in various ways to prevent double PEGylated products due to two possible PEGylation sites 
at the N-terminal α-amino group and ε-amino group of the lysine residue at position 3. One 
strategy was to eliminate the lysine residue through shortening the peptide sequence up to 
proline and replacing lysine with glycine for only the α-amino group. A further strategy was 
to keep the lysine group and protect the N-terminal amino acid with an acetyl group 
(Figure 1). All used peptides are listed in Table 1. 
 
 
Figure 1: N-terminal peptide modification to prevent double PEGylated products. Spantide I 
was either truncated (positions are indicated by the scissors) or acetylated at the N-terminal 
amino group. 
 
Peptide PEGylation: Coupling of peptides to linear and 
branched PEGs 
It is known that the highly conserved and for receptor binding essential region of most 
peptide ligands for the neurokinin-1 receptor is located in the C-terminus of the peptide 
amino acid sequence. Therefore, a PEGylation strategy for amine-directed PEGylation was 
chosen. Using NHS-ester activated PEG-derivatives is a preferred chemistry for obtaining 
the modification of primary amines. Various commercially available functionalized PEGs 
are available on the market, such as various sized linear PEGs and branched multi-armPEGs, 
which could act beside different nanoparticles as scaffolds to obtain star-shaped 
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multivalently receptor binding antagonists after ligand coupling to the end of each PEG-arm 
[11–13] (Figure 2). These 8armPEGs consist of a hexaglycerol core structure synthesized by 
ethoxylation of hexaglycerol (JenKem Technology, Plano, Texas, USA). Succinimydyl 
succinate functionalization for 8armPEG20k was performed by Susanne Kirchhof, 
according to [14] and for mPEG5k by Luise Tomasetti from the Department for 
Pharmaceutical Technology (Universität Regensburg). For later synthesis, mPEG5k-NHS 
ester was bought from Rapp Polymere (Tuebingen, Germany). 
 
 
Figure 2: 8armPEG succinimidyl succinate with a hexaglycerol core structure. Arm chain 
length and final molecular weight are determined by the number of ethylene glycol units. 
 
For PEGylation with linear mPEG5k, various PEGylation conditions were tried to observe 
the influence on peptide PEGyglation in respect to multiple-PEGylated products by 
changing molar ratios and site directed α- or ε-amine group PEGylation by changing pH-
conditions from neutral to basic, respectively. For branched 8armPEGylation, the peptide 
concentration was generally used in excess (1:16) to prevent double PEGylation and cross-
linking and to yield high peptide to PEG ratios (Figure 3). For these samples, a sufficient 
purification procedure was obligatory to completely remove unreacted peptide ligands. The 
standard molar ratio for linear PEGylation was 1:2 for peptide to PEG to ensure total 
PEGylation of peptide ligands and to enforce, in some cases, double PEGylation, e.g. for 
spantide I and unprotected Lys-terminal Short-spantide I. The PEGylation reactions were 
performed in 50 mM filtered borate buffer, pH 8.5. In one trial, this borate buffer was further 
adjusted with 1 M HCl to pH 7.0. Both components, peptide and PEG, were solubilized in a 
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high concentrated solution in the correspondent borate buffer and mixed 1:1 to the final 
concentrations of 4 mM linear PEG to 2 mM peptide. And in case of 8armPEG20k, 0.21 
mM branched 8armPEG20k to 3.36 mM spantide I. The reactions were stirred overnight at 
room temperature in a thin glass vial. The reaction products were purified by size exclusion 
chromatography with a Sephadex-G25 column, PD-10 (GE Healthcare, Freiburg, Germany). 
The collected fractions were analyzed by a combination of tryptophan absorbance and 
emission measurements; also, PEG staining with iodine crystals in a TLC chamber was 
performed in parallel by pipetting 2 µl of each fraction on a TLC plate. The early eluting 
fractions, containing both peptide and PEG, were pooled and further purified by several 
ultrafiltration steps. Because of the high hydration capacity of PEG (two H2O molecules per 
PEG unit), an MWCO of 10 kDa could be used for linear mPEG5k-peptide conjugates 
because their hydrodynamic radii increase up to 5- to 10-fold [2]. The same MWCO was 
used for branched 8armPEG20k-peptide conjugates to remove the much smaller unbound 
peptide molecules easily and efficiently. 
 
Figure 3: Peptide amine groups were coupled to NHS-ester functionalized PEGs. PEGylation 
reactions were performed at room temperature under gentle stirring over approximately 
20 hours. For Lysine directed PEGylation, a basic borate buffer with pH 8.5 was used. 
 
Determination of peptide to PEG ratio for 8armPEG-
peptide conjugates 
To determine how many ligands are bound per branched 8armPEG molecule after in-depth 
purification, the peptide and PEG were quantified in two separate calibration curve based 
assays in a 96-well format. The peptide was quantified via tryptophan emission and PEG via 
Child´s assay [15]. The molar ratio was calculated out of the results of both assays. For PEG-
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quantification, 25 µl of a 0.1 N iodine solution (Carl Roth, Karlsruhe, Germany) were added 
to 50 µl of a 5% barium chloride solution in 1 M HCl, preloaded into a well of an absorbance 
well plate, were intensely mixed with 125 µl of PEG-sample (either PEG-standard or PEG-
peptide conjugate), and were reacted for 20 min at room temperature. The absorbance was 
then detected at 535 nm (Figure 4). 
 
 
Figure 4: Peptide to PEG ratios were determined in two separate quantification steps. The 
ratios represent the ligand coupling quality. 
 
PEG-peptide-conjugate analytics by RP-HPLC/HPLC-MS 
To confirm the success of PEGylation for linear methoxyPEG-peptide-conjugates, an 
HPLC-MS analysis was performed to separate modified from unmodified and single from 
double PEGylated products by HPLC and assign the average masses to each obtained peak. 
Because of an increasing polydispersity with higher molecular weights, the HPLC-MS 
analysis was not possible for branched 8armPEG-peptide-conjugates. Thus, a reverse phase 
high performance liquid chromatography (RP-HPLC) method was developed especially for 
branched 8armPEG-peptide-conjugates to confirm the successful peptide to PEG coupling 
on the one hand, and to have a proof for efficient elimination of unreacted peptide by SEC 
and multiple ultrafiltration steps on the other hand. A Shimadzu Class VP HPLC system, 
composed of a LC-10ATvp pump, an SIL-10ADvp auto injector, a CTO-10 ASvp column 
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oven, an RF-10AXL flurorescence detector, and an SCL-10Avp system controller was used 
(all components: Shimadzu Europe GmbH, Duisburg, Germany). A C18 column with 300 Å, 
5 µm (Vydac, 218 TP) was used as stationary phase for gradient elution within an optimized 
35 min program from 40% to 60% acetonitrile with constant 0.1% TFA within 25 min. The 
peptide was detected by excitation at 280 nm, measuring the emission at 340 nm. For the 
highly hydrophobic peptide GlyShortSP I, an isocratic method could be established, using 
40% acetonitrile and 60% water with constant 0.1% TFA. Both peptide and PEGylated 
peptide are eluting within 25 min (Figure 7). 
PEG-peptide-conjugate analytics by Tricine-SDS-PAGE 
PEGylation success for linear and even branched 8armPEG-peptide conjugates can be 
visualized also by a Tricine-SDS-PAGE, which is an SDS-PAGE with high resolution for 
especially small peptides. The method used was adapted from Hermann Schägger [16]. The 
gel consists of three superposed gels, with increasing acrylamide/bisacrylamide composition 
from the top to the bottom, starting with a 4% stacking gel, followed by a 10% spacer gel 
and a 16% separation gel. For each gel preparation, the appropriate volumes of 30% 
acrylamide solution (Rotiphorese® Gel A, Carl Roth) and 2% bisacrylamide solution 
(Rothiphorese® Gel B, Carl Roth) were mixed to obtain the desired polymer percentages. 
To start the radical polymerization, TEMED and 10% APS solutions were added. For the 
stacking and spacer gels, a 3x gel buffer was used for polymer dilution that consisted of 3 M 
tris, 1 M HCl, and 0.3% SDS, pH 8.45. An amount of 1 µg peptide or PEG was respectively 
loaded in separate gel pockets after mixing with a non-reducing loading buffer consisting of 
3% SDS (w/v), 30% glycerol (w/v), 0.05% Coomassie and 150 mM Tris, adjusted to pH 7 
with 1M HCl. For the gel electrophoresis, two buffers were used at the same time, separated 
by the inner and outer chamber of the gel chamber. The inner chamber was filled with a 
cathode buffer, consisting of 1 M Tris, 1 M tricine, 1% SDS, pH 8.25, which is the sample 
touching buffer while sample loading into the gel pockets. The anode buffer was made of 
1 M tris and 0.225 M HCl to reach a pH of 8.9. This buffer was filled in the outer gel 
electrophoresis chamber. The initial voltage was set to 30 V to allow the samples to penetrate 
into the stacking gel. After 40 min, the voltage was increased to 200 V and run for 1 h 15 min. 
After electrophoresis, the gel was rested for 20 hours in a fixing solution, consisting of 50% 
methanol, 10% acetic acid, and 100 mM ammonium acetate, where the gel shrunk in size. 
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The Coomassie staining was performed in 0.025% Coomassie G-250 with 10% acetic acid 
for double the fixation time. Then the gel was bleached for 1 hour in 10% acetic acid and 
transferred to water. For subsequent iodine staining, the Coomassie stain was removed with 
50% methanol in 50 mM ammonium hydrogen carbonate and washed several times in water. 
The iodine staining was obtained by 10 min incubation in 5% barium chloride solution and 
15 min in iodine solution and 5–10 min in water. 
Circular dichroism for peptide “secondary structure” 
determination 
To exclude changes in the peptide conformation upon PEGylation, which could influence 
the peptide´s ability to bind into the receptor binding pocket, circular dichroism 
measurements were performed before and after PEGylation in water solution. The 
measurement took place under 6 l/min nitrogen flow and below 600 V high tension voltage 
of the lamp in the far UV region from λ = 250 – 190 nm, using a 2 mm quartz cuvette with 
a Jasco J-810 CD spectropolarimeter (Spectroscopic Co. Ltd, Tokyo, Japan). The obtained 
spectra were smoothed with a Savitzky-Golay algorithm, and the mean molar ellipticity was 
calculated. 
ߠ ൌ 	ܥܦ ∗ 100 ∗ ܯܹܿ ∗ ݀ ∗ ݔ  
Θ = mean residue ellipticity in deg*cm2*dmol-1 
CD = measured value in mdeg 
MW = molecular weight in kDa 
c = concentration in mg/ml 
d = layer thickness of cuvette in cm 
x = number of amino acids per protein/peptide 
Binding studies via Aequorin calcium assay 
Neurokinin-1 receptor ligand binding studies were performed with a stable transfected 
neurokinin-1 receptor expressing CHO cell line, which Dr. Ralf Schwandner (Amgen 
Research GmbH, BioPark Regensburg) kindly provided. Besides the neurokinin-1 receptor 
gene, these cells also carry on the same vector a gene for apoaequorin expression, which is 
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a useful tool for intracellular calcium detection and an antibiotic resistance gene against 
hygromycin B for positive clone selection. The vector used is a bicistronic internal ribosome 
entry site (IRES) vector (Clontech, California, USA), which allows the simultaneous 
expression of the neurokinin-1 receptor and the antibiotic resistance separately, but from the 
same RNA transcript, so there is almost no risk of a loss of receptor expression if cells are 
permanently kept in DMEM:F12 (1:1) medium with 1.2 g/l NaHCO3, 15 mM HEPES, 1% 
Penicillin-Streptomycin, 10% FCS and 600 µg/ml hygromycin B (Carl Roth, Karlsruhe, 
Germany) supplementation. The principle of calcium detection via an aequorin-derived 
luminescence, which is triggered by receptor mediated changes in intracellular calcium 
levels after addition of a coelenterazine derivative, was once established by 
EuroScreen [17,18]. 
High cell density frozen aliquots from 1*107 to 2*107 cells per ml were stored in FCS with 
10% DMSO in liquid nitrogen until use, a method to preserve cell viability up to 90%. One 
aliquot was thawed at the day of the calcium assay and directly resuspended in fresh CCM. 
DMSO was removed by centrifugation at 200xg. For intracellular calcium dependent 
apoaequorin activation, the cell penetrating luminescent substance coelenterazine (PJK 
GmbH, Kleinbittersdorf, Germany) was used for cell loading. Therefore, a cell pellet with 
20 million cells was resuspended in 4 ml 5 µg/ml coelenterazine containing, 8 mM 
L-glutamine and 1% PenStrep supplemented with Leibovitz´s medium and incubated for 
2 hours in the dark by gentle shaking in a small Petri dish at 75 rpm at room temperature. 
Then the cell suspension was diluted to 1*106/ml by adding 16 ml of 8 mM L-glutamine and 
1% PenStrep containing Leibovitz´s medium and transferred to a standard sized Petri dish 
for shaking for a further 2 hours in the dark at 100 rpm. After coelenterazine loading, the 
cells were ready for calcium measurements at the MicroLumat Plus luminescence microplate 
reader (Berthold Technologies, Bad Wildbad, Germany). A volume of 50 µl of free 
antagonists, PEGylated antagonists, as well as antagonist activated nanoparticles dilutions 
were filled in separate wells of a white 96-well plate (Greiner Bio-One, Frickenhausen, 
Germany). The two pumps of the luminescence plate reader injection system were 
equilibrated respectively with the prepared CHO-NK1R cell suspension and a 200 pM 
substance P-OMe competitive agonist solution. With a delay of 1.6 seconds, 50 µl cell 
suspensions were injected into the well 50 µl preloaded antagonist solution and incubated 
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for 1 min. In the case of partial agonistic potential of the provided antagonist, an initial 
luminescence emission is provoked in this period. After 1 min of cell and antagonist 
incubation within the well, 100 µl of 200 pM competitive antagonist, which corresponds to 
the approximate EC80 value of 100 pM for substance P-OMe in the final well concentration, 
was injected with the second pump to measure the literal antagonistic luminescence emission 
for different neurokinin-1 receptor antagonists (Figure  5). Since this secondary signal 
becomes increasingly suppressed with increasing concentration and potency of applied 
antagonist, this signal is the basis for the subsequent ligand-specific dose-response curve 
formation to determine IC50 values (Figure 6). Therefore, the areas under the signal curves 
were calculated in triplicate for each antagonist concentration by integration and were 
plotted against the natural logarithm of used concentrations. All dose-response curves were 
normalized against the maximum calculated area in the calcium assay. The obtained dose-
response points were fitted in SigmaPlot with an equation for sigmoidal dose-response with 
variable slope, to determine the ligand specific EC50/IC50 values, which give information 
about the binding affinity. 
 
Figure 5: Principle of aequorin assay: The transfected NK1R cell line expresses a 21 kDa 
photoprotein, derived from the jellyfish Aequorea Victoria, which is named as apoaequorin 
and forms a bioluminescent aequorin complex when linked to the chromophore cofactor 
coelenterazine and Ca2+. The calcium binding induces an oxidation reaction, followed in an 
emission of light and the production of apoaequorin, coelenteramide, and CO2 [1]. 
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Figure 6: The EC50 and IC50 values were determined by sigmoidal dose-response curve fit 
function with variable slope. For the highly potent neurokinin-1 receptor agonist substance P-
methyl ester (SP-OMe), an EC50 value of 41.9 pM and an EC80 of 103 pM were determined. For 
measurements in antagonist mode a competitive concentration of 100 pM SP-OMe was used. 
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Results and discussion 
RP-HPLC for validation of purification procedure and 
successful PEGylation 
For the linear PEG-peptide samples, an equivalent concentration of 20 µM of peptide was 
chosen to compare the areas under the chromatograms and to determine whether 
unPEGylated peptide was still present. A higher peptide concentration of 40 µM was chosen 
for the coupled spantide I, since it represents one of the highest used concentrations in the 
calcium binding studies and is compared to 10 µM free spantide I in the chromatogram 
(Figure 7). This coupling reaction is much more susceptible to failure in following 
purification procedures because of the high excess of used peptide ligand. However, 
compared to the free spantide I, there is no peptide elution at time point 7.4, which indicates 
successful purification of unbound peptide ligands that would disturb the results in ligand 
binding assays. For the 8armPEG20k-peptides, the chromatograms showed very 
heterogeneous and broad elution peaks between 12.5 and 25 min, which indicate different 
molecular sized structures because of heterogenous ligand occupancy per PEG. Also, linear 
mPEG5k-spantide I had a quite irregular peak structure with three not clearly separated 
peaks, which was a first hint for non-site-specific PEGylated products: Only Lys-PEGylated, 
only N-terminal-PEGylated, and double PEGylated. In addition, it could be confirmed that 
the purification procedure was successful by comparing unpurified and purified sample 
chromatograms at the elution time point of free unbound peptide (Figure 8). 
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Figure 7: RP-HPLC chromatograms of a linear mPEG5k- and 8armPEG20k-peptide 
conjugate. For both products, there is no free unbound peptide detectable. 
 
 
Figure 8: RP-HPLC chromatogram for mPEG5k-spantide I before and after thorough 
purification by size exclusion gel chromatography and several ultrafiltration steps. 
 
The challenge of site-specific ligand PEGylation Chapter 5 
 
 
 
- 88 - 
Peptide to PEG ratios 
The determination of peptide to PEG ratios for multivalent branched 8armPEGs showed that 
peptide solubility and the number of PEG binding sites have an influence on PEGylation 
efficiency. The mPEGylation of the most hydrophobic peptide GlyShortSP I was only 
possible when DMSO in a concentration of 15.7% was used for peptide reconstitution and 
the PEG was used in 2-fold molar excess. For 8armPEGylation, where the peptide is used in 
16-fold molar excess, a DMSO concentration of 60% (v/v) was required to avoid peptide 
precipitation. In this case, the purification procedure is quite problematic, as the Sephadex 
G-25 resin and the Amicon ultrafiltration units are, according to the manufacturers, not 
resistant against organic solvents in higher concentrations. In addition, for the quantum 
coupling procedure introducing a sulfhydryl group into the peptide sequence, it was not 
possible to perform this reaction in DMSO. Thus, for further studies, GlyShortSP I was 
excluded. There is an increase in water solubility if a hydrophilic lysine is integrated in the 
peptide sequence; however, its solubility is not comparable to the full-length spantide I, 
which has an additional arginine as hydrophilic amino acid in its sequence. Therefore, 25% 
DMSO (v/v) was used in the PEGylation reaction. The determined peptide to 8armPEG20k 
ratios are the following: 7.89 spantide I per PEG, 7.25 LysShortSP I per PEG and 5.68 
AcLysShortSP I per PEG. These ratios indicate that there is little double PEGylation, which 
would shift the ratio toward the PEG side, for non-acetylated peptide species. The site-
specific mono-PEGylation strongly depends on the buffer conditions, especially the pH-
value and the molar ratio of the educts used. In a PEGylation experiment with LysShortSP I 
and mPEG5k in basic 50 mM borate buffer, pH 8.5, where the educt ratios were varied from 
1:2 to 2:1 for peptide to PEG, it could be observed, that double PEGylation only occurs in 
the case of PEG excess. Therefore, the PEG-cross-linking cases, caused by peptides with 
multiple PEGylation sites, shown in Figure are not relevant for spantide I- and LysShortSPI-
8armPEG20k coupled products. 
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Figure 9: Possible cross-linking events for peptide ligands with two PEG binding sites. For A) 
Branched Polyethylene glycols and B) PEG-coated nanoparticles. The arrows indicate: 1) 
Intramolecular cross-linking and 2) Intermolecular cross-linking. 
 
HPLC-MS for proof of concept of double PEGylation 
In an HPLC-MS study, only the mass for mono-PEGylated LysShortSP I could be observed 
if the peptide was used in 2-fold excess to the used mPEG5k. A second possibility to reach 
controlled mono-PEGylation despite two or more possible PEG coupling sites within the 
peptide is to introduce an appropriate protective group for the N-terminal amine group, such 
as an acetyl group. Figure 10 shows that there is only one peak in the ESI TIC scan for the 
acetylated LysShortSPI, which indicates only one PEG per peptide, slightly shifted to the 
left, where unprotected peptide is used, but in high excess. 
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Figure 10: HPLC-MS analysis shows, that even for LysShort-spantide I, double PEGylations 
take place if PEG is used in excess. Mono-PEGylation occurs only for N-terminal acetylated 
Lys-ShortSP I or if the peptide is used in excess. 
 
Tricine-SDS-PAGE as a qualitative proof for peptide 
PEGylation 
The success of PEGylation could be determined in a qualitative manner by a Tricine-SDS-
PAGE, for peptides coupled with linear mPEG5k. Compared to these, the branched 
8armPEG20k-peptide-conjugates are not as mobile in the gel and became trapped between 
the spacer and the separation gel. The Tricine-SDS-PAGE gels are shown in Figure 11. 
Full-length peptides as well as PEGylated peptides can be observed with a Coomassie 
staining. Surprisingly, the unPEGylated LysShortSP I was not visible. After gel bleaching 
and iodine staining, only the PEGylated products were visible. PEG alone does not move in 
the gel. This method is recommended if only a qualitative proposition is desired for 
PEGylation success because the resolution is highly concentration dependent, especially to 
the peptide, and not comparable to that of an absorbance or fluorescence-based HPLC 
detection method. 
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Figure 11: Tricine-SDS-PAGE gels. On the left: Peptide specific Coomassie staining, and on 
the right: PEG specific iodine staining. 
 
Circular dichroism measurements 
As a check for possible changes in the peptide structure upon PEGylation, CD-spectra were 
recorded. It was found that there is no change in the CD-spectrum of the peptide after 
PEGylation. This indicates that there no modification in the peptide conformation due to the 
addition of one or two PEG chains (Figure 12). Since the peptide is relatively short, a real 
secondary structure cannot be determined, compared to proteins. Both spectra show negative 
maxima at 200 and 222 nm, which is coincides with the data in the literature for spantide I 
in water solution [19]. 
The challenge of site-specific ligand PEGylation Chapter 5 
 
 
 
- 92 - 
 
Figure 12: Circular dichroism spectra before and after PEGylation. There are no significant 
changes in peptide conformation. 
 
Calcium assay binding studies 
The influence of peptide truncation and PEGylation on the peptides´ affinity to neurokinin-1 
receptors were evaluated in the described aequorin calcium assay. The full-length antagonist 
spantide I has a variable potency, ranging from IC50 = 10.9 nM and IC50 = 254.9 nM, 
depending on the reconstitution buffer and whether an initial agonistic signal is measured. 
Independent from this fact, there is a decrease in affinity up to the micromolar range for 
truncated peptides, and even more for mPEGylated peptides (Figure 13/ 14). This result is 
not surprising since it is known that receptor binding takes place with the C-terminal end of 
the peptide and long N-terminal bound PEG chains cause high entropy costs and are able to 
sterically hinder the ligand from gaining access to the receptor binding pocket. In this study 
it was found that this effect is even stronger if two PEG chains are bound to one peptide, 
because of the presence of two PEGylation sites. If there is only one PEGylation-site present, 
as with AcLysShortSP I, the decrease in affinity is only 2.3-fold upon mPEG5k coupling, 
compared to a 6-fold affinity loss for unprotected LysShortSP I and even >107.5-fold for the 
full-length spantide I (Figure 13/14 and Table 2). Compared to the linear mPEGylated 
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AcLysShort spantide I, the affinity for the 8armPEGylated AcLysShort spantide I is much 
worse, which could be due to fewer ligands bound per PEG (only 5.68, compared to the 
others with >7 ligands/PEG), which result in a non-multivalent receptor binding. One further 
indication for this hypothesis is the steep slope for 8armPEG20k-AcLysShortSPI compared 
to other 8armPEG-peptide conjugates, which indicates that there is no cooperativity present 
(Figure 15). As a result, the decrease in affinity is much greater, compared to the linear PEG-
peptide-conjugate, because the effect of steric hinderance is exorbitantly greater. In contrast, 
multivalency could be observed for 8armPEG20k-spantide I and 8armPEG20k-LysShortSP 
I in the form of a regain in affinity, compared to the mPEGylated version. For 8armPEG20k-
spantide I, an IC50 value of 53.4 nM was determined, which is a 4.9-fold affinity loss to the 
unmodified peptide (reconstituted in 0.1% acetic acid/PBS) and even a 4.8-fold gain in 
affinity, if compared to the unmodified spantide I (reconstituted in 1% DMSO), and a 
513-fold improvement in affinity, compared to the mPEG5k-spantide I. A similar effect 
could be observed for the less potent LysShortSP I, where the initial affinity of unmodified 
peptide could also be improved 4.5-fold by multivalent receptor binding (Table 2). 
Table 2: IC50 values of mono- and multivalent antagonists: 
Monovalent antagonists                           
(see Figure 13 and 14) 
Multivalent antagonists           
(see Figure 15) 
Ligand type Free ligand mPEG5k-        coupled ligand 
8armPEG20k-
coupled ligand 
QD-coupled 
ligand 
Spantide I             10.9 nM
*1) 
254.9 nM*2) 27.4 µM  53.4 nM 6.1 nM 
LysShort SP I 5.7 µM 34.0 µM 1.28 µM n.a. 
AcLysShort SP I 2.3 µM 5.4 µM 67.6 µM n.a 
*1) reconstituted in 0.1% acetic acid, *2) reconstituted in 1% DMSO 
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Figure 13: Aequorin assay with CHO-NK1R cells: Dose-response curves of spantide I 
antagonists, including full-length spantide I, reconstituted in different 500 µM stock solution 
buffers with 0.1% acetic acid and 1% DMSO in PBS, respectively, and truncated versions 
(LysShortSP I and AcLysShortSP I). Mean values ± SE, n = 3. Corresponding IC50 values are 
listed in Table 2. 
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Figure 14: Influence of linear mPEG5k-chain on the spantide I, and truncated peptide ligands´ 
affinities. Mean values ± SE, n = 3. Corresponding IC50 values are listed in Table 2. 
 
 
Figure 15: Dose-response curves for multivalent binding antagonists, including branched 
8armPEG20k-peptide-conjugates and PEG-coated QDs. Mean values ± SE, n = 3. 
Corresponding IC50 values are listed in Table 2. 
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In conclusion, it could be shown that the attachment of one or two PEG molecules to a 
peptide causes high entropy costs and results in increasing IC50 values, proportional to the 
number of PEGs chains. Multivalent binding effects may counterbalance these 
pharmacodynamic adverse effects of coupled PEG by slower off-rates, cooperative effects 
due to receptor cross-linking, and a gain in enthalpy [20]. Multivalency by branched 
8armPEG-scaffolds requires seven to eight ligands per 8armPEG20k molecule; otherwise, 
the pharmacodynamic adverse effects of bulky PEG predominate. In addition, there is a lack 
of binding enhancement and therefore no cooperative effect [21]. Not much is known about 
ideal receptor density, the minimum and maximum distances between receptors and the 
optimum of PEG chain length, which are tightly interplaying parameters for multivalent 
drug-receptor binding. One research group investigated the various receptor distances for 
rhodopsin in silico. They found that a linker length of 20–50 Å between two ligands is 
needed for simultaneous receptor binding. The minimum width of two densely packed 
rhodopsin receptors is about 70 Å, and for loosely packed receptors, it is a distance of 100 Å 
or more [20]. Each PEG monomer has a length of 3.5 Å [22]. For mPEG5k, several PEG 
monomers of n = 116 were observed by mass spectrometry. For branched 8armPEG20k, it 
is unfortunately not possible to obtain the exact number of repetitive PEG units, but one arm 
should represent a bit more than PEG2k, which correlates with the PEG layer of QDs. In a 
brush conformation, one PEG arm should therefore have a nominal length of approximately 
165 Å. 
Agonistic potential of antagonists 
For some peptides and peptide-PEG conjugates, an agonistic potential was observed, which 
could be influenced by PEGylation. These observations raised new questions about various 
binding modes for PEGylated and unPEGylated peptides to the neurokinin-1 receptor 
binding pocket. An agonistic potential was measured in the aequorin calcium assay for the 
full-length spantide I, depending on how the peptide was reconstituted (Figure 16, A/B). 
Such preliminary agonistic calcium signals for antagonists are problematic because they 
reduce the number of intracellular available apoaequorin-coelenterazine complexes for the 
secondary antagonistic calcium signals for IC50 value determination. Resulting IC50 values 
should be considered in such cases with caution. In contrast, no agonistic calcium signals 
were measured after PEGylation (Figure 16, A/B). 
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Figure 16: Agonistic potential of unPEGylated spantide I for diluted peptide in 0.1% acetic 
acid. A) Calcium signals, B) Dose-response curves: The agonistic potential of spantide I of the 
same lot can be prevented by changing the solvent into an acetic acid free solution. Other lots 
did not show agonistic effects. There is complete suppression of agonism upon PEGylation. 
Mean values ± SE, n = 3. 
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Interestingly, the opposite effect could be observed for AcLysShort-spantide I, independent 
from acidic reconstitution. Here, the unPEGylated peptide didn´t show any agonistic 
potential, but the mPEGylated and 8armPEGylated-AcLysShortSP I induced high agonistic 
calcium signals (Figure 17, A/B). 
 
Figure 17: Induction of agonistic potential upon PEGylation for AcLysShortSPI. No agonism 
was observed for unPEGylated peptide. All peptides were diluted in PBS without acetic acid. 
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The literature mentions that some neuropeptides exhibit a residual agonistic effect for other 
non-neurokinin receptor species due to the substance P-like N-terminal tripeptide motive 
(Arg-Pro-Lys) [23]. D-amino acids are known to reduce these agonistic effects. Since the 
N-terminal sequence of spantide I is D-Arg-Pro-Lys, an agonistic potential of this drug was 
not expected, least of all for N-terminal PEGylated truncated peptides. One reason for the 
agonistic potential of full-length spantide I could be that proline as a so-called helix breaker 
amino acid, which sometimes causes problems in peptide synthesis, is responsible for 
coexisting shorter peptides without D-Arginine. First, this hypothesis was confirmed by the 
fact that other spantide I lots show reduced or no agonistic potential. But in HPLC-MS 
analysis, the true peptide masses for all used spantide I lots were identified. Another factor 
for high initial calcium signals can be acidic extracellular pH values, due to buffer 
components like acetic acid, which was used for peptide reconstitution. To investigate this, 
the peptide of the same lot was reconstituted in two different 500 µM stock solutions: in 1% 
DMSO/PBS and 0.1% acetic acid/PBS. Compared to the peptide in 0.1% acetic acid, a 
partial agonistic signal of 13.1% of maximum calcium signal for 6 nM spantide I was only 
measured if the peptide was reconstituted in a 1% DMSO/PBS solution. Nevertheless, it 
remains unclear why just mono-PEGylation induces an agonistic effect for AcLysShortSP I, 
independent from acetic acid reconstitution. One option may be that the PEG chain promotes 
another agonist-like peptide-receptor binding mode, also directed by the C-terminus of the 
peptide. Due to the small size and the highly hydrophobic nature of AcLysShortSP I, this 
peptide is possibly able to bind deeper in the receptor binding pocket to simply block the 
receptor. Upon PEGylation, there is an increase in solubility, and due to the bulky PEG 
chain, only the extracellular loops and therefore an agonistic receptor conformation is 
accessible. To obtain proof of this concept, the X-ray structure of the human neurokinin-1 
receptor is necessary, which would make possible further investigation of the binding modes 
of PEGylated peptides in silico, to fully understand how PEGylation influences the peptide´s 
ability to interact with the receptor binding pocket. 
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Conclusion 
There is a high concentration requirement of PEGylated spantide I species for clinical 
efficacy because N-terminal PEGylation decreases binding to membrane receptors but has 
the advantage of reduced clearance and immunogenicity. Double PEGylation of spantide I 
further increases the affinity loss to neurokinin-1 receptors because higher PEG to peptide 
ratio sterically reduces receptor binding at the cell surface, although binding is sufficient at 
very high ligand concentrations. Furthermore, simple N-terminal truncation of the peptide 
sequence leads to a great affinity loss. This indicates that the N-terminus sequence itself 
seems to be involved in receptor recognition and binding. Therefore, N-terminal truncation 
of the peptide sequence of spantide I is not an option to simplify the mono-PEGylation by 
elimination of amino acids, which are responsible for double PEGylation. The agonist 
activity of some peptide antagonists, which seem to be also mediated through the 
neurokinin-1 receptor make it difficult to determine true IC50 values in the aequorin based 
calcium assay due to consumption of bioluminescent aequorin complex. Nevertheless, it 
could be shown that there is a gain in affinity for 8armPEG-20k-spantide I due to multivalent 
receptor binding. 
  
The challenge of site-specific ligand PEGylation Chapter 5 
 
 
 
- 101 - 
Supporting information 
In HPLC-MS analysis, the mass and the number of repetitive PEG units of the succinimidyl 
succinate functionalized mPEG5k was determined. Its mass is 5267.29 Da with 116 PEG 
units with an error of Δ0.5 mDa = 0.4 ppm. Different PEGylated spantide I have different 
retention times in HPLC and therefore different mass peaks can be extracted (Figure 18 and 
Figure 19). 
 
Figure 18: Mass spectra of different obtained peaks for mPEGylation products of spantide I: 
The calculated masses for unreacted mPEG5k, 5267.29 Da (green), mono-PEGylated 
spantide I, 6585.93 Da (black) and double-PEGylatded spantide I, 11804.10 Da (blue), were 
observed. 
The challenge of site-specific ligand PEGylation Chapter 5 
 
 
 
- 102 - 
 
Figure 19: m/z distance of 7.3388 from C12 to C12 indicate the PEG repetition with atomic mass 
of 44. 
 
Unmodified PEGylated QDs were tested in an aequorin based calcium assay to see if 
unspecific calcium signals are generated or if there is a reduction in agonist provoked signal. 
It was found, that no calcium signal is provoked by QDs itself, but the substance P-OMe 
generated calcium signal after 60 seconds incubation of QDs with the cells is also reduced 
in a concentration-dependent manner. Finally, an IC50 of 52.1 nM could be obtained by 
unmodified QDs (Figure  20). This is maybe because of bioluminescence quenching due to 
the generation of light at 488 nm, which ideally fits the excitation and absorbance spectra of 
QDs. Bioluminescence resonance energy transfer (BRET) as a radiationless option for 
minimizing not receptor mediated luminescence signals, is only possible if the distances 
between extracellular QDs and intracellular aequorin complex are small enough. This kind 
of luminescence resonance energy transfer is already described for aequorin and GFP (green 
fluorescent protein) [24]. Nevertheless, the obtained binding curves differ in a linear 
concentration range of 8.5-fold. The question here is, if this difference is obtained by present 
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free spantide I in the sample, because of inefficient nanoparticle purification or due to 
multivalent binding effects. 
 
Figure 20: Unmodified QDs also show a decrease in bioluminescence with increasing particle 
concentration 
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Aprepitant, a small molecular weight antagonist for 
the neurokinin-1 receptor and its functionalization 
for nanoparticle coupling 
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Abstract 
Because many NK1R peptide antagonists, such as spantide I, suffer from poor metabolic 
stability and poor bioavailability, some small molecular weight antagonists for the 
neurokinin-1 receptor with high affinities were developed in the past [1,2]. Unfortunately, 
all of them lack suitable functional groups for common covalent nanoparticle coupling 
chemistries. The most popular representative NK1R antagonist is aprepitant (MK-869), 
which is used as a BBB-passing antiemetic drug for chemotherapy afflicted patients. It is 
supposed that after covalent nanoparticle coupling, aprepitant is not able to pass the BBB 
anymore and therefore can be used as a specific receptor blocker on immune cells in 
inflamed and highly innervated tissues where NK1Rs seem to be over-expressed. In this 
study, the chemical insertion of an alkyl-linker to aprepitant to make the drug molecule 
amenable to covalent nanoparticle coupling chemistry was shown. Since there is little 
information about the exact binding mode of aprepitant, the binding capacity of the alkyl-
linker-modified aprepitant was also checked. Here, it was found that the molecule is still 
active to NK1Rs after alkylation at its triazole group. This provided valuable information 
about its potential conformation within the NK1R binding pocket. In addition, the linker-
modified aprepitant represents, besides peptide antagonists, a promising small molecular 
weight ligand for further binding studies with aprepitant coated nanoparticles. 
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Introduction 
Neuropeptides modulate stress responses by their communication between the cortex and 
peripheral tissues. A perfect example of such a neuropeptide related neuromodulator process 
is the emetic reflex of substance P through NK1Rs, which are present in the brain in the CNS 
and the gastrointestinal tract with the enteric nervous system (ENS) along the so-called 
gut-brain axis [3]. One anti-emetic drug is aprepitant (MK-869), which was approved by the 
US Food and Drug Administration (FDA) in 2003 as an oral formulation and selectively 
antagonizes the human NK1R [4]. It is distributed as hard capsules with various aprepitant 
concentrations (80 mg and 125 mg per capsule) under the trade name Emend®. A second 
pro-drug for intravenous injection is Fosaprepitant (dimeglumine), distributed as Ivemend® 
(Figure 1). Fosaprepitant is converted to aprepitant within 30 min after intravenous 
injection [5]. Both dosage forms are currently the only FDA approved NK1R targeting 
ligands on the market and thus are used for administration in combination with other 
antiemetics (an 5-HT3R antagonist and dexamethasone) in chemotherapy patients to prevent 
the negative acute and delayed side-effects of nausea and vomiting (CINV = chemotherapy-
induced nausea and vomiting) [1,6]. Oral aprepitant administration leads to a peak 
concentration after 4 hours with a half-life of 9–13 hours [7]. The metabolization of 
aprepitant is complex, but it is primarily metabolized through the cytochrome P-450 
pathway [6]. The plasma protein binding is about 95% and the bioavailability ranges 
between 60% and 65% [7]. Aprepitant has a poor water solubility with only 3–7 µg/ml within 
a broad pH range of pH 2–12 [8]. For that reason, the formulation of Emend® is based on 
drug loaded nanoparticles´ technology, to increase the surface area to optimize drug 
absorption in the upper gastrointestinal tract and increase bioavailability [9]. However, this 
technology does not address the aspect of cell or tissue specific NK1R targeting. For this 
strategy, described in Chapter 4, our final goal is to covalently couple aprepitant to PEG-
coated nanoparticles to obtain multivalent binding effects, only at target sites where the 
receptor density is high, which could be the case for either tumors or inflamed tissues. 
However, there are two major drawbacks. First, aprepitant and other commercially available 
NK1R antagonists (a few of them are illustrated in Figure 1) do not exhibit a functional group 
for common PEG-coupling strategies. Second, there is little information about the exact 
binding mode of these drug molecules, which would help to predict negative influences on 
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the drug´s receptor binding affinity after the addition of a short alkyl linker or an even longer 
PEG chain. Here, the decision was to introduce a short alkyl linker with amine functionality 
at the triazole group of Emend® isolated aprepitant, which would make the drug molecule 
amenable for further PEGylation and nanoparticle coupling with well-established coupling 
chemistries. The effect on the binding properties of aprepitant upon triazole group 
modification was checked after alkyl linker addition reaction. 
 
 
Figure 1: Showcase of small molecular antagonists for the neurokinin-1 receptor. Aprepitant 
and Fosaprepitant are two FDA approved antiemetic drugs, distributed by Merck MSD Sharp 
& Dohme GmbH under the trade names Emend® and Ivemend® for oral and intravenous 
application, respectively. CP-96345 was the first NK1R non-peptide antagonist, developed by 
Pfizer, which served as the basis for later aprepitant synthesis [10]. RP-67580 was developed 
by Rhône-Poulenc, which could show inhibition of neurogenic inflammation in rats [11]. 
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Materials and Methods 
All chemicals were purchased from Sigma Aldrich (Taufkirchen, Germany) in analytical 
grade or higher if not stated otherwise. Emend® hard capsules with 125 mg aprepitant were 
purchased from MSD Sharp & Dohme GmbH (Haar, Germany). Pure aprepitant was 
purchased from Cayman Chemical Company (Ann Arbor, Michigan, USA). Thomas Dang-
Lieu (Universität Regensburg, Lehrstuhl für Pharmazeutische Chemie, Prof. Sigurd Elz) 
synthesized Boc-protected alkyl linker (tert-Butyl-(3-bromopropyl) carbamate) (Figure 2). 
Sodium hydride as 60% suspension in paraffin oil was purchased from Merck (Darmstadt, 
Germany). 
Isolation of aprepitant out of Emend® hard gelatin 
capsules 
Emend® hard gelatin capsules contain pellets of nanocrystalline aprepitant [9]. The pellets 
further consist of sucrose, microcrystalline cellulose, hyprolose, and sodium dodecyl 
sulfate [12]. Aprepitant has good solubility in methanol, as well as other organic solvents. 
Compared to these, though, methanol is very easy to remove by vacuum evaporation. 
Therefore, the content of five Emend® capsules was levigated with mortar and pestle and 
subsequently suspended in 55 ml methanol and equally distributed into five 15 ml falcon 
tubes. After 15 min centrifugation at 104 x g, the supernatant was decanted and filtered 
through a 0.2 µm filter. The filter was washed with another 5 ml fresh methanol. All 
sediments were washed separately with 10 ml water and again centrifuged at 104 x g for 
15 min. The supernatants were discarded and the sediments were each washed with 1 ml 
methanol and transferred in 2 ml Eppendorf tubes for a further centrifugation step under the 
same conditions. These supernatants were filtered through a fresh 0.2 µm filter. All drug 
containing methanol fractions were pooled in a 250 ml round bottom flask. The 65 ml 
methanol-drug solution was concentrated by vacuum evaporation at 40°C and 300 mbar to 
a final volume of 16 ml. The round bottom flask was fixed with a tripod sleeve over an ice 
water bath and a magnetic stirrer. With the help of a dropping funnel, twice the volume of 
methanol, which was 32 ml of water was dropped under gentle stirring into the ice cold 
methanol-drug solution for drug precipitation. The white precipitate was filtered through a 
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borosilicate glass frit with pore size 3 with the help of a vacuum pump. The pre-weighted 
frit was dried for several days in an exsiccator until a constant weight was observed. The dry 
weight was 578.3 mg, which represents a yield of 92.5% of the nominal drug content in the 
capsules. 
Boc-alkyl linker (tert-Butyl-(3-bromopropyl) carbamate) 
synthesis 
An amount of 3.45 g (15.5 mmol) of 3-Bromopropylamin hydrobromide was dissolved at 
0°C in 25 ml methanol and mixed with 2.73 g triethylamine (27 mmol) in 1.75-fold molar 
excess. Then 27.5 mmol of Boc anhydride (di-tert-butyl dicarbonate) were dissolved in 
15 ml methanol and added drop by drop under ice cooling. The solution was stirred for 
2 hours at 0°C and dried afterwards under vacuum (Figure 2). 
 
Figure 2: Manufacture of Boc-protected alkyl linker for aprepitant modification 
 
The resulting product was resuspended in 35 ml DMF and transferred into 150 ml citric acid. 
A triple solvent extraction, using a separating funnel was performed by 75 ml ethyl acetate 
addition. The united organic phases were washed with diluted citric acid, saturated sodium 
chloride solution, saturated sodium hydrogen carbonate solution, and once again with 
saturated sodium chloride solution. The resulting solution was dried on sodium sulfate, 
filtered, and constricted under vacuum. The desired product was precipitated overnight in 
ethyl ether. The white crystals were obtained by drying under vacuum. 
Boc-alkyl linker functionalization of aprepitant 
Since there is no functional group for coupling in the original molecular structure of 
aprepitant, an alkyl linker was introduced to enable PEGylation and coupling to 
nanoparticles. The first synthesis strategy intended the addition of an unprotected alkyl linker 
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to deprotonated triazole group of aprepitant, either at the preferred nitrogen position, or the 
oxygen position (Figure 3). Because there was zero yield of the desired products in 
strategy 1, the base Diisopropylethylamine (DIPEA) was added in strategy 2 to reduce 
deprotonation of the drug molecule, which could be one reason for no product yield. 
However, this strategy also did not yield any alkylated aprepitant. Therefore, a third 
experiment commenced, where a Boc-protected alkyl linker (tert-Butyl-(3-bromopropyl) 
carbamate) was used. For all synthesis strategies, the respective work was performed under 
argon inert gas atmosphere to prevent oxidation of the easily inflammable sodium hydride 
in the first deprotonation step as well as oxidation of the aprepitant. 
 
Figure 3: Tested synthesis strategies to introduce an alkyl linker to the 3-oxo-1,2,4 triazol-5-yl 
group of aprepitant for further chemical modification, such as PEGylation or covalent 
coupling to surface-functionalized nanoparticles. Alkyl linker addition was only observed for 
strategy 3 by using a Boc-protected alkyl linker. 
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For the third linker synthesis strategy (Figure 3), 200.15 mg Emend® isolate (aprepitant) 
were transferred in a baked out and argon-floated Schlenk plunger, dissolved in 10 ml 
anhydrous DMF, and subsequently transferred into the argon-floated dropping funnel of the 
experimental setup in Figure 4. Sodium hydride was used as deprotonation reagent in 
1.65-fold molar excess to aprepitant. Therefore, 24.75 mg sodium hydride (60% suspension 
in paraffin oil) were transferred in the baked out and argon-floated Schlenk plunger of the 
experimental setup in Figure 4 and dissolved in 10 ml anhydrous DMF. Because of 
exothermal heating of the deprotonation reaction, the plunger was cooled by a freezing 
mixture, consisting of 115 g sodium chloride and 500 g crushed ice. The aprepitant solution 
was carefully added to the sodium hydride solution under thorough stirring for 15 min. The 
Boc-protected alkyl linker (tert-Butyl-(3-bromopropyl) carbamate) was used in 2-fold 
excess to the deprotonated aprepitant by dissolving 187.12 mg in a separate argon-floated 
Schlenk plunger in 10 ml water-free DMF and transferred in the dropping funnel for the 
second alkylation reaction step. The linker solution was added drop by drop to the 
deprotonated aprepitant. 
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Figure 4: Experimental setup for water-free alkyl linker-aprepitant synthesis to prevent 
oxidation of sodium hydride and aprepitant. 
 
The reaction was further stirred overnight at room temperature under argon atmosphere. The 
dropping funnel was replaced by an argon filled balloon. Then the product was precipitated 
under gentle stirring by the addition of 60 ml ice cold water, which is double the volume of 
the final reaction in anhydrous DMF, again using the dropping funnel. The crystallization 
was completed by further incubation at 4°C overnight. The precipitate was separated from 
the DMF:water mixture by filtration through a borosilicate glass frit with pore size 3 using 
a vacuum pump. The dry product was dissolved in ethanol (Uvasol®) for determining the 
concentration, using a calibration curve of pure aprepitant in ethanol. 
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Analysis of educt and product by HPLC-MS and 1H-NMR 
To confirm successful isolation and purification of aprepitant out of Emend capsules and 
subsequent alkyl linker addition, an HPLC-MS analysis was performed by an electrospray 
ionization mass spectrometer (Agilent Technologies, Waldbronn, Germany). For NMR 
analysis, 10 mg of dried substance before and after alkyl linker synthesis were each 
dispensed in 1 ml deuterated DMSO and filled in glass capillary tubes. 1H-NMR spectra 
were recorded at room temperature on a Bruker Avance 300 spectrometer (Bruker BioSpin 
GmbH, Rheinstetten, Germany). 
Confirmation of GPCR functionality of Boc-alkyl linker-
aprepitant 
Little is known about the exact binding of aprepitant to neurokinin-1 receptors, whether a 
modification at a special site within the molecule would influence the receptor binding 
properties, and if so, to which extent. Therefore, the binding efficiency of pure aprepitant, 
Emend-isolated aprepitant, and alkylated-Emend-isolated aprepitant was checked. For each 
aprepitant type, a 500 µM stock solution in DMF was prepared. Therefore, solvent was 
exchanged from ethanol to DMF by using a SpeedVac. Dilution series of all aprepitant types 
for the determination of IC50 values in an aequorin based luminescence calcium assay were 
made in DPBS, supplemented with 0.03% Pluronic F68. To exclude that DMF caused 
cytotoxicity, the highest used DMF concentration without antagonist was also tested for 
calcium signaling. 
Binding studies via Aequorin calcium assay 
Neurokinin-1 receptor ligand binding studies were performed with a stable transfected 
neurokinin-1 receptor expressing CHO cell line, which Dr. Ralf Schwandner (Amgen 
Research GmbH, BioPark Regensburg) kindly provided. The calcium based binding studies 
were performed according to the assay in Chapter 5. A frozen cell cryovial with 206 cells 
was thawed and washed and finally loaded for 2 hours 5 µg/ml coelenterazine under gentle 
shaking in the dark in 4 ml 8 mM L-glutamine and 1% PenStrep supplemented Leibovitz´s 
medium at room temperature. After dilution to 1*106/ml with the same medium, the cells 
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were incubated for a further 2 hours. The calcium measurements were performed with a 
MicroLumat Plus luminescence microplate reader (Berthold Technologies, Bad Wildbad, 
Germany). Two 1:10 dilution series, starting from 10 µM and 3 µM final well 
concentrations, were prepared for aprepitant (reference substance), Emend-isolated 
aprepitant and Boc-alkyl linker-aprepitant and were filled in triplicate in separate wells of a 
white 96-well plate (Greiner Bio-One, Frickenhausen, Germany). The two pumps of the 
luminescence plate reader injection system were equilibrated respectively with the prepared 
CHO-NK1R cell suspension and a 200 pM substance P-OMe competitive agonist solution. 
With a delay of 1.6 seconds, 50 µl cell suspension were injected into the well with 50 µl 
preload of antagonist and incubated for 1 min. Then 100 µl of competitive antagonist (final 
EC80 substance P-OMe) was injected with the second pump to measure the literal 
antagonistic luminescence emission. The areas under the signal curves were calculated in 
triplicate for each antagonist concentration by integration and were plotted against the 
natural logarithm of used concentrations. All dose-response curves were normalized against 
the maximum calculated area in the calcium assay. The obtained dose-response points were 
fitted in SigmaPlot with an equation for sigmoidal dose-response with variable slope, to 
determine the ligand specific IC50 values, which provide information about the binding 
affinity. 
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Results and discussion 
HPLC-MS and 1H-NMR analysis of Emend® capsule 
isolate 
The success of aprepitant extraction out of Emend® hard capsules was verified by 
HPLC-MS analysis and 1H-NMR. A dry yield of 92.5% could be obtained by the drug 
isolation procedure. In HPLC-MS analysis, no impurities or side products could be detected. 
The observed mass of 535.2 corresponded to the expected mass of pure aprepitant, and the 
UV spectrum of the extracted mass peak was identical to that obtained for the pure reference 
substance with two typical maxima at 264 nm and 272 nm (Figure 5). 
 
Figure 5: HPLC-ESI-MS chromatogram for Emend® isolate (TIC scan) and corresponding 
absorbance spectrum. The elution peak of aprepitant occured after 3.7 minutes. No impurities 
were detectable. The peak UV absorbance spectrum shows the typical shape for aprepitant 
with its maxima at 264 nm and 271 nm. The detected mass of 535.2 corresponds to the expected 
molecular weight of pure aprepitant. 
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The 1H-NMR spectrum of Emend® isolate has shown the expected proton peaks for 
aprepitant. In total, 21 protons were detected (Figure 6). Typical solvent residual peaks of 
water and (CD3)2SO were detected at 3.33 ppm and 2.50 ppm, respectively [13]. 
 
Figure 6: 1H-NMR spectrum of isolated aprepitant (300 MHz, (CD3)2SO). Abbreviations: 
s = singulet, d = doublet, t = triblet, m = multiplet: δ = 1.36 (d, J = 407.7 Hz, 3 H, f-H), δ = 2.38 
(t, J = 714.7 Hz, 1 H, j/k-H), δ = 2.79 (m, J = 837.1 Hz, 2 H, j/k-H), δ = 3.49 (d, J = 1046.1 Hz, 2 
H, o/p-H), δ = 3.63 (d, J = 1088.4 Hz, 1 H, i-H), δ = 4.12 (t, J = 1235.0 Hz, 1 H, j/k-H), δ = 4.33 
(d, J = 1300.3 Hz, 1 H, h-H), δ = 4.94 (m, J = 1482.4 Hz, 1 H, e-H), δ = 7.08 (t, J = 2124.9 Hz, 2 
H, a-H), δ = 7.37 (s, J = 2211.4 Hz, 2 H, c-H), δ = 7.51 (t, J = 2253.8 Hz, 2 H, b-H), δ = 7.86 (s, J 
= 2358.39 Hz, 1 H, d-H), δ = 11.33 (d, J = 3399.9 Hz, 2 H, g-H). 
 
HPLC-MS and NMR analysis of Boc-alkylated aprepitant 
The correct mass of Boc-alkylated aprepitant was verified by HPLC-MS analysis and 
1H-NMR. For relative comparison of aprepitant peaks in HPLC-MS analysis, the UV 
detector was set at 264 nm (Figure 7). The observed mass of the main product was 
692.3 g/mol and correlated with the expected mass of Boc-alkylated aprepitant. A later, 
much smaller eluting peak mass of 849.4 g/mol indicated a double-Boc-alkylated side 
product. Only negligible amounts of unreacted aprepitant were detected. 
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Figure 7: HPLC-ESI analysis of Boc-protected propylamine-aprepitant. The shown elution 
profile was detected with UV detector at 264 nm. The correct mass peak for Boc-alkylated 
aprepitant was detected at 3.5 min with a mass of 692.3. The mass of a second, less dominant 
peak at 4.0 min was 849.3781 and corresponds to the mass of a double-alkylated product. Only 
small amounts of non-alkylated aprepitant were detected at 2.9 min with an extracted mass 
of 535.2. 
 
The 1H-NMR analysis after tert-Butyl-(3-bromopropyl)carbamate addition could not be 
conclusively interpreted due to further proton peaks caused by either double-Boc-alkylated 
aprepitant side products or the alkylation at the less preferred oxygen position at the triazole 
ring. This was additionally indicated by a total of more than 36 protons (Figure 8). The 
typical solvent residual peaks of water and (CD3)2SO were detected at 3.33 ppm and 
2.50 ppm, respectively, and an additional DMF peak at 7.95 ppm [13]. 
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Figure 8: 1H-NMR spectrum of Boc-protected amine-linker synthesis product (300 MHz, 
(CD3)2SO). Abbreviations: s = singulet, d = doublet, t = triblet, m = multiplet: δ = 1.35-1.36 
(J = 406.7 Hz, 3 H, f-H), δ = 1.36-1.45 (J = 421.6 Hz, 9 H, q-H), δ = 1.68 (m, J = 503.6 Hz, 1 H, 
o/p-H), δ = 1.78 (m, J = 539.0 Hz, 2 H, m-H), δ = 2.35 (m, J = 704.9 Hz, 1 H, j/k-H), δ = 2.73 (s, 
J = 819.2 Hz, 2 H, j/k/g-H), δ = 2.89 (s, J = 867.3 Hz, 2 H, j/k/g-H), δ = 2.94-3.17 (m, J = 910.4 
Hz, 2 H, n-H), δ = 3.37-3.50 (m, J = 1031.8 Hz, 2 H, o/p-H), δ = 3.50-3.58 (m, J = 1051.8 Hz, 1 
H, i-H), δ = 3.59-3.69 (m, J = 1093.3 Hz, 2 H, l-H), δ = 4.11 (m, J = 1234.1 Hz, 1 H, j/k-H), 
δ = 4.30 (m, J = 1290.0 Hz, 1 H, h-H), δ = 4.97 (m, J = 1290.0 Hz, 1 H, e-H), δ = 6.87 (t, J = 2062.7 
Hz, 1 H, r-H), δ = 7.18 (t, J = 2153.8 Hz, 2 H, a-H), δ = 7.44 (d, J = 2241.4 Hz, 2 H, c-H), δ = 7.53 
(t, J = 2259.9 Hz, 2 H, b-H), δ = 7.85 (s, J = 2357.4 Hz, 2 H, d-H) 
 
Binding studies via aequorin assay 
The binding capacities of pure aprepitant as a reference substance, Emend® isolated 
aprepitant and Boc-alkylated aprepitant were tested in an aequorin luminescence-based 
calcium assay. It was found that the isolated aprepitant from Emend® capsules showed 
almost the same binding affinity as the pure substance, which confirmed the validity of the 
used isolation and purification procedure. After alkylation, the binding affinity was 3.9-fold 
reduced. Due to the quite high initial affinity of 35.4 nM of unmodified aprepitant, the 
affinity is still in the nanomolar concentration range with and IC50 of 115.2 nM (Figure 9). 
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Figure 9: The determined affinity of the Emend® isolate with an IC50 = 29.7 is close to that of 
pure aprepitant with an IC50 = 35.4 nM. The addition of a Boc-alkyl linker for further chemical 
modification negatively influences the binding affinity in the form of a 3.9-fold drop-in affinity 
to an IC50 = 115.2 nM. 
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Conclusion 
To overcome the limitations of post-synthetic modification of small molecular weight 
neurokinin-1 receptor antagonists due to the lack of functional groups, it could be shown 
that chemical modification of the triazole group of aprepitant is possible by using a strong 
deprotonation reagent and a tert-Butyl-(3-bromopropyl)carbamate as an alkyl linker with 
Boc-protected amine functionality. In a binding study with the final product, it was found 
that the affinity dropped 3.9-fold, but still has an acceptable IC50 of 115.2 nM and therefore 
represents a promising antagonist for nanoparticle functionalization and further multivalent 
receptor binding studies. One drawback of this Boc-protected antagonist was the Boc-group 
cleavage under conditions, which are strong enough for deprotection on the one hand, and 
mild enough to keep the basic morpholine-ring structure of aprepitant intact on the other 
hand [8]. A better option would have been the introduction of an alkyl linker without the 
Boc-protecting group, but there is currently no way to perform such an alkylation. Therefore, 
it is proposed that the best way to obtain an amine-alkyl-linker functionalized aprepitant is 
to start the design of the desired drug molecule by stepwise synthesis from the very 
beginning instead of post-synthetic linker addition. 
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Abstract 
For peptide ligands, immobilized on the surface of nanoparticles for multivalent GPCR 
targeting, the question arises as to whether these ligands are susceptible to enzymatic 
cleavage even though there is a shielding against macrophages and enzyme attack by the 
flexible nanoparticle´s PEG corona, in which coupled ligands are able to isolate themselves. 
Especially if the cutting site within a peptide sequence is localized a favorable distance away 
from the PEG anchor position, a ligand cleavage seems to be possible. However, is it 
possible to process a ligand specifically at a target site, where a special enzyme is produced 
in high rates and if this is so, is the particle still able to bind to a specific GPCR? As a model 
for such a ligand conversion into its active form, angiotensin I was chosen, which is 
processed by ACE to angiotensin II. Angiotensin II is the preferred ligand for AT1 receptors 
(AT1Rs), which is expressed, for example, in rat mesangial cells. In the first part of this 
work, a renal cell line was sought, expressing both ACE and AT1R at high levels. In the 
second part, we investigated the mechanistic principle of enzymatic ligand activation on the 
surface of nanoparticles in general. In the performed PCR experiments, only rat and human 
mesangial cells, but not rat tubule cells, were identified as AT1R positive cell types. 
However, in a functional calcium assay, only the rat mesangial cells gave a positive signal 
for the AT1R. According to PCR results, ACE is only expressed by human mesangial cells 
and tubule cells. In a functional Förster Resonance Energy Transfer (FRET) based assay, 
where Captopril was used as an ACE specific inhibitor, it was observed that ACE is most 
selectively expressed by the renal tubule cell line NRK-52E. The enzymatic cleavage 
mechanism of angiotensin I ligands on QDs was examined using highly efficient 
recombinant human ACE. In a Fura-2 calcium assay, a significantly different calcium 
mobilization of enzyme incubated angiotensin I-modified QDs was measured, which was 
the first hint for successful nanoparticle activation. In contrast, in FACS binding studies, no 
significant greater binding was observed for enzymatically activated QDs. 
 
Enzymatic ligand activation on the surface of nanoparticles Chapter 7 
 
 
 
- 127 - 
Intoduction 
Angiotensin II is degraded within seconds by peptidases in the blood [1]. Sensitivity to 
enzymatic cleavage processes and opsonization after they were administered are chief 
causes [2]. Most cleavage mechanisms are driven by the recognition from immune system 
and reticuloendothelial system (RES) affiliated cells [3]. For better resistance against these 
clearance causes, nanoparticles used for drug delivery are shielded by so-called stealth 
coatings, which are, in most cases, hydrophilic and non-charged polymers such as PEG and 
polysaccharides or zwitterionic polymers or even biomimetic red blood cell (RBC) 
membranes [4–6]. However, in some cases cleavage processes are not unwanted. There are 
many cleavage mechanisms of precursor peptides and proteins that are essential to bring 
them into an active form, as is the case for the Renin-Angiotensin-System (RAS) involved 
in the regulation of blood pressure [7]. The RAS can be described as a kind of cleavage 
cascade, where the liver and renal derived precursor angiotensinogen is cleaved by renin in 
the kidney to angiotensin I, which itself is further shortened by ACE to angiotensin II [8]. 
Although ACE is not the best example for producing beneficial therapeutic effects—rather 
the opposite is the case since angiotensin II is known to cause hypertension [9,10]. Also, in 
diabetic nephropathy, intrarenal angiotensin II production is increased because of higher 
local ACE activity. However, this kind of enzyme driven activation can be one further key 
mechanism to overcome the problem of off-target cell and tissue targeting. To date, only 
highly selective ligands, multiple selective ligands, and some enzyme driven shielding 
mechanisms were taken into account, when ligands are immobilized on the surface of 
nanoparticles [11–13]. According to our current state of knowledge, there is no evidence that 
the ligand itself is activated by an enzyme driven cleavage mechanism to obtain multivalent 
GPCR targeting through a peptide ligand decorated nanoparticle. This study was performed 
to investigate whether it is possible to activate angiotensin I coated QDs in vitro by human 
recombinant ACE. Therefore ACE-incubated QDs were added to AT1R positive mesangial 
cells to examine their binding ability by GPCR triggered calcium mobilization 
measurements, fluorescence microscopy, and flow cytometry. In parallel, there was a search 
for an appropriate cell line that expresses both targets, ACE and the AT1R. Therefore, we 
performed RT-PCR experiments, calcium measurements as a proof for the presence of 
functional AT1 receptors, and a FRET-based assay for ACE detection. 
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Materials and methods 
All chemicals were obtained from Sigma Aldrich (Taufkirchen, Germany) in analytical 
grade unless stated otherwise. Dulbecco’s phosphate-buffered saline (DPBS) pH 7.4 
consisting of 1.5 mM KH2PO4, 8 mM Na2HPO4, 2.7 mM KCl and 138 mM NaCl was 
purchased from Life Technologies/Thermo Scientific (Darmstadt, Germany). Ultrapure 
water was obtained from a Milli-Q water purification system (Millipore, Billerica, MA, 
USA). Rat mesangial cells were a gift from Prof. Armin Kurtz (Department of Physiology, 
University of Regensburg, Germany). NRK-52E tubule cells were obtained from Prof. 
Joachim Wegener (Department of Analytical Chemistry, University of Regensburg, 
Germany). The human mesangial cells were a gift from Dr. Miriam Banas (Internal Medicin 
II/Nephrology, University of Regensburg). Rat mesangial cells were cultured in RPMI 1640 
+ glutamate, 2 g/l NaHCO3, 100 nM Hydrocortisone, 10 ml/l Insulin-Transferrin-
Natriumselenit (ITS), 1% Penicillin/ Streptomycin, 10% FCS. NRK-52E; tubule cells were 
cultured in DMEM, 5% FCS; and human mesangial cells were cultured DMEM, 
supplemented with 4 mM L-Glutamine, 1% Penicillin/Streptomycin, 10% FCS. 
Determination of renal cell lines for AT1 receptor and ACE 
expression by RT-PCR 
Various renal cell types, such as mesangial cells and tubule cells, were examined for AT1R 
and ACE expression by RT-PCR. The peqGOLD Total RNA Kit and the peqGOLD DNase 
I Digest Kit were used for mRNA extraction and to remove potentially present DNA. Both 
kits were used according to the manufacturer´s instructions. The RNA content was 
determined at a NanoDrop UV meter. Then 2 µg RNA were reverse-transcribed with the 
peqGOLD cDNA Synthesis Kit H Minus, using an oligo(dT) primer and random primer mix 
of 170 ng to 30 ng. The resulting cDNAs were used as templates for amplification in PCRs. 
For PCR, the peqGOLD Taq-DNA-Polymerase was used. For each reaction, a total volume 
of 25 µl with a primer content of 10 pmol and 1 µl of cDNA template were used. As reaction 
buffer, 10x reaction buffer S was chosen with a MgCl2 content of 15 mM. All other 
components were applied according the manufacturer´s instructions. The primers were 
ordered from Eurofins Genomics, Ebersberg, Germany (Table 1). 
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Table 1: Primer sequences 
Target Sequence (5´-> 3´) Tm in °C 
GC content 
in % 
Human ACE [14] 
Forw.: GGTGGTGTGGAACGAGTATG 
Rev.: TCGGGTAAAACTGGAGGATG 
59.4 
57.3 
55.0 
50.0 
Rat ACE [15] 
Forw.: TCCTGCTAGACATGGAGACGA 
Rev.: CAGCTCTTCCACACCCAAAG 
59.8 
59.4 
52.4 
55.0 
Human AT1R [16] 
Forw.: GCTTTCCTACCGCCCCTCAGA 
Rev.: TTTCGAACATGTCACTCAACCTCAA 
63.9 
61.1 
61.9 
40.0 
Human AT1R 
(used for rat) [17] 
Forw.: GGCCAGTGTTTTTCTTTTGAATTTAGCAC 
Rev.: TGAACAATAGCCAGGTATCGATCAATGC 
62.8 
63.6 
37.9 
42.9 
 
The following PCR programs were used: 
1. Denaturation  94°C   2 min 
2. Denaturation  94°C   30 sec 
3. Annealing  60°C1)/57°C2)  60 sec1)/30 sec2) 401)/352) cycles 
4. Elongation  72°C   30 sec 
5. Final elongation 72°C    7min 
6.   4°C   ∞ 
1) NRK-52E tubule cells, 2) human and rat mesangial cells 
The amplified cDNA was visualized by gel electrophoresis with 2% agarose 
(Invitrogen/Thermo Scientific, Darmstadt, Germany) in 1x TAE buffer. The bands were 
visualized by adding 0.4 µg/ml ethidium bromide to pre-solid gel. For sample load, 20 µl of 
PCR reaction product was mixed with 4 µl 6x Loading Dye (Peqlab, Erlangen, Germany). 
For fragment size determination the peqGOLD 50 bp DNA ladder was used. 
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Examination of supernatants of NRK-52E rat tubule cells 
for peptidase activity 
In calcium measurements of CCM supernatants, supplemented with angiotensin I for 
cell-derived ACE conversion to angiotensin II, the renal rat tubule cell line NRK-52E was 
examined for functional ACE expression. Angiotensin I was incubated in a time range of 
25 hours and the influence of zinc addition to the medium was evaluated. The NRK-52E 
cells were grown to 85% confluency in 1x DMEM with phenol red and 5% FCS in T25 cell 
culture flasks. Then the medium was replaced by differently concentrated angiotensin I 
containing 1xDMEM media (1 µM and 2 µM) without phenol red and without FCS, but 
either with or without 10 µM ZnCl2. As a control for successful angiotensin I conversion, 
the ACE inhibitor Captopril was used in 25-fold excess to angiotensin I. At time points 2 h, 
4 h, 6 h and 25 h, a supernatant volume of 155 µl was sampled and frozen at -20°C until 
calcium measurement. 
Fura-2 calcium assay 
AT1 receptor positive mesangial cells were grown until confluency, washed twice with warm 
DPBS, and loaded for 1 hour at room temperature with 5 µM calcium chelator Fura-2 
acetoxy methyl ester (Life Technologies/Thermo Scientific, Darmstadt, Germany) in the 
presence of 2.5 mM ABC transporter inhibitor probenecid (Santa Cruz, Heidelberg, 
Germany) in Leibovitz medium. Due to acetoxy methyl ester cleavage, Fura-2 can penetrate 
cells and is trapped there by the action of probenecid. The excess of Fura-2 was removed by 
5 min centrifugation at 200 x g, two washing steps in probenecid containing Leibovitz 
medium, and further centrifugal steps. Finally, the cells were resuspended in probenecid 
containing medium to a cell density of 1*106 cells/ml. In a 96-well plate (Greiner Bio-One, 
Frickenhausen, Germany), 50 µl of each medium supernatant, collected from NRK-52E cells 
were provided. Medium without cell contact was used as a control. All other samples for 
calcium measurements, such as free angiotensin I or angiotensin I-modified QDs, were 
diluted in DPBS. With the help of a BMG Omega Microplate reader and its injector system, 
150 µl of the Fura-2 loaded mesangial cell suspension was injected to mix with the tubule 
supernatants to measure calcium influx in dual excitation mode. Therefore, excitation filters 
Enzymatic ligand activation on the surface of nanoparticles Chapter 7 
 
 
 
- 131 - 
340/20 nm and 380/nm were used. For both, excitations the emissions were detected using 
a 510/20 nm band-pass filter. The calcium influx into cells was calculated based on the 
Grynkiewitcz equation, which is proportional to the 510 nm emission ratio by excitation at 
340 nm and 380 nm. The maximum and minimum calcium signals were obtained by 
complete cell lysis after 0.1 % Triton X 100 without (max) and with 4.5 mM EGTA (min) 
for total calcium complexation in two separate wells. 
The binding affinity of angiotensin I to AT1 receptors 
To determine whether angiotensin I is also able to bind to AT1 receptors, a dose-response 
curve was recorded in a calcium assay. As a control for selective angiotensin I binding to 
solely AT1 receptors, the highly selective AT1 receptor antagonist EXP3174 (Santa Cruz, 
Heidelberg, Germany) was used, which is a Losartan derivative. 
Determination of enzyme activity by a FRET-based 
cleavage assay 
As a fluorogenic protease substrate Mca-Arg-Pro-Pro-Gly-Phe-Ser-Ala-Phe-Lys(Dnp)-
OH[Mca=(7-methoxycoumarin-4-yl)acetyl;Dnp=2,4-dinitrophenyl] (Enzo Life Sciences 
GmbH, Lörrach, Germany) was used. It is substrate for ECE-1 and ECE-2, ACE1 and ACE2, 
neprilysin, MMP-2 and MMP-9, and thimet oligopeptidase, as well as cathepsin A, 
cathepsin X/Z, BACE, and insulinase, but not MMP-1. The fluorescence of Mca at 390 nm 
is efficiently quenched by the Dnp group in the peptide sequence by its proximity until 
enzymatic cleavage separates them. In presence of an enzyme, this FRET state becomes 
interrupted and donor emission at 390 nm can be measured after excitation at 340 nm. 
Therefore, this peptide is a valuable tool for time related enzyme activity studies (Figure 1). 
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Figure 1: Principle of FRET assay for the determination of ACE activity. Before a peptide is 
cleaved, FRET-based transfer of donor emitting fluorescence is absorbed by a donor in tight 
proximity, within the so-called Förster distance. After protease cleavage, the quenching is 
interrupted so that direct donor emission can be measured. 
 
For standard curve preparation, various FRET substrate concentrations from 2.5 to 12.5 µM 
were converted by 0.2 ng/µl recombinant human ACE (R&D Systems, Bio-Techne GmbH, 
Wiesbaden-Nordenstadt, Germany). Therefore, 10 µg of ACE were diluted to a final stock 
concentration of 1 µM (0.143 µg/µl) in a sterile buffer, consisting of 12.5 mM Tris, 75 mM 
NaCl, 0.5 µM ZnCl2, pH 7.5. ACE stock solution aliquots of 5 µl were stored at -20°C in 
sterile Protein LoBind Tubes (Eppendorf AG, Hamburg, Germany) until use. For the FRET 
measurement, the enzyme was diluted in the same buffer to 0.4 ng/µl. This enzyme solution 
was kept on ice until use. For the assay, 50 µl of the enzyme solution was preloaded into a 
black 96-well plate (Greiner Bio-One, Frickenhausen, Germany) and 50 µl of substrate, 
diluted in Leibovitz medium was added. For ACE specific enzyme inhibition, another 
equivalent substrate dilution series, supplemented with a constant Captopril concentration 
of 10 µM was prepared. The enzyme kinetics were immediately captured with a BMG 
Omega Microplate reader, heated at 37°C within 6 hours. 
For measuring the ACE activity of cells were seeded in a cell type dependent ideal density 
from 10,000 to 25,000 in a black 96-well plate with clear bottom and CellBIND surface 
(Corning, Wiesbaden, Germany) and were grown for 24 h at 37°C and 5% CO2 atmosphere. 
The medium was removed and cells were washed once with warm DPBS. Then various 
FRET substrate concentrations from 2.5 µM to 10 µM either without or with competitive 
10 µM Captopril addition, all diluted in Leibovitz were added and the kinetic measurements 
over 6h at 37°C were started immediately. 
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In vitro ACE driven activation of angiotensin I-modified 
quantum dots 
The synthesis of angiotensin I-modified QDs is described in Chapter 3. For the in vitro 
conversion of angiotensin I decorated QDs, human recombinant ACE was used (Figure 2). 
 
Figure 2: Principle of enzymatic activation of ligand decorated nanoparticles. Angiotensin I is 
attached to the PEG chains on the surface of QDs. The particles are then incubated with soluble 
ACE and subsequently tested for their interaction with AT1R positive cells. 
 
The QDs were mixed in Protein LoBind Bind Tubes to a final concentration of 40 nM or 
80 nM with 5 nM ACE in DPBS and were supplemented with or without either 8 µM 
Captopril or 24 µM EXP3174. The tubes were incubated for 1.5 hours at 37°C to start 
enzymatic angiotensin I conversion. For a following Fura-2 calcium assay, 50 µl of each 
sample was loaded in a 96-well plate and mixed by an injection of 150 µl AT1R positive 
mesangial cell suspension, leading to a final QDs concentration of 10 nM or 20 nM and 
6 µM of AT1R inhibitor EXP3174. 
Fluorescence microscopy 
Angiotensin I functionalized QDs were enzymatically activated by human recombinant ACE 
before they were used in 2D cell culture studies. 1 pmol QDs were converted in a 5 nM 
solution of ACE in DPBS at 37°C for 2 hours. After this enzymatic ligand conversion step, 
the QDs were further diluted to a final concentration of 10 nM with Leibovitz´s medium, 
containing final 0.3% BSA. This solution was administered to AT1 receptor positive rat 
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mesangial cells, seeded into 8-well µ-slides (Ibidi, Martinsried, Germany) and incubated for 
80 min at 37°C, 5% CO2 atmosphere to assess nanoparticle binding. Unbound nanoparticles 
were removed by two consecutive washing steps with pre-warmed DPBS and the cells were 
covered with warm Leibovitz´s medium. The enzyme driven nanoparticle binding upon 
peptide ligand conversion was examined by fluorescence microscopy, using a 63x Plan-
Apochromat (NA 1.4) oil immersion objective with a Zeiss Axiovert 200 microscope 
equipped with an LSM 510 laser-scanning device (Zeiss, Jena, Germany). The QDs were 
excited with an argon-ion laser at 488 nm, and fluorescence emission was recorded using a 
560–615 nm band-pass filter. For image acquisition, AIM 4.2 software (Zeiss, Jena, 
Germany) was used. Images were processed using ImageJ software. 
Flow cytometry analysis 
Rat mesangial cells of passage 92 were seeded in a density of 105 cells per well in a 24-well 
plate (Corning, Wiesbaden, Germany) and were grown for 48 hours. An amount of 2 pmol 
angiotensin I-modified QDs were pre-incubated for 2 hours at 37°C with 5 nM human 
recombinant ACE in DPBS either with or without 10 µM Captopril. Then the solutions were 
diluted to a final QD concentration of 10 nM in Leibovitz´s medium, containing final 0.3% 
BSA. As a second inhibitor control, 2.5 µM EXP3174 was included. In each well, 200 µl of 
QD sample solution was added after washing the cells once with warm DPBS. The cells 
were incubated for 1 hour with the nanoparticles at 37°C and 5% CO2, before the solutions 
were aspirated. The cells were washed with warm DPBS and detached by trypsinization for 
5 min at 37°C. The enzyme was inactivated by addition of warm 10% FCS containing 
Leibovitz´s medium. The cell suspensions were transferred in 1.5 ml Eppendorf tubes and 
kept on ice. The cells were spun down at 4°C and 200*g. The resulting pellets were washed 
in ice cold DPBS and centrifuged again under the same conditions. Finally, the pellets were 
resuspended in 200 µl DPBS for FACS analysis with a FACSCalibur flow cytometer 
(Becton Dickinson, Franklin Lakes, NJ, USA). Cell bound QDs were excited at 488 nm and 
detected in the FL-2 channel with band-pass filter 585/42 nm. The voltage was set at 702 
and 104 events were detected. Flow cytometry data were analyzed by Flowing Software 
version 2.5 (Turku Centre for Biotechnology, Turku, Finland). Only the population of viable 
cells was gated and used for GeoMean fluorescence intensity determination. 
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Results and discussion 
RT-PCR to determine AT1 receptor and ACE expression 
in renal cell lines 
With the help of reverse transcription PCR, the cell types that express mRNA for either ACE 
or the AT1 receptor, or both in the best case, could be shown. It was found that human 
mesangial cells showed expected bands for AT1R and ACE at 84 bp and 428 bp, respectively 
(Figure 3A). The rat tubule cell line NRK-52E exhibits only ACE expression, indicated by 
a band at 142 bp, but no receptor expression (Figure 3B). Rat mesangial cells express the 
AT1R due to a band at 210 bp but not ACE, even if cells were stimulated with high glucose 
concentrations (Figure 3C). In the pathogenesis of diabetic nephropathy, high extracellular 
glucose also seems to be directly involved in the subsequent production of cytokines and 
growth factors by glomerular, tubular, vascular, and interstitial cells [7]. The stimulation of 
cells in 2D culture with glucose is recommended in the literature to influence the AT1R and 
ACE expression with increasing glucose concentration [18]. The normal glucose 
concentration is 10 mM, high glucose is 30 mM, and very high is 60 mM. 
 
Figure 3: RT-PCR amplified cDNA products, separated in 2% agarose gels 
Therefore, the human mesangial cells seemed to be a promising target cell line for further 
experiments. Unfortunately, these human mesangial cells did not show a clearly positive 
response to angiotensin II in calcium measurements, which indicates that only a few 
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functional receptors are present on the cell surface. For the NRK-52E tubule cells, no 
calcium signal could be measured, which corresponds to the data obtained by RT-PCR 
(Figure 4). 
 
 
Figure 4: Comparison of calcium signals for different cell types 
 
The binding affinity of angiotensin I to AT1 receptors 
Besides angiotensin II, angiotensin I is also likely to bind to the AT1 receptors. However, 
compared to angiotensin II, angitoensin I binds with about a 54-fold lowered affinity to the 
AT1 receptor (Figure 5). In regard of this fact, for further experiments concerning the effects 
of ACE dependent angiotensin I conversion, only substrate concentrations lower than 
300 nM were used. A 10-fold excess of EXP3174 could markedly suppress the generated 
calcium signal, which indicates the selective binding of angiotensin I to AT1 receptors. 
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Figure 5: Angiotensin I shows selective affinity to AT1 receptors in a concentration-dependent 
manner, which can be suppressed by EXP3174. 
 
Examination of supernatants of NRK-52E rat tubule cells 
by calcium measurements 
The medium supernatants of NRK-52E tubule cells produced an increase in calcium signal, 
dependent on the applied angiotensin I concentration and incubation time (Figure 6). 
Contrary to the expectation, the administration of additional zinc in the form of ZnCl2 
supplemented medium did not improve the cell-derived enzymatic angiotensin I to 
angiotensin II conversion. The signals with zinc including samples show lowered calcium 
signals (Figure 7). One explanation could be that Zn2+ is likely to bind to Fura-2 when it is 
internalized into cells and will therefore compete with Ca2+ ions for chelator binding sites. 
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Figure 6: Calcium measurements of NRK-52E cell medium supernatants after angiotensin I 
incubation. Over time, angiotensin I is converted into angiotensin II, which leads to an AT1R 
mediated increase in intracellular calcium. 
 
 
Figure 7: The addition of zinc in the CCM leads to decreased calcium levels, perhaps because 
of zinc complexation with Fura-2 calcium chelator. 
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Determination of enzyme activity by a FRET-based 
cleavage assay 
The FRET substrate Mca-Arg-Pro-Pro-Gly-Phe-Ser-Ala-Phe-Lys(Dnp)-OH was completely 
converted by 0.02 µg of human recombinant ACE in a substrate concentration range of 2.5 
to 12.5 µM. There is a steep increase in substrate conversion for very high substrate 
concentrations. After 1 hour of substrate incubation, a saturation plateau occurs (Figure 8). 
 
 
Figure 8: Cleavage of different FRET substrate concentrations by 0.02 µg human recombinant 
ACE: Increasing FRET substrate concentrations generates higher fluorescence intensities by 
enzyme triggered dequenching of peptide FRET pairs. 
 
The inhibition of the human recombinant ACE with 10 µM Captopril was particularly 
successful for FRET substrate concentrations ≤ 5 µM. Therefore, using Captopril in 2-fold 
excess to substrate or higher (Figure 9) is recommended. 
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Figure 9: Captopril is an efficient inhibitor for human recombinant ACE. It is necessary to use 
Captopril in a 2-fold excess to substrate used, to accomplish total ACE inhibition or to block 2 
ng/µl ACE. 
 
For quantitative analysis, enzyme kinetic parameters like Vmax and KM were determined by 
double reciprocal representation of the Michaelis-Menten enzyme kinetic in the form of a 
Lineweaver-Burk-Plot linearization, using a standard curve for FRET substrate conversion 
by human recombinant ACE (Figure 11). All obtained enzyme kinetic curves of various cell 
types for the various FRET substrate concentrations used were fitted with a nonlinear 
polynomial quadratic regression function (f = y0 + a*x + b*x2) in SigmaPlot to determine 
the initial velocity V0, which corresponds to a in the equation (Figure 10). The Lineweaver-
Burk-Plot illustration also offers information about the kind of enzymatic inhibition of ACE 
by Captopril. For example, whether it is competitive (Figure 12–14). The experimental data 
were not shown due to the linear extrapolation to x-axis intercept, which led to overlapping 
data points. 
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Figure 10: FRET kinetics for various tested renal cell lines with and without ACE inhibitor 
Captopril under substrate incubation. 
 
 
Figure 11: Standard curve of human recombinant ACE: Increasing FRET substrate 
concentrations were converted by 0.02 µg human recombinant ACE (n=2), shown in Figure 8. 
The maximum fluorescence emission was used for standard curve formation. 
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Figure 12: Lineweaver-Burk-Plots (double reciprocal plots of enzyme kinetics) of rMCs. After 
Captopril administration, an increase in slope is visible, which is an indicator for competitive 
inhibition of ACE by Captopril. 
 
 
Figure 13: Lineweaver-Burk-Plots (double reciprocal plots of enzyme kinetics) of rat NRK-52E 
renal tubule cells. The effect of slope increase is most clearly visible for NRK-52E cells, which 
is an indication for the most selective FRET substrate conversion due to ACE. 
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Figure 14: Lineweaver-Burk-Plots (double reciprocal plots of enzyme kinetics) of hMCs. The 
Lineweaver-Burk-Plot slopes with and without Captopril overlap each other and therefore 
suggest that the FRET substrate conversion may not be ACE-derived. 
 
Increasing KM values represent the substrate concentration, which is necessary to reach the 
half-maximum velocity. After inhibitor addition, an increasing KM value suggests that there 
must be an inhibitor specific blockade of the enzyme, which is targeted by the used substrate. 
This was the case for rat NRK-52E tubule cells and rat mesangial cells, but surprisingly not 
for human mesangial cells. The initial substrate concentration is lower for NRK-52E tubule 
cells, compared to both mesangial cell types, which indicates a higher enzymatic activity of 
the tubule cells. Also, the literature explains that the conversion of angiotensin I via ACE is 
localized on the proximal tubule cell brush border [19]. For the rat mesangial cells, 4.2-fold 
more FRET substrate must be converted, compared to tubule cells. Here, the human 
mesangial cells show no ACE-derived enzyme activity (Figure 14). In the case of a 
competitive inhibitor, Vmax remains unchanged, which is the case for all tested cell types 
(Table 2). 
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Table 2: Calculated parameters 
Cell type 
Vmax          
No inhibitor 
Vmax 
(+ Captopril) 
KM (µM)   
No inhibitor 
KM (µM) 
 (+ Captopril) 
fold 
KM increase 
NRK-52E 1.26 1.26 0.015 0.032 2.1 
rMCs (AT1R+) 1.28 1.29 0.063 0.081 1.3 
hMCs 1.27 1.27 0.036 0.036 1.0 
 
In general, such linearization methods for gaining insight into enzyme kinetics and inhibition 
mechanisms are controversial, particularly with respect to their reliability. This is especially 
true in this case, where the enzyme specificity of the FRET substrate is not warranted, and 
the kinetics of cell-derived enzymes differ quite strongly to that of rhACE, which was used 
for standard curve preparation. To obtain a more reliable linear extrapolation, more than four 
data points and more inhibitor concentrations should be tested. Another parameter for 
improvement is the cell density, which also determines enzyme concentration. 
In vitro enzymatic conversion of angiotensin I 
functionalized quantum dots 
The buffer corrected calcium signals, measured for ACE activated QDs for 10 nM and 20 
nM QDs, differ significantly from these obtained by control QDs, which were unmodified 
QDs (only data for 10 nM QDs) and angiotensin I-modified QDs without ACE or including 
Captopril as enzyme inhibitor (Figure 15). Enzyme activated QD binding to AT1R can be 
blocked by EXP3174 (data only for 10 nM QDs). 
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Figure 15: Fura-2 calcium signaling for ACE activated QDs. The GPCR binding of enzyme 
activated QDs results in higher calcium signals, than the control groups. Data were obtained 
by two independent experiments with dilutions in triplicate with QDs of different distributors 
(Life Technologies and Strem Chemicals). Levels of statistical significance are indicated as 
p < 0.01. 
 
Fluorescence microscopy 
In fluorescence microscopy studies, a higher QD binding was observed if angiotensin I-
modified particles were processed by human recombinant ACE before administration to 
AT1R positive rat mesangial cells (Figure 16 A). The binding of particles was reduced by 
Captopril (Figure 16 B). 
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Figure 16: Fluorescence microscopy pictures of mesangial cells incubated with ACE activated 
angiotensin I-QDs (A), Captopril-inhibited angiotensin I-QDs (B), and not activated 
angiotensin I-QDs (without ACE) (C). Compared to not activated QD controls (B,C), the ACE 
converted angiotensin I-QDs show AT1 receptor mediated binding and uptake (A). 
 
Flow cytometry analysis 
As proof of the conclusions drawn based on the microscopic images, the 
angiotensin I-modified QD binding to AT1R positive mesangial cells was also checked after 
pre-incubation of the particles with rhACE and in the presence of Captopril and EXP3174 
inhibitors. During this experiment, no significant differences were found between ACE-
incubated angiotensin I-modified QDs and the controls, without either ACE or 
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enzyme/receptor competing antagonists. A high unspecific binding was observed for 
unmodified amino-PEG QDs (Figure 17). 
 
 
Figure 17: FACS analysis showed no significant differences between angiotensin I-modified 
QDs. There is a high unspecific binding of unmodified QDs. 
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Conclusion 
The present experiments show that enzymatically processed angiotensin I coated 
nanoparticles can selectively bind to AT1R positive mesangial cells. To date, it is not clear 
whether multivalent receptor binding is induced after enzymatic processing of 
angiotensin I-modified QDs, because the measured calcium responses were very low and 
because microscopy pictures and flow cytometry data did not clearly show strong differences 
in receptor binding between enzymatically converted nanoparticles and the respectively used 
controls with either enzyme inhibitor or receptor blocker. There may be multiple reasons for 
this. The coupling efficiency of angiotensin I to QDs is too low and/or the ligand conversion 
efficiency by ACE is too low. A further reason may be that free unbound angiotensin I is not 
completely removed from the QD sample. Thus, free converted angiotensin I can compete 
with angiotensin I-modified QDs for receptor binding sites. Nevertheless, in each experiment 
the binding of angiotensin I coated nanoparticles before ACE-derived processing is lower 
compared to converted QDs, indicating a certain conversion, which may be insufficient to 
reach multivalent particle binding. Such an enzyme driven nanoparticle binding could be 
one step further towards preventing unspecific nanoparticle binding and uptake to and from 
off-target cells. In future experiments, artificial human recombinant ACE should be replaced 
by natural cell-derived ACE, expressed ideally by one cell type. Particularly in diabetic 
nephropathy, this kind of particle can be used as a probing system to better understand the 
sites of action and interaction of ACE and AT1R in renal tissues. Therefore, the parallel 
injection of the inhibitors Captopril and EXP3174 is recommended to avoid enzymatic 
cleavage of ligands by enzymes in the blood stream and nanoparticle binding to off-target 
cells before they arrive at the target site in the kidney. 
Since it is known that in addition to synovium derived cells, bovine chondrocytes in 2D cell 
cultures also express AT1 receptors for angiotensin II, independent from interleukin-1 
stimulation, cartilage cells could be a potential target for antiangiogenic drugs 
(Supplementary information, Figure 20). Therefore, angiotensin I-modified QDs could also 
be an effective tool to investigate the influence of ACE in the progression of RA. Moreover, 
these QDs could be used as a diagnostic marker for various disease states. 
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Supplementary information 
TEM images of quantum dots 
A volume of 1 µl of a 60 mM QD solution in water was fixed on TEM grids. Although QDs 
show high self-contrast, they were stained with phosphotungstic acid, pH 7. With the 
staining, a light corona is visible for the PEGylated QDs, which could be due to the dense 
PEG shell surrounding the dark QD core. The TEM images did not show significant 
aggregation for amino-PEG QDs, neither before nor after ligand coupling. They are in the 
expected core size range of 10 nm (Figure 18). 
 
Figure 18: TEM images of QDs before and after angiotensin I modification. 
 
Investigation of ACE-2 expression 
The expression of ACE-2, another angiotensin-converting enzyme, which seems to have 
adverse renoprotective effects compared to ACE in diabetic nephropathy was also 
investigated [20,21]. This enzyme catalyzes two steps in the renin-angiotensin system: 
Angiotensinogen to angiotensin I and subsequently to angiotensin (1–9), ACE-derived 
angiotensin II to the shorter peptide fragment angiotensin (1–7) [7]. Therefore, the presence 
of this enzyme is not useful or beneficial for our experiments, since it degrades angiotensin II 
as the targeting ligand for the AT1R. In an RT-PCR, it was found that the NRK-52E tubules 
cell line used, as well as rat mesangial cells do not express ACE-2. In human mesangial cells, 
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a band at 238 bp for ACE-2 was observed in addition to other unspecific bands. Human 
ACE-2 primer sequence was used from [22] and rat ACE-2 primer sequence was used 
from [15] (Figure 19). 
 
Figure 19: RT-PCR ACEs of different cell lines. Only human mesangial cells express both 
converting-enzymes: ACE (428 bp) and ACE-2 (238 bp). The rat mesangial and tubule cells 
used do not express ACE-2 (129 bp). 
 
IL-1α and IL-1β stimulation of bovine chondrocytes in 2D 
culture 
Besides the kidney, which is, in the disease state of diabetic nephropathy, an AT1R and ACE 
positive target site, cartilage cells were also tested for AT1R expression. To evaluate whether 
the AT1R is expressed in general and whether there is a change in expression in the state of 
inflammation, primary bovine chondrocytes were stimulated in 2D culture with two different 
interleukins and the mRNA for RT-PCR was subsequently isolated. Therefore, bovine 
chondrocytes of the first passage were cultured in T25 cell culture flasks (Corning, 
Wiesbaden, Germany) in CCM, consisting of DMEM (Gibco/Thermo Scientific, Darmstadt, 
Germany), 10 mM HEPES, non-essential amino acid (Gibco/Thermo Scientific, Darmstadt, 
Germany), 46 µg/ml proline, 50 µg/ml ascorbic acid, 1% Penicillin/Streptomycin 
(Gibco/Thermo Scientific, Darmstadt, Germany), and 10% FCS. Confluent cells were 
washed with warm DPBS and then stimulated with interleukins, either 10 ng/ml IL-1α or 
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IL-β (PreproTech, Hamburg, Germany) in phenol red free CCM without FCS and 0.1% BSA 
and incubated for 24 h at 37°C and 5% CO2 atmosphere. The isolation of RNA, reverse 
transcription, and PCR were performed with Peqlab kit systems. AT1R mRNA expression 
was detected before and after interleukin stimulation by the expected band 210 bp. The 
sample without interleukin stimulation exhibited even more expression (Figure 20). These 
results are consistent with those in the literature for human chondrocytes [23]. 
 
Figure 20: AT1 receptor expression in bovine chondrocytes in 2D culture. Cells were stimulated 
with either human IL-1α or IL-1β for 24 hours to mimic an inflammatory state. AT1R is 
expressed independently from interleukin-1 stimulation. 
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The goal of this thesis was to investigate the neurokinin-1 receptor (NK1R) as a potential 
target site for multivalent receptor blockade. Since the NK1R is peripherally expressed on 
various cell types of the human body and its expression increases when an immune response 
occurs, this receptor seems to offer great potential for selective and specific antagonistic 
surface receptor targeting with a minimizing effect of inflammation and pain. 
In the experiments described in Chapter 3, it was found that the inflammatory factor IL-1β 
has a direct influence on NK1R expression levels in U87 MG glioblastoma and 
MDA-MB-231 breast cancer cell lines and primary bovine chondrocytes in 2D cell culture. 
For U87 MG and MDA-MB-231 cells, it was found that the NK1R mRNA is upregulated 
within the first 3 hours of IL-1β stimulation, but down-regulated for long-term IL-1β 
stimulation. Here, less NK1R expression at the mRNA level was observed for MDA-MB-231 
cells than for U87 MG cells. In receptor binding experiments, approximately 2% of the 
maximum intracellular calcium signals were reached, compared to NK1R positive 
transfected CHO cells, indicating only a low NK1R density on these cell types. These results 
were quite disappointing because these non-transfected cells could not be used for further 
receptor binding studies of antagonist modified multivalent binding nanoparticles in 
fluorescence-based calcium assays. Nevertheless, NK1R mRNA was found in bovine 
chondrocytes and the results of NK1R immunostaining in bovine cartilage tissue sections 
were quite promising. In addition, it could be demonstrated in 2D cell cultures that IL-1β 
and substance P together contribute to the regulation of the chondrocytes´ surrounding 
extracellular matrix (ECM) behavior by the selective regulation of matrix-
metalloproteinases´ (MMPs) gene expression. In this context, it could be shown that 
MMP-13 in particular is regulated in a time and concentration-dependent manner by 
substance P and can be antagonized by the specific NK1R antagonist spantide I, which allows 
us to assume that this intracellular signaling pathway is triggered via NK1Rs. This aspect is 
intriguing since the literature also mentions that MMP-13 has an impact on the progression 
of arthritis. Finally, it is concluded that the short version of the NK1R may be more prominent 
on the surface of all tested cell types and may offer the opportunity for NK1R targeting, 
particularly due to the impact on MMP regulation. Due to the lack of the C-terminal 
Gq-protein binding site of this truncated NK1R splice variant, no intracellular calcium signals 
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were detectable. For this reason, the NK1R transfected CHO cells were used for further 
studies to predict the affinity of generated multivalent ligands. 
In Chapter 4, fluorescent PEGylated QDs were used for ligand coupling to the surface of 
nanoparticles and to study their interactions with neurokinin-1 receptor positive cells. The 
introduction of thiol groups into cysteine-free peptide ligands is a common strategy for 
coupling well water-soluble ligands to maleimide functionalized nanoparticles such as QDs. 
It was found that thiolation reaction is quite efficient for the very hydrophilic angiotensin I, 
which was used in Chapter 7, whereas it is highly reduced for spantide I, although there are 
two different modification sites for 2-iminothiolane. In nanoparticle uptake experiments 
with receptor positive CHO-NK1R cells, a high unspecific nanoparticle binding for 
amino-PEG modified QDs was examined. Here, free amino-PEG groups showed high 
unspecific binding to cells. In general, unspecific nanoparticle binding strongly hampers the 
argument of receptor mediated multivalent nanoparticle binding and uptake by GPCR. 
However, it was shown in FACS displacement experiments with high concentrations of free 
competing antagonists that nanoparticle binding was inhibited. This indicated receptor 
mediated nanoparticle binding. However, the previous low thiolation efficiency for the 
peptide may be the main reason for a low nanoparticle coupling propensity. In addition, 
double thiolated peptides may cause low ligand densities on the surface of nanoparticles. 
This also minimizes the chance for multivalent interactions. Since the C-terminal receptor 
interacting part of the peptide mainly consists of hydrophobic amino acids, there is also the 
chance for ligand inversion inside the PEG shell, a phenomenon that is also discussed for 
highly hydrophobic small non-peptide receptor antagonists. 
Besides PEGylated QDs, branched 8-arm PEGs were used in Chapter 5 for multivalent cell 
interaction studies. In contrast to QDs, PEGs are classified as non-toxic biomaterials; 
additionally, they do not interfere with luminescence-based calcium assays. It was found that 
there is a high concentration requirement of PEGylated spantide I species because 
N-terminal PEGylation decreases binding to membrane receptors but has the advantage of 
reduced clearance and immunogenicity. Double PEGylation of spantide I further increases 
the affinity loss to neurokinin-1 receptors because a higher PEG to peptide ratio sterically 
reduces receptor binding at the cell surface, although binding is sufficient at very high ligand 
concentrations. Furthermore, simple N-terminal truncation of the peptide sequence leads to 
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a great affinity loss. This indicates that the N-terminus sequence itself seems to be involved 
in receptor recognition and binding. Therefore, N-terminal truncation of the peptide 
sequence of spantide I is not an option to simplify the mono-PEGylation by elimination of 
amino acids, which are responsible for double PEGylation. The agonistic activity of some 
peptide antagonists makes it difficult to determine true IC50 values in the aequorin based 
calcium assay because of the consumption of bioluminescent aequorin complex. However, 
it was shown that there is a gain in affinity for 8armPEG-20k-spantide I due to multivalent 
receptor binding. 
In Chapter 6, a small molecular weight antagonist, aprepitant, was modified to make it 
amenable for further PEG coupling, either to branched PEGs or PEG-coated nanoparticles. 
To overcome the limitations of post-synthetic modification of small molecular weight 
neurokinin-1 receptor antagonists due to the lack of functional groups, it could be shown 
that chemical modification of the triazole group of aprepitant is possible by using a strong 
deprotonation reagent and a tert-Butyl-(3-bromopropyl)carbamate as an alkyl linker with 
Boc-protected amine functionality. In a binding study with the final product, it was found 
that the affinity dropped 3.9-fold but still has an acceptable IC50 of 115.2 nM and therefore 
represents a promising antagonist for nanoparticle functionalization and further multivalent 
receptor binding studies. One drawback of this Boc-protected antagonist was the Boc-group 
cleavage under conditions, which are strong enough for deprotection on the one hand and 
mild enough to keep the basic morpholin-ring structure of aprepitant intact on the other hand. 
A better option would have been the introduction of an alkyl linker without a Boc-protecting 
group, but to date, there is no way to perform such an alkylation. Therefore, it is proposed 
that the best way to obtain an amine-alkyl-linker functionalized aprepitant would be to start 
the design of the desired drug molecule by stepwise synthesis from the very beginning 
instead of post-synthetic linker addition. 
Another new strategy for site-specific multivalent nanoparticle targeting is presented in the 
final chapter, Chapter 7. This strategy is based on an enzyme driven activation mechanism 
of ligands which are immobilized on the surface of nanoparticles. For these studies, the ACE 
driven angiotensin I to angiotensin II conversion was used and the successful conversion 
was checked by AT1 receptor binding studies. The results of these experiments have shown 
that enzymatically processed angiotensin I coated nanoparticles are able to selectively bind 
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to AT1R positive mesangial cells. To date, it is not clear whether multivalent receptor 
binding is induced after enzymatic processing of angiotensin I-modified QDs because the 
measured calcium responses were very low, and microscopy pictures and flow cytometry 
data did not clearly show strong differences in receptor binding between enzymatically 
converted nanoparticles and the respectively used controls with either enzyme inhibitor or 
receptor blocker. There may be multiple reasons. The coupling efficiency of angiotensin I to 
QDs is too low and/or the ligand conversion efficiency by ACE is too low. A further reason 
may be that free unbound angiotensin I is not completely removed from the QD sample. 
Thus, free converted angiotensin I can compete with angiotensin I-modified QDs for 
receptor binding sites. Nevertheless, in each experiment, the binding of angiotensin I coated 
nanoparticles before ACE-derived processing is lower, compared to converted QDs, which 
indicates a certain conversion. Such an enzyme driven nanoparticle binding could be one 
step further in preventing unspecific nanoparticle binding and uptake to and from off-target 
cells. In future experiments, artificial human recombinant ACE should be replaced by natural 
cell-derived ACE, expressed ideally by one cell type. Particularly in diabetic nephropathy, 
this kind of particle can be used as a probing system to better understand the sites of action 
and interaction of ACE and AT1R in renal tissues. Therefore, the parallel injection of the 
inhibitors Captopril and EXP3174 is recommended to avoid enzymatic cleavage of ligands 
by enzymes in the blood stream and nanoparticle binding to off-target cells before they arrive 
at the target site in the kidney. 
Since it is known that in addition to synovium derived cells, bovine chondrocytes in 2D cell 
cultures also express AT1 receptors for angiotensin II, independent from interleukin-1 
stimulation, cartilage cells may also be a potential target for antiangiogenic drugs. Therefore, 
the present angiotensin I-modified QDs may also be an effective tool for investigating the 
influence of ACE in the progression of RA. Moreover, these QDs might be used as a 
diagnostic marker for different disease states. 
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Abbreviations 
1H-NMR   proton nuclear magnetic resonance spectroscopy 
2D/ 3D  two-dimensional/ three-dimensional 
ACE    angiotensin-converting enzyme 
Ang I/Ang II  angiotensin I/ angiotensin II 
aprepitant  neurokinin-1 receptor antagonist (MK-869) 
APS   Ammonium persulfate 
AT1R   angiotensin II receptor 
ATCC   American Type Culture Collection 
BBB   blood–brain barrier 
bp   base pairs 
BSA   bovine serum albumin 
CCM   cell culture medium 
CD   circular dichroism 
cDNA   copy deoxyribonucleic acid 
Cd   cadmium 
CdSe   cadmium selenide 
CGRP   calcitonin gene-related peptide 
CHO cells  chinese hamster ovary cell line 
CLSM   confocal laser scanning microscopy 
CNS   central nervous system 
COX   cyclooxygenase 
DABCO  1,4-Diazabicyclo[2.2.2]octane 
DAPI   2-(4-Amidinophenyl)-1H-indole-6-carboxamidine 
DBA-1J mice  mice with type II collagen-induced arthritis 
DMEM  Dulbecco´s modified Eagle´s medium 
DMF   dimethylformamide 
Appendix 
 
 
 
- 163 - 
DMSO  dimethylsulfoxide 
DNA   deoxyribonucleic acid 
DPBS   Dulbecco´s phosphate-buffered saline 
DTNB   5,5'-dithio-bis-[2-nitrobenzoic acid], (Ellman´s reagent) 
ECM   extracellular matrix 
EDTA   ethylendiaminetetraacetic acid 
EDC   1-ethyl-3-3(3-dimethylaminopropyl) carbodiimide 
EMEM  minimum essential medium containing Earl´s salts 
ENS   enteric nervous system 
EPR   enhanced permeability and retention 
FACS   fluorescence activated cell sorting 
FCS   fetal calf serum 
FDA   Food and Drug Administration 
FITC   fluorescein isothiocyanate 
Fura-2 AM  fura-2-acetoxymethyl ester (ratiometric calcium indicator) 
GAPDH  glyceraldehyde 3-phosphate dehydrogenase 
GFP   green fluorescent protein 
GPCR   G protein-coupled receptor 
GRK   G protein-coupled receptor kinases 
HEPES  2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid 
HPLC   High-performance liquid chromatography 
IBD   inflammatory bowel disease 
IL   interleukin 
IL-1ra   interleukin-1 receptor antagonist 
MCF-7  human breast cancer cell line 
MDA-MB-231 human breast cancer cell line 
MMP   matrix metalloprotease 
mRNA  messenger ribonucleic acid 
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MS   multiple sclerosis 
MWCO  molecular-weight cutoff 
NFκB   nuclear factor 'kappa-light-chain-enhancer' of activated B-cells  
NHS   N-hydroxysuccinimide 
NK1R/NK2R/NK3R neurokinin receptors 
NSAIDs  nonsteroidal anti-inflammatory drugs 
OA   osteoarthritis 
OSM   oncostatin M 
PBS   Phosphate-buffered saline 
PCR   polymerase chain reaction 
qPCR   quantitative real-time PCR 
RA   rheumatoid arthritis 
RT-PCR  reverse transcription PCR 
PEG   polyethylene glycol 
PD-ECGF  platelet-derived endothelial cell growth factor  
PFA   Paraformaldehyde (Polyoxymethylene) 
QD   quantum dot 
rcf   relative centrifugal force 
SDS   sodium dodecyl sulfate 
SEC   size-exclusion chromatography 
SP   substance P, neurokinin-1 receptor agonist 
SP I   spantide I, neurokinin-1 receptor antagonist 
Sulfo-SMCC  sulfosuccinimidyl-4-(N-maleimidomethyl)-cylohexane-1-
carboxylate 
SYBR Green asymmetrical cyanine dye 
TAE buffer tris-acetate-EDTA buffer 
TCEP tris(2-carboxyethyl)phosphine 
TEM   transmission electron microscopy 
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TEMED  tetramethylethylenediamine 
TFA   trifluoroacetic acid 
TGF-β   transforming growth factor beta 
TLC   Thin-layer chromatography 
TNF-α   tumor necrosis factor alpha 
TNF-R  tumor necrosis factor receptor 
Tricin   O-methylated flavone 
Tris   tris(hydroxymethyl)aminomethane 
TRIzol   guanidinium thiocyanate-phenol-chloroform extraction reagent 
Tween 20  polyoxyethylene (20) sorbitan monolaurate (Polysorbate 20) 
U87 MG  human gliloblastoma cell line   
UC11   human astrocytoma cell line 
UV   ultraviolet light or irradiation 
VEGF   vascular endothelial growth factor 
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